Steroid compound and antibody conjugate thereof

Delivering the glucocorticoid payload to target cells through antibody-drug conjugates solves the problem of side effects of glucocorticoid treatment and improves efficacy and safety.

CN118955604APending Publication Date: 2024-11-15REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410947679.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-01-08
Filing Date
2019-01-08
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing glucocorticoid treatments have a widespread expression of their receptors in most organ systems, resulting in side effects and are difficult to target the side effects caused by activation of glucocorticoid receptors in non-target cells, and lack effective methods to reduce side effects.

Method used

Develop antibody-drug conjugates containing glucocorticoid payloads, using the target specificity of the antibody to combine with the mode of action of glucocorticoids, and use antibody conjugates to reduce the non-inflict target cells. Effects of target cells.

Benefits of technology

Effectively reduce the side effects of glucocorticoid treatment and improve efficacy and safety, especially in reducing the side effects caused by non-target cell activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_10
    Figure SMS_10
  • Figure SMS_11
    Figure SMS_11
Patent Text Reader

Abstract

The invention relates to steroid compounds and antibody conjugates thereof. Described herein are protein steroid conjugates that are useful, for example, for targeted-specific delivery of glucocorticoids (GCs) to cells.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims and enjoys priority to U.S. Provisional Patent Application No. 62 / 614,905, entitled “Steroids and Antibody Conjugates Thereof,” filed on January 8, 2018. The contents of this provisional patent application are incorporated herein by reference in their entirety for all purposes. Sequence Listing

[0002] This application contains a sequence listing, which has been submitted in ASCII format by EFS-Web and is incorporated herein by reference in its entirety. The ASCII copy was created on January 3, 2019, is named 114581_00228_ST25.txt, and is 11,186 bytes in size. Field of the Invention

[0003] The present invention provides steroid compounds, protein (eg, antibody) conjugates thereof, and methods for treating diseases, disorders, and conditions comprising administering the steroid compounds and conjugates. Background of the Invention

[0004] Antibody-drug conjugates (ADCs) are antibodies covalently linked to biologically active small molecule drugs, thereby combining the targeting specificity of the antibody with the mode of action and potency of the small molecule drug. The therapeutic role of ADCs has been demonstrated in cancer treatment and is a major ongoing focus of research. (bentruximab vedotin) and (ado-trastuzumab emtansine conjugate) are ADCs approved for the treatment of certain cancer types, and several other ADCs are currently in clinical development.

[0005] Glucocorticoid (GC) is a small molecule steroid compound that is combined with glucocorticoid receptor (GR) and is used for anti-inflammatory and immunosuppressive therapy. However, due to the widespread expression of glucocorticoid receptor in many cell types, glucocorticoid treatment is affected by most organ system toxicity. Therefore, new glucocorticoid and the side effects (particularly those caused by glucocorticoid receptor activation in non-target cells) caused by glucocorticoid administration are needed. The present invention provides solutions to other unmet needs in the above-mentioned needs and the field involved in the present invention. The present invention includes antibody-drug conjugates containing glucocorticoid payloads. Abstract

[0006] The present invention provides compounds and methods useful for treating various diseases, disorders, or conditions.

[0007] The first aspect relates to a compound represented by formula (III): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 Connected to L in formula (III), -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (III), -CH2-NH-, wherein the N is connected to L in formula (III), wherein said N is connected to L in formula (III) and wherein Ar is an optionally substituted arylene group or an optionally substituted heteroarylene group, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III) and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (III) Connect, or where X 4 Connected to L in formula (III); or Two R's x are all F; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (III) is connected, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Connected to L in formula (III), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (III), -CH2-NH-, wherein the N is connected to L in formula (III), wherein said N is connected to L in formula (III) and wherein Ar is an optionally substituted arylene group or an optionally substituted heteroarylene group, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III) and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -,That Medium X 2 Connected to L in formula (III), or where X 4 connected to L in formula (III); and X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; z is an integer selected from 1 to 30 (inclusive); L is a linker; and BA is a binding agent.

[0008] The second aspect relates to a compound represented by formula (I): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; a) Two Rs x Both are H; and R 3 Yes-C(O)R Z ;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b ; -CH2NH2; or R Z Yes-C 4-10 -alkylene-C(O)OH;-(C1-C 10-alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , where each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups; wherein Ar is an optionally substituted aryl or heteroaryl; or NR 15 R 15a ; R 15 is H or C1-C6 alkyl, and R 15a Yes-(C1-C 10 -alkylene)-SH or -(C 1-6 -alkylene)-C(O)NHNH2; b) Two Rs x Both are F; and R 3 Yes-C(O)R Z ;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b ; -CH2NH2; or R Z Yes-C 4-10 -alkylene-C(O)OH;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , where each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups; wherein Ar is an optionally substituted aryl or heteroaryl; or NR 16 R 16a ; R 16 is H or C1-C6 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-SH, -(C1-C 10 -alkylene)-NH2, -(C1-C 10 -alkylene)-NH(C 1-6 alkyl), or -(C 1-6 -alkylene)-C(O)NHNH2; and Each R50 、R 50a and R 50b are each independently H or C1-C6-alkyl; R c 、R d 、R e and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , Among them, each R g are independently -(C 1-6 -alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl); or R c 、R d 、R e and R f middle One of the groups is hydroxyalkyl, and the others are -H; and m is 0 or 1.

[0009] The third aspect relates to a compound represented by formula (II): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 With (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (II) 3 ) 0-1 connect, The attachment point on the right hand side (i.e., N) is the same as (L 3 )0-1 Connect, -CH2-NH-, wherein said N and (L in formula (II) 3 ) 0-1 connect, Wherein said N and (L 3 ) 0-1 wherein Ar is an optionally substituted arylene or an optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With (L in formula (II) 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With (L in formula (II) 3 ) 0-1 Connect and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 With (L in formula (II) 3 ) 0-1 Connect, or where X 4 and L in formula (II) 3 connect; or Two R's x are all F; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b With (L in formula (II) 3 ) 0-1 connect, The attachment point on the right hand side (i.e., N) is the same as (L 3 ) 0-1 Connect, -CH2-NH-, wherein N and (L 3 ) 0-1 connect, Wherein said N and (L 3 ) 0-1 wherein Ar is an optionally substituted arylene or an optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -,in NR 50a With (L in formula (II) 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With (L in formula (II) 3 ) 0-1 Connect and each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups, -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -, where X 2 With (L in formula (II) 3 ) 0-1 Connect, or where X 4 With (L in formula (II) 3 ) 0-1 Connect; and X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; RG is the active group; L 2 is a linker for connection; and L 3 When present, it is a self-immolative linker.

[0010] On the other hand, the present invention relates to a pharmaceutical composition comprising a compound represented by Formula (I), Formula IP, Formula IP-1, Formula (III-P), Formula III-P-1, Formula (3000), or Formula (III), and a pharmaceutically acceptable carrier, diluent, and / or excipient.

[0011] On the other hand, the present invention relates to a method for treating various diseases, disorders or conditions, which comprises administering a compound of Formula I, Formula IP, Formula IP-1, Formula (III-P), Formula III-P-1, Formula (3000), or Formula (III), or administering a pharmaceutical composition comprising a compound of Formula I, Formula IP, Formula IP-1, Formula (III-P), Formula III-P-1, Formula (3000), or Formula (III) and a pharmaceutically acceptable carrier, diluent, and / or excipient. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1A 、 1B and 1C and Figure 2 GR activation of steroid-ADCs as tested in Example 7 is shown.

[0011] Figure 3 Scheme 1 is shown. Synthesis of spacer-budesonide 1c-1e, 1g-1i, and 1j-11. Detailed Description of the Invention A. Definition

[0012] As used herein, "alkyl" refers to a monovalent and saturated hydrocarbon group. Unless otherwise specified, an alkyl group is optionally substituted and may be linear, branched, or cyclic, i.e., a cycloalkyl group. Alkyl groups include, but are not limited to, groups having 1 to 20 carbon atoms, i.e., C 1-20 Alkyl; 1-12 carbon atoms, i.e. C 1-12 Alkyl; 1-8 carbon atoms, i.e. C 1-8 Alkyl; 1-6 carbon atoms, i.e. C 1-6 Alkyl; and 1-3 carbon atoms, i.e. C 1-3 Cycloalkyl is a subset of alkyl, including but not limited to cycloalkyl groups having 3-20 carbon atoms, i.e., C 3-20 Alkyl; 3-12 carbon atoms, i.e. C 3-12 Alkyl; 3-10 carbon atoms, i.e. C 3-10 Alkyl; 3-8 carbon atoms, i.e. C 3-8 Alkyl; and 3-6 carbon atoms, i.e. C 3-6 Examples of alkyl moieties include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, pentyl moieties, hexyl moieties, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0013] "Alkylene" is a divalent alkyl group wherein alkyl is as defined herein.

[0014] As used herein, "aminoalkyl" refers to an alkyl group substituted with one or two -NH2 groups.

[0015] As used herein, "alkenyl" refers to a monovalent hydrocarbon radical moiety containing at least two carbon atoms and one or more non-aromatic carbon-carbon double bonds. Unless otherwise indicated, alkenyl groups are optionally substituted and may be straight-chain, branched, or cyclic. Alkenyl groups include, but are not limited to, groups having 2-20 carbon atoms, i.e., C 2-20 Alkenyl; 2-12 carbon atoms, i.e. C 2-12 Alkenyl; 2-8 carbon atoms, i.e. C 2-8 Alkenyl; 2-6 carbon atoms, i.e. C 2-6 Alkenyl; and 2-4 carbon atoms, i.e. C 2-4 Cycloalkenyl is a subset of alkenyl, including but not limited to cycloalkenyl groups having 3-20 carbon atoms, i.e., C 3-20 Alkenyl; 3-12 carbon atoms, i.e. C 3-12 Alkenyl; 3-10 carbon atoms, i.e. C 3-10Alkenyl; 3-8 carbon atoms, i.e. C 3-8 Alkenyl; and 3-6 carbon atoms, namely C 3-6 Examples of alkenyl moieties include, but are not limited to, ethenyl, propenyl, butenyl, and cyclohexenyl.

[0016] "Alkenylene" is a divalent alkenyl radical wherein alkenyl is as defined herein.

[0017] As used herein, "alkynyl" refers to a monovalent hydrocarbon radical moiety containing at least two carbon atoms and one or more carbon-carbon triple bonds. Unless otherwise indicated, alkynyl groups are optionally substituted and may be straight-chain, branched, or cyclic. Alkynyl groups include, but are not limited to, groups having 2-20 carbon atoms, i.e., C 2-20 Alkynyl; 2-12 carbon atoms, i.e. C 2-12 Alkynyl; 2-8 carbon atoms, i.e. C 2-8 Alkynyl; 2-6 carbon atoms, i.e. C 2-6 Alkynyl; and 2-4 carbon atoms, i.e., C 2-4 Cycloalkynyl is a subset of alkynyl, including but not limited to cycloalkynyl groups having 3-20 carbon atoms, i.e., C 3-20 Alkynyl; 3-12 carbon atoms, i.e. C 3-12 Alkynyl; 3-10 carbon atoms, i.e. C 3-10 Alkynyl; 3-8 carbon atoms, i.e. C 3-8 Alkynyl; and 3-6 carbon atoms, i.e. C 3-6 Examples of alkynyl moieties include, but are not limited to, ethynyl, propynyl, and butynyl.

[0018] "Alkyne" is a divalent alkynyl group wherein alkynyl is as defined herein.

[0019] As used herein, "alkoxy" refers to a monovalent and saturated hydrocarbon moiety wherein the hydrocarbon includes a single bond to an oxygen atom, and wherein the free radical is located on the oxygen atom, such as ethoxy CH3CH2-O·. Alkoxy substituents are attached to the compound they replace via the oxygen atom of the alkoxy substituent. Unless otherwise specified, alkoxy groups are optionally substituted and may be linear, branched, or cyclic, i.e., cycloalkoxy groups. Alkoxy groups include, but are not limited to, groups having 1-20 carbon atoms, i.e., C 1-20 Alkoxy; 1-12 carbon atoms, i.e. C 1-12 Alkoxy; 1-8 carbon atoms, i.e. C 1-8 Alkoxy; 1-6 carbon atoms, i.e. C 1-6 Alkoxy; and 1-3 carbon atoms, namely C 1-3 Cycloalkoxy is a subset of alkoxy, including but not limited to cycloalkoxy groups having 3-20 carbon atoms, i.e., C 3-20 Alkoxy; 3-12 carbon atoms, i.e. C3-12 Alkoxy; 3-10 carbon atoms, i.e. C 3-10 Alkoxy; 3-8 carbon atoms, i.e. C 3-8 Alkoxy; and 3-6 carbon atoms, namely C 3-6 Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, isobutoxy, pentoxy moieties, hexoxy moieties, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, and cyclohexyloxy.

[0020] As used herein, "aryl" refers to a monovalent radical portion of a monocyclic or polycyclic system containing at least one aromatic ring wherein the ring atoms are carbon atoms. Aryl is optionally substituted. When the aryl is monocyclic, the aryl is phenyl. When the aryl is polycyclic, such as bicyclic or tricyclic, at least one ring is aromatic and the other rings may be aromatic or partially unsaturated. Examples of aryl moieties include, but are not limited to, aryl groups having 6 to 20 ring carbon atoms, i.e., C 6-20 Aryl; 6 to 15 ring carbon atoms, i.e. C 6-15 Aryl, and 6 to 10 ring carbon atoms, namely C 6-10 Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, fluorenyl, azulenyl, anthracenyl, phenanthrenyl, and pyrenyl.

[0021] As used herein, "arylene" refers to a divalent aromatic radical, wherein aryl is as defined herein. In some embodiments, the arylene is optionally substituted on one of the carbon atoms that does not provide a point of attachment to the rest of the molecule. In some embodiments, the arylene is not optionally substituted. In some embodiments, the arylene is phenylene. In some embodiments, the arylene is It is optionally substituted. In some embodiments, the arylene group is It is not optionally substituted. In some embodiments, The phenylene group in is optionally substituted. In some embodiments, The phenylene group in is not optionally substituted.

[0022] As used herein, "arylalkyl" or "aralkyl" refers to a monovalent radical portion of an alkyl compound radical, wherein the alkyl compound is substituted with an aryl substituent, i.e., the aromatic compound includes a single bond connected to the alkyl group, and wherein the free radical is located on the alkyl group. The arylalkyl group is connected to the chemical structure shown via the alkyl group. In some embodiments, arylalkyl includes benzyl, phenylethyl-1-yl, and phenylethyl-2-yl, etc. Unless otherwise indicated, arylalkyl is unsubstituted. However, when substituted, the arylalkyl, i.e., the aryl group and / or the alkyl group, is substituted as disclosed herein. Examples of arylalkyl include, but are not limited to, benzyl.

[0023] As used herein, "haloalkyl" refers to an alkyl group as defined herein, wherein the alkyl group includes at least one substituent selected from halogen, such as F, Cl, Br, or I. In some embodiments, the alkyl group is substituted with 1, 2, 3, or 4 independently selected halogen atoms.

[0024] As used herein, "haloalkoxy" refers to an alkoxy group as defined above, wherein the alkoxy group includes at least one substituent selected from halogen, such as F, Cl, Br or I.

[0025] As used herein, "heteroalkyl" refers to an alkyl group in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkenyl" refers to an alkenyl group in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkynyl" refers to an alkynyl group in which one or more carbon atoms are replaced by a heteroatom. Suitable heteroatoms include, but are not limited to, independently selected nitrogen, oxygen, and sulfur atoms. Unless otherwise indicated, heteroalkyl groups are optionally substituted. Examples of heteroalkyl moieties include, but are not limited to, aminoalkyl, sulfonylalkyl, and sulfinylalkyl. Examples of heteroalkyl moieties also include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl.

[0026] The "heteroaryl" used in the present invention refers to a monovalent group portion of an aromatic compound atomic group, wherein the ring atoms include carbon atoms and at least one oxygen, sulfur, nitrogen or phosphorus atom. Heteroaryl includes monocyclic, fused bicyclic or fused tricyclic groups, wherein the ring containing the monocyclic group is aromatic, and at least one of the fused rings containing the bicyclic or tricyclic group is aromatic. Fused bicyclic groups include bridged ring systems. Examples of heteroaryl group moieties include, but are not limited to, those having 5 to 20 ring atoms, 5 to 15 ring atoms, and 5 to 10 ring atoms. Heteroaryl is optionally substituted. In some embodiments, the heteroaryl ring includes 1, 2, 3 or 4 (in some embodiments, 1, 2 or 3; in some embodiments, 1 or 2; in some embodiments, 1) independently selected oxygen, sulfur, nitrogen and / or phosphorus atoms. In some embodiments, heteroaryl is 1,2,4-triazolyl, 1,3,5-triazolyl, phthalimide, pyridinyl, pyrrolyl, imidazolyl, thienyl, furanyl, indolyl, 2,3-dihydro-1H-indolyl (including, for example, 2,3-dihydro-1H-indol-2-yl or 2,3-dihydro-1H-indol-5-yl, etc.), isoindolyl, dihydroindolyl, isoindolinyl, benzimidazolyl, benzodioxazol-4-yl, benzofuranyl, cinnolinyl, indolizinyl, naphthyridin-3-yl, phthalazin-3-yl, phthalazin-4-yl , pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, oxadiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl (including, for example, tetrahydroisoquinolin-4-yl or tetrahydroisoquinolin-6-yl, etc.), pyrrolo[3,2-c]pyridinyl (including, for example, pyrrolo[3,2-c]pyridin-2-yl or pyrrolo[3,2-c]pyridin-7-yl, etc.), benzopyranyl, thiazolyl, isothiazolyl, thiadiazolyl, benzothiazolyl, benzothiophenyl.

[0027] As used herein, "heteroarylene" refers to a divalent heteroaryl group, wherein heteroaryl is as defined herein. In some embodiments, the heteroarylene is optionally substituted on one of the carbon atoms or substitutable nitrogen atoms that does not provide a point of attachment to the rest of the molecule. In some embodiments, the heteroarylene is not optionally substituted. In some embodiments, the heteroarylene is pyridinediyl.

[0028] "Heterocycloalkyl" as used herein refers to a cycloalkyl group in the above-defined "alkyl" group in which one or more carbon atoms are replaced by independently selected heteroatoms. Suitable heteroatoms include, but are not limited to, nitrogen, oxygen, and sulfur atoms. Unless otherwise indicated, heterocycloalkyl is optionally substituted. Examples of heterocycloalkyl moieties include, but are not limited to, morpholinyl, piperidinyl, tetrahydropyranyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, thiazolidinyl, dioxolane, dithiolanyl, tetrahydropyranyl, or tetrahydrothiopyranyl.

[0029] As used herein, "hydroxyalkylene" refers to an alkylene group as defined herein, wherein the alkylene group includes at least one hydroxyl group. In some embodiments, the alkylene group is substituted with 1, 2, 3, or 4 hydroxyl groups.

[0030] As used herein, "N-containing heterocycloalkyl" refers to a cycloalkyl group in an "alkyl" as defined above in which one or more carbon atoms are replaced by heteroatoms and at least one heteroatom is a nitrogen atom. Suitable independently selected heteroatoms include, but are not limited to, oxygen atoms and sulfur atoms, in addition to nitrogen atoms. N-containing heterocycloalkyl is optionally substituted. Examples of N-containing heterocycloalkyl moieties include, but are not limited to, morpholinyl, piperidinyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl, or thiazolidinyl.

[0031] As used herein, "optionally substituted" when used to describe a moiety (e.g., optionally substituted arylene, optionally substituted heteroarylene, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, and optionally substituted arylalkyl) means that the moiety is optionally attached to one or more substituents on any substitutable atom in the moiety. Examples of such substituents include, but are not limited to, halogen, cyano, nitro, haloalkyl, azido, epoxy, optionally substituted heteroaryl, optionally substituted heterocycloalkyl, where R A 、R B and R C is independently, at each occurrence, a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylaryl group, an arylalkyl group, a heteroalkyl group, a heteroaryl group, or a heterocycloalkyl group, or R A and R B With the atom being connected with them, form saturated or unsaturated heterocycle (i.e. heterocycloalkyl or heteroaryl), wherein the ring is optionally substituted, and wherein except nitrogen ring atoms, one or more ring atoms are optionally the heteroatoms independently selected from nitrogen, oxygen, sulphur and phosphorus.In certain embodiments, when group part is optionally replaced by optionally substituted heteroaryl, optionally substituted heterocycloalkyl or optionally substituted saturated or unsaturated heterocycle (i.e. heterocycloalkyl or heteroaryl) substituted, the substituent on the optionally substituted heteroaryl, optionally substituted heterocycloalkyl or optionally substituted saturated or unsaturated heterocycle (i.e. heterocycloalkyl or heteroaryl), if they are substituted, then not further optionally substituted by the substituent replaced by other substituent.In some embodiments, when group of the present invention is optionally substituted, unless otherwise stated, the substituent being connected with the group is unsubstituted, i.e. the optionally substituted arylene replaces as substituent not further substituted arylene.

[0032] As used herein, "binding agent" refers to any protein-based or peptide-based molecule that is capable of specifically binding to a given binding partner. In some embodiments, the binding agent is an antibody or antigen-binding fragment thereof. In some embodiments, the binding agent is not albumin.

[0033] As used herein, "amide synthesis conditions" refer to reaction conditions suitable for promoting the formation of amides, for example, by reacting a carboxylic acid, an activated carboxylic acid, or an acyl halide with an amine. In some embodiments, "amide synthesis conditions" refer to reaction conditions suitable for promoting the formation of an amide bond between a carboxylic acid and an amine. In some of these embodiments, the carboxylic acid is first converted to an activated carboxylic acid before reacting the activated carboxylic acid with the amine to form an amide. Suitable conditions for achieving amide formation include, but are not limited to, those utilizing reagents for achieving the reaction between carboxylic acids and amines, including, but not limited to, dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate (PyBOP), (7-azobenzotriazol-1-yloxy)tripyrrolidinylphosphonium hexafluorophosphate (PyAOP), tripyrrolidinylphosphonium bromide hexafluorophosphate (PyBrOP), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethylurea. Hexafluorophosphate (HBTU), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluoroborate (TBTU), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), 2-chloro-1,3-dimethylimidazolium hexafluorophosphate (CIP), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), and carbonyldiimidazole (CDI). In some embodiments, the carboxylic acid is first converted to an activated carboxylate and then reacted with an amine to form an amide bond. In some embodiments, the carboxylic acid is reacted with a reagent. The reagent activates the carboxylic acid by deprotonating the carboxylic acid and then reacting with an amine to form an amide bond. In certain embodiments, the carboxylic acid reacts with a reagent. The reagent activates the carboxylic acid by deprotonating the carboxylic acid and then, due to the nucleophilic attack of the deprotonated carboxylic acid on the protonating agent, forms a product complex with the deprotonated carboxylic acid. For some carboxylic acids, before the activated ester is converted into a carboxylic acid, the activated carboxylate is more susceptible to the nucleophilic attack of an amine. This results in the formation of an amide bond. Therefore, the carboxylic acid is described as activated. Exemplary reagents include DCC and DIC.

[0034] As used herein, "therapeutically effective amount" refers to an amount sufficient to provide a therapeutic benefit in treating or managing a disease or condition, or delaying or minimizing one or more symptoms associated with a disease or condition.

[0035] As used herein, "pharmaceutically acceptable salt" refers to any salt suitable for administration to a patient. Suitable salts include, but are not limited to, those disclosed in Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1, which is incorporated herein by reference. Examples of salts include, but are not limited to, acid-derived, base-derived, organic, inorganic, amine, and alkali or alkaline earth metal salts, including but not limited to calcium salts, magnesium salts, potassium salts, sodium salts, hydrochlorides, hydrobromides, sulfates, nitrates, phosphates, acetates, propionates, glycolates, pyruvates, oxalates, maleates, malonates, succinates, fumarates, tartrates, citrates, benzoates, cinnamates, mandelates, methanesulfonates, ethanesulfonates, p-toluenesulfonates, and salicylates, etc.

[0036] Certain groups, molecules / group moieties, substituents, and atoms are depicted with a wavy line intersecting or covering a bond to indicate the atom through which the group, molecule / group moiety, substituent, atom is attached. For example, a phenyl group substituted with a propyl group may be represented as: Has the following structure: As used herein, the illustrative description of substituents attached to cyclic groups (e.g., aromatic rings, heteroaromatic rings, fused rings, and saturated or unsaturated cycloalkyl or heterocycloalkyl) through bonds between ring atoms is intended to indicate that, unless otherwise indicated, the cyclic group may be substituted with a substituent at any ring position of the cyclic group or on any ring of a fused ring group according to the techniques described herein or immediately disclosed techniques known in the art. For example, the group wherein the subscript q is an integer from 0 to 4 (inclusive), and wherein the substituent R 1 The positions of are generally described, i.e., not directly connected to any vertex of the bond line structure, i.e., a specific ring carbon atom, including the following, where the substituent R 1 Non-limiting examples of groups attached to specific ring carbon atoms:

[0037] When the compound nomenclature conflicts with or is inconsistent with the structural formula, the structural formula controls unless the context, such as data provided by NMR characterization data, may dictate otherwise.

[0038] The phrase "reactive group" ("RG") refers to a functional group or group portion that reacts with the active (reactive) portion of an antibody, a modified antibody, or an antigen-binding fragment thereof. In certain embodiments, the "reactive group" is a functional group or group portion that reacts with a cysteine ​​residue or a lysine residue of an antibody or an antigen-binding fragment thereof (e.g., a maleimide or NHS ester). In certain embodiments, the "reactive group" is a functional group or group portion that can undergo a click chemistry reaction. In some embodiments of the click chemistry reaction, the reactive group comprises an alkyne that can undergo a 1,3-cycloaddition reaction with an azide. Such suitable reactive groups include, but are not limited to, strained alkynes, such as those suitable for strain-promoted alkyne-azide cycloaddition (SPAAC), cycloalkynes such as cyclooctynes, benzoannulated alkynes, and alkynes that can undergo a 1,3-cycloaddition reaction with an azide in the absence of a copper catalyst. Suitable alkynes also include, but are not limited to, DIBAC (wherein the -C(O)CH2CH2C(O)- portion of the DIBAC group is replaced by L 2 ), DIBO (wherein the -O- portion of the DIBO group is replaced by L 2 Contains), BARAC (wherein the BARAC group part of the Partly L 2 covered), DIFO (wherein the -O- portion is L 2 (including substituted alkynes such as fluorinated alkynes, aza-cycloalkynes, BCN, and derivatives thereof. Linker-payloads containing such reactive groups can be used to couple antibodies that have been functionalized with an azide group. Such functionalized antibodies include antibodies functionalized with an azide-polyethylene glycol group. In certain embodiments, such functionalized antibodies are obtained by reacting an antibody containing at least one glutamine residue (e.g., heavy chain Q295 (EU numbering)) with a compound of the formula H2N-LL-N3 in the presence of the enzyme transglutaminase, wherein LL is a divalent polyethylene glycol group.

[0039] In some embodiments, the reactive group (RG) is an alkyne, e.g. It can be synthesized by click chemistry with azides (e.g. ) reaction to form click chemistry products, such as In some embodiments, the reactive group is an alkyne, for example (where L 2 Contains -OCH2C(O)-), which can be reacted with azide (e.g. ) reaction to form click chemistry products, such as In some embodiments, the reactive group is an alkyne, e.g. It can be synthesized by click chemistry with azides (e.g. ) reaction to form click chemistry products, such as its regioisomers, or mixtures thereof. In some embodiments, the reactive group is a functional group, such as It reacts with cysteine ​​residues on antibodies or antigen-binding fragments thereof to form bonds therewith, e.g. Wherein Ab refers to an antibody or an antigen-binding fragment thereof, S refers to the S atom on a cysteine ​​residue, and the functional group is bound to Ab via the S atom on the cysteine ​​residue. In some embodiments, the active group is a functional group, for example It reacts with lysine residues on antibodies or antigen-binding fragments thereof to form bonds therewith, e.g. Wherein Ab refers to an antibody or an antigen-binding fragment thereof, N refers to the N atom on a lysine residue, and the functional group binds to Ab via the N atom on the lysine residue.

[0040] The phrase "active group residue" (-L 1 -) refers to the product of the reaction of the functional group in the linker group portion with the active part of the binding agent (BA), including click chemistry products. The active group residue is formed by the reaction of the active group on the amino acid of the binding agent and attached to the binding agent (e.g., antibody) and attached to the connecting linker. In some embodiments, the active group residue is a group containing 1,2,3-tetrazole, that is, it is formed by the reaction of an alkyne with an azide. In some embodiments, the active group residue is (a) wherein S refers to the S atom on a cysteine ​​residue, (a) is linked to Ab via the S atom on the cysteine ​​residue, and is In some embodiments, the reactive group residue is wherein N refers to the N atom on a lysine residue and is represented by a functional group such as It is formed by reacting with lysine residues on antibodies or their antigen-binding fragments.

[0041] In some embodiments, the linker -L- comprises a reactive group residue having a moiety: 1 is an active group residue having the following moieties: Its regioisomers, or mixtures thereof, wherein In some embodiments, the linker -L- comprises an active group residue having the following moiety, and L 1 is an active group residue having the following moieties: Its regioisomers, or mixtures thereof, wherein In some embodiments, the linker -L- comprises an active group residue having the following moiety, and L 1 is an active group residue having the following moieties: Among them -OCH2C(O)- is contained in L 2 , its regioisomers, or mixtures thereof, wherein In some embodiments, the linker -L- comprises an active group residue having the following moiety, and L 1 is an active group residue having the following moieties: Its regioisomers, or mixtures thereof, wherein In some embodiments, the linker -L- comprises an active group residue having the following moiety, and L 1 is an active group residue having the following moieties: in is a bond to a cysteine ​​residue of the antibody or antigen-binding fragment thereof. In some embodiments, the linker -L- comprises an active group residue having the following moiety, and L 1 is an active group residue having the following moieties: in is a bond to a lysine of the antibody or antigen-binding fragment thereof. In these embodiments, the bond to the binding agent is either direct or through a linker. In certain embodiments, the binding agent is modified with an azide to facilitate attachment to a linker -L- or L- 1 bonded to form active group residues.

[0042] The "connector" used in the present invention (L 2 ) refers to a divalent group that is cleavable or non-cleavable. A cleavable linker is a linker that is cleaved by intracellular metabolism after internalization (e.g., cleavage by hydrolysis, reduction, or enzymatic reaction). A non-cleavable linker is a linker that releases the attached payload by lysosomal degradation of the antibody after internalization. Suitable linkers for connection include, but are not limited to, acid-labile linkers, hydrolytically unstable linkers, enzymatically cleavable linkers, reduction-labile linkers, and non-cleavable linkers. Suitable linkers also include, but are not limited to, linkers that are or contain glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, hydrazones, maleimido-caproyl units, disulfide units (e.g., –S–S–, –S–C(R 1b R 2b )–, where R 1b and R2b are independently H or hydrocarbon groups), carbamate units, p-aminobenzyl units (PAB), phosphate units (e.g., mono-, di-, or tri-phosphate units), and peptide units (e.g., peptide units comprising 2, 3, 4, 5, 6, 7, 8, or more amino acid residues, including but not limited to valine-citrulline residue units). As used herein, "hexanoyl" refers to a -(CH2)5-C(O)- group. In some embodiments, L 2 Contains cyclodextrin (CD). In some embodiments, L 2 Contains -C(O)CH2CH2C(O)-, -C(O)CH2CH2CH2C(O)-, -OCH2C(O)-, -O-, or

[0043] As used herein, "self-immolative linker" refers to any such group known to those skilled in the art. In a particular embodiment, the self-immolative group is p-aminobenzyl (PAB), i.e. or its derivatives. Useful derivatives include p-aminobenzyloxy, i.e. and p-aminobenzyloxycarbonyl (PABC), i.e. Those skilled in the art will recognize that a self-immolative group is capable of undergoing a chemical reaction that releases the remaining atoms of the linker from the payload. B. Steroid Payload

[0044] Steroids suitable for use in the conjugates of the present invention include budesonide and prodrugs thereof, budesonide analogs or derivatives (including fluorinated analogs and derivatives) and prodrugs thereof, and steroids and prodrugs thereof listed in Table A. In some embodiments, upon binding to the target antigen of the antibody, the antibody-drug conjugate releases budesonide, prodrugs of budesonide, budesonide analogs or derivatives (including fluorinated analogs and derivatives), prodrugs of budesonide analogs or derivatives (including fluorinated analogs and derivatives), steroids listed in Table A, or prodrugs of steroids listed in Table A. In Table A, the following compounds are linked to BA of the compound represented by formula (III), formula (III-P), formula III-P-1, or (3000) via the hydroxyl group of the -C(O)CH2OH group (i.e., via -C(O)CH2-O-SP-L-), or via the hydroxyl group of Mapracorat (i.e., via -O-SP-L-); or via the hydroxyl group of the -C(O)CH2OH group (i.e., via -C(O)CH2-O-SP-(L 3 ) 0-1 -L 2 -), or through the hydroxyl group of Mapracorat (i.e., through -O-SP-(L3 ) 0-1 -L 2 -) is connected to RG of the compound represented by formula (II), formula (II-P), formula II-P-1, or (2000). Table A

[0045] In some or any embodiments, the compound of formula (3000) or formula (2000) comprises a prodrug of a steroid in Table A, wherein SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 connect, The attachment point on the right hand side (i.e., N) is the same as L in equation (3000) or (L in equation (2000). 3 ) 0-1 Connected, -CH2-NH-, wherein N is connected to L in formula (3000) or to (L in formula (2000) 3 ) 0-1 connect, Where N is equal to L in formula (3000) or equal to (L in formula (2000) 3 ) 0-1 Connection, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 Connect and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -, where X 2 With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 Connect, or where X 4 With L in formula (3000) or with (L in formula (2000) 3 ) 0-1 connect.

[0046] In some embodiments, the present invention provides a compound represented by formula (IP): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; R 3 Yes-C(O)R Z or R Z Yes-C 4-10 -alkylene-C(O)OH or NR 15 R 15a ; R 15 is H or alkyl, and R 15a Yes-(C 1-6 -alkylene)-C(O)NHNH2; R c 、R d 、R e and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , Among them, each R g are independently -(C 1-6-alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl); or R c 、R d 、R e and R f middle One of the groups is hydroxyalkyl, and the others are -H; and m is 0 or 1.

[0047] In some embodiments, the present invention provides a compound represented by formula (IP-1): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; R 3 Yes-C(O)R Z or R Z Yes-C 4-10 -alkylene-C(O)OH or NR 5 R 5a ; R 15 is H or alkyl, and R 15a Yes-(C 1-6 -alkylene)-C(O)NHNH2; R c 、R d 、R e and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , Among them, each R g are independently -(C 1-6 -alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl); or R c 、R d 、R e and R f middle One of the groups is hydroxyalkyl, and the others are -H; and m is 0 or 1.

[0048] In some embodiments, the present invention provides a compound represented by formula (I), formula (IP), or formula (IP-1), wherein R4 In some embodiments, R 4 is not cycloalkyl. In some of these embodiments, R 4 is a straight chain or branched chain alkyl group. In some of these embodiments, R 4 In some of these embodiments, R 4 is arylalkyl. In some of these embodiments, R 4 is an N-containing heterocycloalkyl. In some embodiments, R 4 is an alkyl group, such as, but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or nonyl. 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is octyl or nonyl. In some embodiments, R 4 is an aryl group, such as, but not limited to, phenyl, phenol, or naphthyl. In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is a heteroaryl group, such as but not limited to a thienyl group. 4 is an arylalkyl group, such as but not limited to benzyl. In some embodiments, R 4 is a N-containing heterocycloalkyl group, such as but not limited to piperidinyl. In some embodiments of formula (I), two R x are both H. In some embodiments of Formula (I), two R x All are F.

[0049] In some or any embodiments, the present invention provides compounds of formula (I), wherein the two R x Both F, and R 3 Yes-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR50a R 50b or -C(O)R Z , and R Z It is NR 16 R 16a or -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , among which C1-C 10 -Alkylene groups are independently optionally substituted with one or more hydroxy groups.

[0050] In some embodiments of Formula (I), Formula (IP), or Formula (IP-1), two R x Both H, and R 3 Yes-C(O)R Z In some or any embodiments of Formula (I), (IP), or (IP-1), R Z Yes-C 4-10 -alkylene-C(O)OH. In some or any embodiments of Formula (I), (IP), or (IP-1), R Z Yes – C 4-6 -alkylene-C(O)OH. In some or any embodiments of Formula (I), (IP), or (IP-1), R Z Is -C4-alkylene-C(O)OH. In some or any embodiments of Formula (I), (IP), or (IP-1), R Z is -C5-alkylene-C(O)OH. In some or any embodiments of Formula (I), (IP), or (IP-1), R Z is -C6-alkylene-C(O)OH. In some or any embodiments of Formula (I), (IP), or (IP-1), R Z It is NR 15 R 15a In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 Is H or C 1-3 -alkyl, and R 15a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 is H or methyl, and R 15a Yes-(C 1-3-alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 It is H, and R 15a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 is methyl, and R 15a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 It is H, and R 15a is -(C1-alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), (IP), or (IP-1), R 15 is methyl, and R 15a is -(C1-alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 15 is H or C1-C6 alkyl, and R 15a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R 15 is H or C1-C3 alkyl, and R 15a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R 15 is H or CH3, and R 15a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R Z Yes-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , among which C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (I), R Z Yes -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a R 50b In some or any embodiments of Formula (I), R Z Yes -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR50a R 50b .

[0051] In some embodiments, the present invention provides a compound represented by formula (I), wherein a) Two Rs x Both are H; and R 3 Yes-C(O)R Z ;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b ;or R Z Yes-C 4-10 -alkylene-C(O)OH;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , where each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups; or NR 15 R 15a ; R 15 is H or C1-C6 alkyl, and R 15a Yes-(C1-C 10 -alkylene)-SH or -(C 1-6 -alkylene)-C(O)NHNH2; or b) Two Rs x Both are F; and R 3 Yes-C(O)R Z ;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b ;or R Z Yes-C 4-10 -alkylene-C(O)OH;-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , where each C1-C 10-alkylene is independently optionally substituted with one or more hydroxyl groups; or NR 16 R 16a ; R 16 is H or C1-C6 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-SH, -(C1-C 10 -alkylene)-NH2, -(C1-C 10 -alkylene)-NH(C 1-6 alkyl), or -(C 1-6 -alkylene)-C(O)NHNH2; and Each R 50 、R 50a and R 50b are each independently H or C1-C6-alkyl; R c 、R d 、R e and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , Among them, each R g are independently -(C 1-6 -alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl); or R c 、R d 、R e and R f middle One of the groups is hydroxyalkyl, and the others are -H; and m is 0 or 1.

[0052] In some embodiments of Formula (I), two R x Both F, and R 3 Yes-C(O)R Z In some or any embodiments, R z yes In some or any embodiments of Formula (I), R Z Yes-C 4-10 -alkylene-C(O)OH. In some or any embodiments of Formula (I), R Z Yes – C 4-6 -alkylene-C(O)OH. In some or any embodiments of Formula (I), R Zis -C4-alkylene-C(O)OH. In some or any embodiments of Formula (I), R Z is -C5-alkylene-C(O)OH. In some or any embodiments of Formula (I), R Z is -C6-alkylene-C(O)OH. In some or any embodiments of Formula (I), R Z It is NR 16 R 16a In some or any embodiments of Formula (I), R 16 Is H or C 1-3 -alkyl, and R 16a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 is H or methyl, and R 16a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 It is H, and R 16a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 is methyl, and R 16a Yes-(C 1-3 -alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 It is H, and R 16a is -(C1-alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 is methyl, and R 16a is -(C1-alkylene)-C(O)NHNH2. In some or any embodiments of Formula (I), R 16 is H or C1-C6 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R 16 is H or C1-C3 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R 16 is H or CH3, and R 16a Yes-(C1-C 10 -alkylene)-SH. In some or any embodiments of Formula (I), R 16 is H or C1-C6 alkyl, and R 16a Yes-(C1-C 10-alkylene)-NH2. In some or any embodiments of Formula (I), R 16 is H or C1-C3 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-NH2. In some or any embodiments of Formula (I), R 16 is H or CH3, and R 16a Yes-(C1-C 10 -alkylene)-NH2. In some or any embodiments of Formula (I), R 16 is H or C1-C6 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-NH(C 1-6 In some or any embodiments of Formula (I), R 16 is H or C1-C3 alkyl, and R 16a Yes-(C1-C 10 -alkylene)-NH(C 1-6 In some or any embodiments of Formula (I), R 16 is H or CH3, and R 16a Yes-(C1-C 10 -alkylene)-NH(C 1-6 In some or any embodiments of Formula (I), R Z Yes-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b , where each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (I), R Z Yes -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a R 50b In some or any embodiments of Formula (I), R Z Yes -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a R 50b .

[0053] In some embodiments of Formula (I), (IP), or (IP-1), two R x Both H, and R 3 Yes-(C1-C 10 -alkylene)-NR50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), (IP), or (IP-1), R 3 is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), (IP), or (IP-1), R 3 is -(C1-C3-alkylene)-NR 50 C(O)-(C1-C3-alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), (IP), or (IP-1), R 3 is -(straight chain C1-C3-alkylene)-NR 50 C(O)-(straight-chain C1-C3-alkylene)-NR 50a R 50b .

[0054] In some embodiments of Formula (I), two R x Both F, and R 3 Yes-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), R 3 is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), R 3 is -(C1-C3-alkylene)-NR 50 C(O)-(C1-C3-alkylene)-NR 50a R 50b In some or any embodiments of Formula (I), R 3 is -(straight chain C1-C3-alkylene)-NR 50 C(O)-(straight-chain C1-C3-alkylene)-NR 50a R 50b .

[0055] In some embodiments of Formula (I), (IP), or (IP-1), two Rx Both H, and R 3 yes In some embodiments of Formula (I), (IP), or (IP-1), m is 0. In some embodiments of Formula (I), (IP), or (IP-1), m is 1. In some embodiments of Formula (I), (IP), or (IP-1), m is 1, and R f is -H or -OH. In some embodiments of Formula (I), (IP), or (IP-1), m is 1. In some embodiments of Formula (I), (IP), or (IP-1), m is 1, and R c 、R d 、R e and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , where each R g are independently -(C 1-6 -alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl). In some embodiments of Formula (I), (IP), or (IP-1), m is 1, and R c Yes-CH2OR g , and the others are each independently -H, -OH, or hydroxyalkyl. In some embodiments of Formula (I), (IP), or (IP-1), m is 1, and R c 、R d 、R e and R f One of the Rs is hydroxyalkyl, and the others are -H. In some embodiments of Formula (I), (IP), or (IP-1), m is 1, and R c is a hydroxyalkyl group, and R d 、R e and R f All are -H.

[0056] In some embodiments of Formula (I), two R x Both F, and R 3 yes In some embodiments of formula (I), m is 0. In some embodiments of formula (I), m is 1. In some embodiments of formula (I), m is 1, and R f is -H or -OH. In some embodiments of Formula (I), m is 1. In some embodiments of Formula (I), m is 1, and R c 、R d 、Re and R f One of them is -CH2OR g , and the others are independently -H, -OH, hydroxyalkyl, -C(O)OH, or -CH2OR g , where each R g are independently -(C 1-6 -alkylene)-C(O)OH or -(C 1-6 -alkylene)-C(O)O(alkyl). In some embodiments of Formula (I), m is 1, and R c Yes-CH2OR g , and the others are each independently -H, -OH, or hydroxyalkyl. In some embodiments of formula (I), m is 1, and R c 、R d 、R e and R f One of the Rs is hydroxyalkyl, and the others are -H. In some embodiments of Formula (I), m is 1, and R c is a hydroxyalkyl group, and R d 、R e and R f All are -H.

[0057] In some embodiments of Formula (I), two R x Both F, and R 3 yes

[0058] In some or any embodiments, the present invention provides a compound of formula (Z): in R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; Two R's x Both H, or two R x Both are F; and SP is -CH2NH-, wherein said NH is attached to H, or SP is wherein the NH of SP is connected to H in formula (Z), or SP is wherein the N of SP is connected to H in formula (Z). In some or any embodiments, the two R x are both H. In some or any embodiments, two R x In some or any embodiments, R 4 In some or any embodiments, R 4 In some or any embodiments, R 4is an alkyl group, such as, but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or nonyl. 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some or any embodiments, SP is -CH2NH-, wherein said NH is attached to H. In some or any embodiments, SP is wherein NH is linked to H in formula (Z). In some or any embodiments, R 4 It is an alkyl group, with two R x are F, and SP is wherein NH is connected to H in formula (Z). In some embodiments, the compound represented by formula (Z) is In some embodiments, the compound represented by formula (Z) is In some embodiments, the compound represented by formula (Z) is In some embodiments, the compound represented by formula (Z) is

[0059] Steroid compounds suitable for use in the conjugates of the present invention include those listed in the following table. Table 1. Budesonide-Spacer (Budesonide-SP) or its stereoisomers or mixtures of stereoisomers; and optionally its pharmaceutically acceptable salts, solvates or stereoisomers. In some embodiments, in each of the above structural formulas The n-propyl group is in the R configuration, i.e., in the R configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is in the S configuration, i.e., in the S configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0060] In some embodiments of formula (I), the present invention provides a compound shown in formula 1d, 1e, 1g, 1h, 101a, 101b, 101c, 101d, 102c, 102d, 102e, 102f, 103a, 103b, 104a, or 104b, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments of formula (I), the present invention provides a compound shown in formula 1d, 1e, 1g, or 1h, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. In some embodiments, the n-propyl group of the compound shown in formula 1d, 1e, 1g, 1h, 101a, 101b, 101c, 101d, 102c, 102d, 102e, 102f, 103a, 103b, 104a, and 104b is in the R configuration. In some embodiments, the n-propyl group of the compounds of Formulas 1d, 1e, 1g, 1h, 101a, 101b, 101c, 101d, 102c, 102d, 102e, 102f, 103a, 103b, 104a, and 104b is in the S configuration. In some embodiments, the n-propyl group of the compounds of Formulas 1d, 1e, 1g, 1h, 101a, 101b, 101c, 101d, 102c, 102d, 102e, 102f, 103a, 103b, 104a, and 104b is a mixture of R and S configurations. In some embodiments, the n-propyl group of the compounds represented by Formula 1d, 1e, 1g, 1h, 101a, 101b, 101c, 101d, 102c, 102d, 102e, 102f, 103a, 103b, 104a, and 104b is a mixture of R and S configurations, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0061] Included within the scope of the present invention are pharmaceutically acceptable salts, solvates, crystalline forms, amorphous forms, polymorphic forms, regioisomers, stereoisomers, metabolites, and physiological adducts of the steroid payloads described herein. C. Protein-steroid conjugates

[0062] The present invention provides protein conjugates of the steroid compounds of the present invention. Such conjugates include proteins, such as antibodies or antigen-binding fragments thereof, which are, for example, conjugated to the steroid compounds of the present invention by -L- and -L- 1 -L 2 -(L 3 ) 0-1 - covalently linked to a compound as described in Section B above.

[0063] In some or any embodiments, the present invention provides a compound of formula (3000): BA-(L-SP-D) z or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in, D is selected from a) The two R in formula (a) x Both H; R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 Connected to L in formula (3000), -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (3000), -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (3000), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (3000), -CH2-NH-, wherein the N is connected to L in formula (3000), wherein the N is connected to L in formula (3000) and wherein Ar is an optionally substituted arylene group (in some embodiments, ) or optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and formula (3000) The L connection in -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and formula (3000) The L connection and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene -C(O)NH-X 2 -, where X 2 Connected to L in formula (3000), or where X 4 and formula (3000) L connection in; or The two R in formula (a) x All are F; R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b Connected to L in formula (3000), -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Connected to L in formula (3000), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (3000), -CH2-NH-, wherein N is connected to L in formula (3000), wherein the N is connected to L in formula (3000) and wherein Ar is an optionally substituted arylene group (in some embodiments, ) or optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50aConnected to L in formula (3000), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (3000) and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Connected to L in formula (3000), or where X 4 connected to L in formula (3000); and b) Compounds in Table A above, wherein the compounds in Table A are hydroxylated via a -C(O)CH2OH group (i.e., via -C(O)CH2-O-SP-L-), or connected to BA of the compound represented by formula (3000) through the hydroxyl group of Mapracorat (i.e., through -O-SP-L-); X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g, where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; z is an integer selected from 1 to 30 (inclusive); L is a linker; and BA is a binding agent.

[0064] In some or any embodiments, the present invention provides a compound of formula (III-P): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, wherein: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 Connected to L in formula (III), -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Connected to L in formula (III), or where X 4 Connected to L in formula (III); X 1 Yes-N(C 1-3 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or alkyl; R d 、R e and R fare independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; z is an integer selected from 1 to 30 (inclusive); L is a linker; and BA is a binding agent.

[0065] In some or any embodiments, the present invention provides a compound of formula (III-P-1): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 Connected to L in formula (III), -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Connected to L in formula (III), or where X 4 Connected to L in formula (III); X 1 Yes-N(C 1-3 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; z is an integer selected from 1 to 30 (inclusive); L is a linker; and BA is a binding agent.

[0066] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein R 4 In some embodiments, R 4 is not cycloalkyl. In some of these embodiments, R 4 is a straight chain or branched chain alkyl group. In some of these embodiments, R 4 In some of these embodiments, R 4 is arylalkyl. In some of these embodiments, R 4 is an N-containing heterocycloalkyl. In some embodiments, R 4 is an alkyl group, such as, but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or nonyl. 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is octyl or nonyl. In some embodiments, R 4 is an aryl group, such as, but not limited to, phenyl, phenol, or naphthyl. In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R4 is a heteroaryl group, such as but not limited to a thienyl group. 4 is an arylalkyl group, such as but not limited to benzyl. In some embodiments, R 4 is a heterocycloalkyl group containing N, such as but not limited to piperidinyl. In some or any embodiments, two R x are both H. In some or any embodiments, two R x In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is a mixture of R and S configurations. 4 It is a mixture of R and S configurations, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0067] In some embodiments, the present invention provides a compound represented by formula (III), wherein Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 Connected to L in formula (III), (III-P), or (III-P-1); -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is the same as formula (III), (III-P) or (III-P-1) in which L is connected; -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), (III-P), or (III-P-1); -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With formula (III), (III-P), or L in (III-P-1) is connected; -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a-, of which NR 50a Connected to L in formula (III), (III-P), or (III-P-1) and each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxyl groups; -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 is connected to L in formula (III), (III-P), or (III-P-1); or where X 4 Connected to L in formula (III), (III-P), or (III-P-1) or Two R's x are F; and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b Connected to L in formula (III), (III-P), or (III-P-1); -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b connected to L in formula (III), (III-P), or (III-P-1); The right-hand attachment point (ie, N) is connected to L in formula (III); -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a connected to L in formula (III), (III-P), or (III-P-1); -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III), (III-P), or (III-P-1) and each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxyl groups, or -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2Connected to L in formula (III), (III-P), or (III-P-1).

[0068] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein the two R x are H, and SP is -C(O)-C1-C 10 -alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-C2-C5-alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-CH2CH2-C(O)-.

[0069] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are all F, and SP is -C(O)-C1-C 10 -alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-C2-C5-alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-CH2CH2-C(O)-.

[0070] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein the two R x are H, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (III), (III-P), or (III-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (III), (III-P), or (III-P-1) 3 In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein X 1 Yes-N(C 1-3In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(C 1-3 alkyl)-C2-C5-alkylene-X 1 In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(C 1-3 alkyl)-CH2CH2-X 1 -. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(CH3)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-.

[0071] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are F, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (III) 3 Connection, or -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-C1-C6-alkylene-X 1b -, where X 1b and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-C1-C3-alkylene-X 1b -, where X 1b and L in formula (III) 3In some embodiments, the present invention provides a compound represented by formula (III), wherein SP is -C(O)-N(H)-CH2CH2-X 1b -. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-C2-C5-alkylene-N(CH2CH3)-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-CH2CH2-N(CH3)-.

[0072] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are F, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-C1-C6-alkylene-X 1b -, where X 1b and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-C1-C3-alkylene-X 1b -, where X 1b and L in formula (III) 3 In some embodiments, the present invention provides a compound represented by formula (III), wherein X 1b Yes-N(C 1-3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-C2-C5-alkylene-X 1b In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-CH2CH2-X 1b-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(CH3)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(CH2CH3)-C2-C5-alkylene-N(CH2CH3)-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-.

[0073] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are F, and SP is The right-hand attachment point (ie, N) is connected to L in formula (III).

[0074] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are H, and SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), or -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III), or -C(O)-N(C 1-3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III). 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound represented by formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III).

[0075] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are all F, and SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), or -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III), or -C(O)-N(C 1-3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III). 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III). In some embodiments, the present invention provides a compound represented by formula (III), wherein SP is -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (III).

[0076] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are H, and SP is -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a is connected to L in formula (III). In some or any embodiments of formula (I), SP is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(C1-C3-alkylene)-NR 50C(O)-(C1-C3-alkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(linear C1-C3-alkylene)-NR 50 C(O)-(straight-chain C1-C3-alkylene)-NR 50a -.

[0077] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are all F, and SP is -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a is connected to L in formula (III). In some or any embodiments of formula (I), SP is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(C1-C3-alkylene)-NR 50 C(O)-(C1-C3-alkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(linear C1-C3-alkylene)-NR 50 C(O)-(straight-chain C1-C3-alkylene)-NR 50a -.

[0078] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are H, and SP is -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a - connected to L in formula (III) and each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (III), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a -.

[0079] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are F, and SP is -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a - connected to L in formula (III) and each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (III), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a In some or any embodiments of Formula (III), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a -.

[0080] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are H, and SP is -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(R 5 )-C1-C5-alkylene-C(O)NH-NH-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(R 5 )-CH2-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (III), wherein R 5 In some embodiments, the present invention provides a compound of formula (III), wherein R 5 It is H or CH3.

[0081] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x are F, and SP is -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2and L in formula (III) 3 In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(R 5 )-C1-C5-alkylene-C(O)NH-NH-. In some embodiments, the present invention provides a compound of formula (III), wherein SP is -C(O)-N(R 5 )-CH2-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (III), wherein R 5 In some embodiments, the present invention provides a compound of formula (III), wherein R 5 It is H or CH3.

[0082] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein the two R x are H, and SP is where X 4 and L in formula (III), (III-P), or (III-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (III), (III-P), or (III-P-1), wherein the two R x are F, and SP is where X 4 and L in formula (III), (III-P), or (III-P-1) 3 In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is and X 3 In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is and X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein SP is and X 3 In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein R d 、R e and R fare independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein R d and R e are independently -H or -OH. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein m is 0. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein m is 1. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein m is 1, and R f It is -H or –OH.

[0083] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein the two R x are H, and SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (III), (III-P), or (III-P-1) 3 connection; SP is where X 3 is -CH2-, m is 1, and R d 、R e and R f All are -H; or SP is where X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 connection, m is 1, and R d 、R e and R f In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-, In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein the two R xare F, and SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (III), (III-P), or (III-P-1) 3 connection; SP is where X 3 is -CH2-, m is 1, and R d 、R e and R f All are -H; or SP is where X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 connected, m is 1, and R d 、R e and R f In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-,

[0084] In some embodiments, the present invention provides a compound of formula (III), wherein the two R x All F or two R x Both H or R x As specified in this paragraph; SP is (Two of the R x All are F), (Two of the R x All are F),

[0085] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein z is 1. In some embodiments, z is 2. In some other embodiments, z is 3. In some embodiments, z is 4. In some embodiments, z is 5. In some other embodiments, z is 6. In some embodiments, z is 7. In some other embodiments, z is 8. In some embodiments, z is 9. In some embodiments, z is 10. In some other embodiments, z is 11. In some other embodiments, z is 12. In some other embodiments, z is 13. In some other embodiments, z is 14. In some other embodiments, z is 15. In some other embodiments, z is 15. In some other embodiments, z is 16. In some other embodiments, z is 17. In some other embodiments, z is 18. In some embodiments, z is 19. In some other embodiments, z is 20. In some other embodiments, z is 21. In some other embodiments, z is 22. In some other embodiments, z is 23. In some other embodiments, z is 24. In some other embodiments, z is 25. In some other embodiments, z is 26. In some other embodiments, z is 27. In some other embodiments, z is 28. In some other embodiments, z is 29. In some other embodiments, z is 30. In some embodiments, z is an integer selected from 1-15 (inclusive). In certain embodiments, z is selected from 1-10. In certain embodiments, z is selected from 1-5. In certain embodiments, z is selected from 2-5. In certain embodiments, z is selected from 2-4.

[0086] In some embodiments, -L- or -L in Formula (III), (III-P), or (III-P-1) 1 -L 2 -(L 3 ) 0-1 -, refers to any divalent group or group portion that allows a binding agent (e.g., an antibody or antigen-binding fragment thereof) to be linked, attached, or bound to a payload compound (e.g., a steroid) according to the present invention. Typically, suitable -L- or -L- conjugates of the antibody conjugates of the present invention are 1 -L 2 -(L 3 ) 0-1- are those that are sufficiently stable to take advantage of the circulating half-life of the antibody and at the same time are capable of releasing their payload upon antigen-mediated internalization of the conjugate. Linkers can be cleavable or non-cleavable. Cleavable linkers are linkers that are cleaved by intracellular metabolism after internalization, for example by hydrolysis, reduction or enzymatic reaction. Non-cleavable linkers are linkers that release the attached payload by lysosomal degradation of the antibody after internalization. Suitable linkers include, but are not limited to, acid-labile linkers, hydrolytically unstable linkers, enzymatically cleavable linkers, reduction-labile linkers, self-immolative linkers and non-cleavable linkers. Suitable linkers also include, but are not limited to, linkers that are or contain glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, carbamates, hydrazones, maleimido-caproyl units, disulfide units (e.g., –S–S–, –SSC (R 1 )(R 2 )–, where R 1 and R 2 are independently hydrogen or hydrocarbon), p-aminobenzyl (PAB) units, phosphate units, such as mono-, di- or tri-phosphate units, and peptides, such as peptide units containing 2, 3, 4, 5, 6, 7, 8, or more amino acid units, including but not limited to valine-citrulline units, valine-alanine units, valine-arginine units, valine-lysine units, -lysine-valine-citrulline units and -lysine-valine-alanine units. In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 - are derived from the reaction of the "active group" (RG) of formula (II) (and its embodiments) with the active portion of the antibody. The linking group is any divalent group that bridges the BA to the payload. The linking group can also be any trivalent group that bridges the BA, payload, and cyclodextrin moieties. In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 -L- and -L- are trivalent and include a cyclodextrin moiety linked to a trivalent group (e.g., a lysine residue) in the linking group. 1 -L 2 -(L 3 ) 0-1 - all contain a reactive group residue, which is a functional group or group portion that reacts with the active portion of the antibody, modified antibody or antigen-binding fragment thereof.

[0087] In some embodiments, the present invention provides compounds of formula (III), (III-P), or (III-P-1), wherein L and -L 1 -L 2 -(L 3 ) 0-1 -All included or its regioisomers or mixtures of isomers; or a stereoisomer or a mixture of stereoisomers thereof, wherein S refers to the S atom on a cysteine ​​residue, and the active group residue is linked to BA via the S atom on the cysteine ​​residue; or Wherein N refers to the N atom on the lysine residue, and the active group residue is connected to BA via the N atom on the lysine residue.

[0088] In some embodiments, the present invention provides compounds of formula (III), (III-P), or (III-P-1), wherein L and -L 1 -L 2 -(L 3 ) 0-1 -All included

[0089] In some embodiments, the present invention provides compounds of formula (III), (III-P), or (III-P-1), wherein L and -L 1 -L 2 -(L 3 ) 0-1 -All included or its regioisomers or mixtures of isomers; or a stereoisomer or a mixture of stereoisomers thereof, wherein S refers to the S atom on a cysteine ​​residue, and the active group residue is linked to BA via the S atom on the cysteine ​​residue; or Wherein N refers to the N atom on the lysine residue, and the active group residue is connected to BA via the N atom on the lysine residue; and L and -L 1 -L 2 -(L 3 ) 0-1 -All included

[0090] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -. In some embodiments, there is L 3 In some embodiments, L3 Does not exist.

[0091] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 1 Selected from or its regioisomers or mixtures of isomers; or a stereoisomer or a mixture of stereoisomers thereof, wherein S refers to the S atom on a cysteine ​​residue, and the active group residue is linked to BA via the S atom on the cysteine ​​residue; or Wherein N refers to the N atom on the lysine residue, and the active group residue is connected to BA via the N atom on the lysine residue. In some embodiments, the present invention provides a compound represented by formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 1 yes In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 1 yes In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 1 yes In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 1 yes In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3) 0-1 -, and L 1 yes

[0092] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 3 yes wherein the NH group and L 2 Connection, when SP is -C(O)-C1-C 10 -alkylene-C(O)-; or L 3 yes wherein the NH group and L 2 Connection, when SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -or-C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -; or L 3 Does not exist, when SP is In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 )-, and L 3 yes wherein the NH group and L 2 Connection, when SP is -C(O)-C1-C 10 -alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 3 yes wherein the NH group and L 2 Connection, when SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -or-C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 3 Does not exist, when SP is

[0093] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 2 Include -C(O)CH2CH2C(O)NH-, -OCH2C(O)-, or cyclodextrin residue (CD); or a combination thereof. In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 2 Include In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and L 2 Containing a CD, wherein the CD is selected from the group consisting of:

[0094] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L is -L 1 -L 2 -(L 3 ) 0-1 -, and -L2 -(L 3 ) 0-1 -Include

[0095] In some embodiments, the present invention provides a compound of formula (III), (III-P), or (III-P-1), wherein L 2 Include L 1a is the active group residue; CD is cyclodextrin; AA 4 It is a trivalent linker; AA 5 is the peptide residue; PEG is polyethylene glycol; a is an integer selected from 0 to 5 inclusive. In some embodiments, AA 4 is an amino acid residue; AA 5 is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue; PEG is a polyethylene glycol residue; wherein represents the atom through which the indicated chemical group is attached to the adjacent group in the formula, CD, at each occurrence, is each independently absent or each independently a cyclodextrin residue, wherein at least one CD is present, and subscript a is an integer selected from 0 to 5 (inclusive); in these embodiments, subscript a is 0, 1, 2, 3, 4, or 5. In some embodiments, subscript a is 0. In some embodiments, subscript a is 1. In some embodiments, subscript a is 2. In some embodiments, subscript a is 3. In some embodiments, subscript a is 4. In some embodiments, subscript a is 5. In some embodiments, AA 4 or AA 5 In some embodiments, any of the amino acids AA, AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA 4is an amino acid selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine or citrulline, a derivative thereof, or a combination thereof. In certain embodiments, AA 4 is lysine or a derivative of lysine. In certain embodiments, AA 4 In certain embodiments, AA 4 In certain embodiments, AA 4 In certain embodiments, the AA 5 is a dipeptide residue. In certain embodiments, the AA 5 In certain embodiments, the AA 5 In certain embodiments, the AA 5 In certain embodiments, the AA 5 In certain embodiments, the AA 5 In certain embodiments, the AA 5 In certain embodiments, the AA 5 is a tripeptide residue. In certain embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 is a tetrapeptide residue. In some embodiments, the AA 5 In some embodiments, the AA 5 is a pentapeptide residue. In some embodiments, the AA 5 It's glycine-glycine-glycine-glycine-glycine.

[0096] In certain embodiments, the reactive group residue is derived from the reaction of RG with a cysteine ​​residue or a lysine residue of an antibody or antigen-binding fragment thereof. In certain embodiments, the reactive group residue is derived from a click chemistry reaction. In some embodiments of the click chemistry reaction, L 1Derived from a 1,3-cycloaddition reaction between an alkyne and an azide. Non-limiting examples of such reactive group residues include those derived from strained alkynes, such as those suitable for strain-promoted alkyne-azide cycloaddition (SPAAC), cycloalkynes such as cyclooctynes, benzoannulated alkynes, and alkynes capable of undergoing a 1,3-cycloaddition reaction with an azide in the absence of a copper catalyst. Suitable L 1 Also included are but not limited to those derived from DIBAC (wherein the -C(O)CH2CH2C(O)- portion of the DIBAC group is replaced by L 2 ), DIBO (wherein the -O- portion of the DIBO group is replaced by L 2 Contains), BARAC (wherein the BARAC group part of the Partly L 2 Conjugates comprising such reactive group residues may be derived from antibodies that have been functionalized with an azide group. Such functionalized antibodies include antibodies functionalized with an azide-polyethylene glycol group. In certain embodiments, such functionalized antibodies are derived from reacting an antibody comprising at least one glutamine residue with a compound of the formula H2N-LL-N3 in the presence of an enzyme transglutaminase (e.g., a microbial transglutaminase), wherein LL is a divalent polyethylene glycol group. Suitable glutamine residues of antibodies include Q295, or those derived by insertion or mutation, such as an N297Q mutation.

[0097] In some embodiments, the BA of the conjugate of the present invention is an antibody or an antigen-binding fragment thereof. In some embodiments, the conjugate of the present invention is derived from an azide-functionalized antibody. In certain embodiments, the BA of the conjugate of the present invention is: wherein Ab is an antibody or antigen-binding fragment thereof, n is an integer selected from 1 to 10 (inclusive), z is the number of linker payload moieties, and Is with L or –L 1 -L 2 -(L 3 ) 0-1 -attached bond, for example, is a bond to a moiety derived from a 1,3-cycloaddition reaction between an alkyne and an azide. In certain embodiments, z is 3. In certain embodiments, z is 2 or 4, i.e., the conjugate comprises 2 or 4 linker payload moieties.

[0098] In some embodiments, -L- and -L 1 -L 2 -L 3 - are all formula (LA ) shown as a divalent group portion; –L 1 –(SP 1 ) q –(A) z –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w – (L A ); Among them L 1 Having the definition described in the present invention; A is an amino acid or peptide; R a is H or alkyl; B is aryl, heteroaryl, or heterocycloalkyl, wherein the aryl, heteroaryl, or heterocycloalkyl is optionally substituted by alkyl, -OH, or -NR a R b replace; SP 1 and SP 2 and q, z, s, t, u, v, and w are each independently 0 or 1.

[0099] In some other embodiments, -L- and -L 1 -L 2 -L 3 - are all formula (L B ) shown as a trivalent group portion; –L 1 –(SP 1 ) q –(A) z –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w – (L B ); Among them L 1 Having the definition described in the present invention; A is a tripeptide or tetrapeptide, wherein at least one amino acid of the tripeptide or tetrapeptide is directly or indirectly linked to a cyclodextrin moiety; R a is H or alkyl; B is aryl, heteroaryl, or heterocycloalkyl, wherein the aryl, heteroaryl, or heterocycloalkyl is optionally substituted by alkyl, -OH, or -NR a R b replace; SP 1 and SP 2 and q, z, s, t, u, v, and w are each independently 0 or 1.

[0100] In some embodiments, the cyclodextrin (CD) is directly connected to an amino acid residue, such as a lysine amino acid residue. This means that the CD is one key position away from the lysine amino acid covalent linker. In some of these embodiments, the covalent linker is also directly connected to a payload group portion. This means that the covalent linker is one key position away from a payload (such as, but not limited to, a steroid payload of the present invention). In some of these embodiments, the covalent linker is also directly connected to a CD group portion. This means that the covalent linker is one key position away from a CD (such as, for example, a CD of the present invention). In some of these embodiments, the covalent linker is a lysine amino acid or a derivative thereof.

[0101] In some embodiments, the CD is indirectly linked to a linker group (e.g., L, -L 2 -(L 3 ) 0-1 - and –L 1 -L 2 -(L 3 ) 0-1). This means that the CD is more than one bond position away from the covalent linker. This also means that the CD is connected to the covalent linker through another group portion. For example, the CD can be connected to a maleimide group, which is connected to a polyethylene glycol group, which is connected to the covalent linker. In some of these embodiments, the covalent linker is also indirectly connected to a payload group portion. This means that the covalent linker is more than one bond position away from a payload (such as, but not limited to, a steroid payload of the present invention). This also means that the covalent linker is connected to the payload through another group portion. For example, the covalent linker can be connected to a dipeptide, such as, but not limited to, Val-Ala or Val-Cit, which can be connected to a p-aminobenzoyl group, which can be connected to the payload. In some of these embodiments, the covalent linker is also indirectly connected to a cyclodextrin group portion. This means that the covalent linker is more than one bond position away from the cyclodextrin (e.g., the cyclodextrin of the present invention). This also means that the covalent linker is attached to the cyclodextrin through another moiety. For example, the covalent linker can be attached to a polyethylene glycol group, which can be attached to a reactive group, which can be attached to the cyclodextrin. In some of these embodiments, the covalent linker is a lysine amino acid or a derivative thereof.

[0102] In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 -All are –L 1 –(SP 1 ) q –(A) z– In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 -All are –L 1 –(SP 1 ) q –(A) 2– In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 - are all formula (L A1 ) shown in the group part: where R AA1 and R AA2 Each is independently an amino acid side chain. A1In some embodiments, SP 1 is a divalent polyethylene glycol group, and L 1 It is the 1,3-cycloaddition product of the reaction between alkynes and azides.

[0103] In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 -All are –L 1 –(SP 1 ) q –(A) z In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 -All are –L 1 –(SP 1 ) q –(A)2–. In some embodiments, -L- and -L 1 -L 2 -(L 3 ) 0-1 - are all formula (L B1 ) shown in the group part: where R AA1 and R AA2 Each is independently an amino acid side chain. AA3 is an amino acid side chain directly or indirectly linked to a cyclodextrin moiety. B1 In some embodiments, SP 1 is a divalent polyethylene glycol group, and L 1 It is the 1,3-cycloaddition product of the reaction between alkynes and azides.

[0104] In some embodiments, -L- or -L 1 -L 2 -L 3 - has the following structure: –L 1 –(SP 1 )q–Z 1 –Z 2 –Z 3 0–1 – in: L 1 and SP 1 All have the definitions described in the present invention; q is 0 or 1; Z 1is a polyethylene glycol group or a hexanoyl group; Z 2 is a dipeptide, tripeptide, or tetrapeptide; and Z 3 It is a PAB group. In some embodiments, L 1 Derived from click chemistry active groups, and Z 1 is a polyethylene glycol group. In certain embodiments, L 1 -(SP 1 )qZ 1 -yes: or a mixture thereof; or In some embodiments, the dipeptide is valine-citrulline or valine-alanine. In some embodiments, the tripeptide is glutamic acid-valine-citrulline. In some embodiments, the tetrapeptide is glycine-glycine-phenylalanine-glycine.

[0105] In some embodiments, the L 1 Derived from a click chemistry active group. In some embodiments, L 1 yes: or a mixture thereof; or a mixture thereof; wherein It is the bond connecting to the binding agent.

[0106] In some other embodiments, the L 1 is selected from a group that reacts with a cysteine ​​residue or a lysine residue on an antibody or antigen-binding fragment thereof. 1 yes in It is a bond to a cysteine ​​residue of a binding agent (eg, an antibody). In some embodiments, L 1 yes

[0107] In some embodiments, SP 1 Selected from: In some embodiments, SP 1 yes In some other embodiments, SP 1 yes In other embodiments, SP 1 yes In other embodiments, SP 1 yes In some other embodiments, SP 1 yes In any of the above embodiments, the subscripts a, b, and c are each independently an integer selected from 1 to 20, inclusive.

[0108] In some embodiments, R AA3 Selected from wherein CD is a cyclodextrin moiety. In some embodiments, R AA3 Selected from

[0109] In some embodiments, SP 1 Selected from:

[0110] In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes

[0111] In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes

[0112] In some embodiments, -L 1 -L 2 -Include: or a mixture thereof; or a mixture thereof; or a mixture thereof; or wherein b, c, and d, at each occurrence, are independently selected from integers from 1 to 20, inclusive. In some of these embodiments, the subscripts b, c, and d, at each occurrence, are independently selected from integers from 1 to 6, inclusive.

[0113] In some embodiments, –SP 1 Selected from: or a mixture thereof; or a mixture thereof thing;

[0114] In some embodiments, A is a peptide selected from valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, asparagine-threonine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid-asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, or asparagine-alanine.

[0115] In some embodiments, A is valine-citrulline, or citrulline-valine.

[0116] In some embodiments, A is valine-alanine, or alanine-valine.

[0117] In some embodiments, A is lysine-valine-alanine, or alanine-valine-lysine.

[0118] In some embodiments, A is lysine-valine-citrulline, or citrulline-valine-lysine.

[0119] In some embodiments, A is glutamate-valine-citrulline, or citrulline-valine-glutamate.

[0120] In some embodiments, A is valine.

[0121] In some embodiments, A is alanine.

[0122] In some embodiments, A is citrulline.

[0123] In some embodiments, A is In some of these embodiments, R AA1 is an amino acid side chain, and R AA2 It is the amino acid side chain.

[0124] In some embodiments, A is In some of these embodiments, R AA1 is the amino acid side chain, R AA2 is the amino acid side chain, and R AA3 It is an amino acid side chain that is directly or indirectly linked to a cyclodextrin moiety.

[0125] In some embodiments, A is

[0126] In some embodiments, A is

[0127] In some embodiments, A is

[0128] In some embodiments, A is in represents a bond directly or indirectly attached to a cyclodextrin moiety.

[0129] In some embodiments, including any of the preceding embodiments, CD, at each occurrence, is independently selected from In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is

[0130] In some embodiments, A is or its isomers.

[0131] In some embodiments, R a It’s H.

[0132] In some embodiments, R a It is an alkyl group.

[0133] In some embodiments, R a is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, or pentyl.

[0134] In some embodiments, B is aryl.

[0135] In some embodiments, B is phenyl.

[0136] In some embodiments, B is phenyl or pyridinyl.

[0137] In some embodiments of the invention, B is: In these embodiments, R 10 is alkyl, alkenyl, alkynyl, alkoxy, aryl, alkylaryl, arylalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, heterocycloalkyl, hydroxy, cyano, nitro, NR a R b In these embodiments, the subscripts p and m are each independently selected from integers from 0 to 4 (inclusive).

[0138] In some embodiments of the invention, B is: In these embodiments, p is 0, 1, 2, 3, or 4. In some of these embodiments, R 1 In each occurrence, is independently alkyl, alkoxy, haloalkyl, or halogen. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 It's a halogen.

[0139] In the formula (L A ) in some embodiments, the –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w yes:

[0140] In the L or L 1 -L 2 -(L 3 ) 0-1 In any embodiment of the present invention, one or more enhancement groups may be combined with L or L 1 -L 2 -(L 3 ) 0-1The side chain of any amino acid in the amino acid is connected. Useful amino acids for connecting the enhancing group include lysine, asparagine, aspartic acid, glutamine, glutamic acid, and citrulline. The connection to the enhancing group can be a key directly connected to the amino acid side chain, or the connection can be indirectly connected via a spacer group and / or an active group. Useful spacer groups and active groups include any spacer groups and active groups described in the present invention. The enhancing group can be any group that a person skilled in the art considers useful. For example, the enhancing group can be any group that imparts a beneficial effect to a compound, a payload, a linker payload, or an antibody conjugate, including but not limited to biology, biochemistry, synthesis, solubilization, imaging, detection, and reactive effects, etc. In certain embodiments, the enhancing group is a hydrophilic group. In certain embodiments, the enhancing group is a cyclodextrin. In certain embodiments, the enhancing group is an alkyl sulfonic acid, a heteroalkyl sulfonic acid, an alkylene sulfonic acid, a heteroalkylene sulfonic acid, a heteroalkylene taurine, a heteroalkylene phosphoric acid or a phosphate ester, a heteroalkylene amine (e.g., a quaternary amine), or a heteroalkylene sugar. In certain embodiments, carbohydrates include but are not limited to monosaccharides, disaccharides, and polysaccharides. Exemplary monosaccharides include glucose, ribose, deoxyribose, xylose, arabinose, mannose, galactose, fructose, and the like. In certain embodiments, sugars include sugar acids, such as glucuronic acid, and also include conjugated forms, such as glucuronides (i.e., by glucuronidation). Exemplary disaccharides include maltose, sucrose, lactose, lactulose, trehalose, and the like. Exemplary polysaccharides include amylose, amylopectin, glycogen, inulin, cellulose, and the like. Cyclodextrin can be any cyclodextrin known to those skilled in the art. In certain embodiments, the cyclodextrin is α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, or a mixture thereof. In certain embodiments, the cyclodextrin is α-cyclodextrin. In certain embodiments, the cyclodextrin is β-cyclodextrin. In certain embodiments, the cyclodextrin is γ-cyclodextrin. In certain embodiments, the reinforcing group can improve the solubility of the remainder of the conjugate.

[0141] In certain embodiments, the reinforcing group is an alkylsulfonic acid, a heteroalkylsulfonic acid, an alkylenesulfonic acid, a heteroalkylenesulfonic acid, a heteroalkylenetaurine, a heteroalkylenephosphoric acid or phosphate, a heteroalkyleneamine (e.g., a quaternary amine), or a heteroalkylene sugar. In certain embodiments, carbohydrates include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Exemplary monosaccharides include glucose, ribose, deoxyribose, xylose, arabinose, mannose, galactose, fructose, and the like. In certain embodiments, carbohydrates include sugar acids, such as glucuronic acid, and also include coupled forms, such as glucuronic acids (i.e., by glucuronidation). Exemplary disaccharides include maltose, sucrose, lactose, lactulose, trehalose, and the like. Exemplary polysaccharides include amylose, amylopectin, glycogen, inulin, cellulose, and the like. Cyclodextrins can be any cyclodextrin known to those skilled in the art. In certain embodiments, the cyclodextrin is α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, or a mixture thereof. In certain embodiments, the cyclodextrin is alpha cyclodextrin. In certain embodiments, the cyclodextrin is beta cyclodextrin. In certain embodiments, the cyclodextrin is gamma cyclodextrin. In certain embodiments, the reinforcing group can improve the solubility of the rest of the conjugate. In certain embodiments, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is substituted or unsubstituted. In certain embodiments, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is -(CH2) 1-5 SO3H, –(CH2) n –NH-(CH2) 1-5 SO3H, –(CH2) n –C(O)NH-(CH2) 1-5 SO3H, –(CH2CH2O) m –C(O)NH-(CH2) 1-5 SO3H, –(CH2) n –N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, –(CH2) n –C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or –(CH2CH2O) m –C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, wherein n is 1, 2, 3, 4, or 5, and m is 1, 2, 3, 4, or 5. In one embodiment, the alkylsulfonic acid or alkylenesulfonic acid is -(CH2) 1-5 In another embodiment, the heteroalkylsulfonic acid or heteroalkylenesulfonic acid is -(CH2) n –NH-(CH2)1-5 SO3H, wherein n is 1, 2, 3, 4, or 5. In another embodiment, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is -(CH2) n –C(O)NH-(CH2) 1-5 SO3H, wherein n is 1, 2, 3, 4, or 5. In another embodiment, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is -(CH2CH2O) m –C(O)NH-(CH2) 1-5 SO3H, wherein m is 1, 2, 3, 4, or 5. In another embodiment, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is -(CH2) n –N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, wherein n is 1, 2, 3, 4, or 5. In another embodiment, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is -(CH2) n –C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, wherein n is 1, 2, 3, 4, or 5. In another embodiment, the alkylsulfonic acid, heteroalkylsulfonic acid, alkylenesulfonic acid, or heteroalkylenesulfonic acid is –(CH2CH2O) m –C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, wherein m is 1, 2, 3, 4, or 5.

[0142] The present invention provides an antibody-drug conjugate comprising an antibody or antigen-binding fragment thereof conjugated to a compound selected from Table 1. In some embodiments, the compound has a structure as shown in Formula 1d, 1e, 1g, or 1h.

[0143] The present invention also provides an antibody-drug conjugate of the formula Ab-L-SP-D or BA-L-SP-D, wherein D is a budesonide prodrug or a budesonide analog or derivative (including fluorinated analogs and derivatives) prodrug, and wherein Ab, BA, L and SP are defined as described in any embodiment of the present invention. In some embodiments, D in Ab-L-SP-D and BA-L-SP-D and in formulas (II) and (III) are Selected from: In some embodiments of Ab-L-SP-D, BA-L-SP-D and Formula (III), SP is capable of releasing D or In some embodiments, under physiological conditions, the bond between L and SP is cleaved to release the steroid prodrug, i.e., H-SP-D or and the bond between SP and D or SP and The bond between is subsequently cleaved to release the biologically active steroid. In some embodiments, in each of the above structural formulas The n-propyl group is in the R configuration, i.e., in the R configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is in the S configuration, i.e., in the S configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1. Table 3. Antibody-drug conjugates

[0144] The present invention also provides an antibody-steroid conjugate having a structure shown in the following formula: Where BA contains the following structure wherein Ab is a monoclonal antibody, a polyclonal antibody, an antibody fragment, or a bispecific antibody; R is C 2-4 -alkylene; and n is an integer selected from 2 to 4 (including 2 and 4). In some embodiments, in each of the above structural formulas The n-propyl group is in the R configuration, i.e., in the R configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is in the S configuration, i.e., in the S configuration at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk. In some embodiments, in each of the above structural formulas The n-propyl group is a mixture of R and S configurations, that is, a mixture of R and S configurations at the carbon indicated by the asterisk, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0145] In certain embodiments, BA is an antibody, and z is an integer selected from 1-30, inclusive. In some embodiments, z is an integer selected from 1 to 4, inclusive. In some embodiments, z is 4. In some embodiments, z is 2.

[0146] The present invention also provides binding agent conjugates of budesonide, budesonide prodrugs, budesonide analogs or derivatives (including fluorinated analogs and derivatives), or prodrugs of budesonide analogs or derivatives (including fluorinated analogs and derivatives).

[0147] Suitable binding agents for any of the conjugates provided herein include, but are not limited to, antibodies, lymphokines, hormones, growth factors, viral receptors, interleukins, or any other cell-binding or peptide-binding molecules or substances.

[0148] In some embodiments, the binding agent is an antibody. The term "antibody" as used herein means any antigen binding molecule or molecular complex comprising at least one complementary determining region (CDR) that specifically binds to or interacts with a specific antigen. The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and multimers thereof (e.g., IgM). Each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or V H ) and a heavy chain constant region. The heavy chain constant region comprises three domains, C H 1. C H 2 and C H 3. Each light chain comprises a light chain variable region (abbreviated as LCVR or V L ) and a light chain constant region. The light chain constant region comprises a domain (C L 1). The VH and V L The V region can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L Each antibody is composed of three CDRs and four FRs, arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In some embodiments, the FRs of the antibody (or antigen-binding portion thereof) may be identical to human germline sequences, or may be natural or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

[0149] The term "antibody" as used in the present invention also includes antigen-binding fragments of complete antibody molecules. The term "antigen-binding portion" of an antibody as used in the present invention, "antigen-binding fragment" of an antibody, etc. include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. Antigen-binding fragments of an antibody can be derived from complete antibody molecules using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques involving manipulation and expression of DNA encoding antibody variable domains and optional constant domains. Such DNA is known and / or easily obtained from, for example, commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. DNA can be sequenced and chemically manipulated or manipulated using molecular biology techniques, for example, one or more variable domains and / or constant domains can be arranged into a suitable configuration, or codons can be introduced to produce cysteine ​​residues, modify, add or delete amino acids, etc.

[0150] The amino acid sequences of antibodies can be numbered using any known numbering scheme, including the scheme described by Kabat et al. ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Plückthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme). Unless otherwise indicated, the numbering scheme used in the present invention is the Kabat numbering scheme. When referring to residues in the constant region of an antibody heavy chain, the "EU numbering scheme" is generally used (e.g., as reported by Kabat et al., supra). However, the choice of numbering scheme is not intended to imply the absence of differences in their sequences, and those skilled in the art can readily confirm sequence positions by inspecting the amino acid sequences of one or more antibodies.

[0151] In some embodiments, the BA antibody is a functionalized antibody having the following structure: In some embodiments, R is alkylene, alkenylene, or alkynylene. In some embodiments, R is alkylene. In some embodiments, R is C 2-4 -alkylene. In certain embodiments, R is ethylene. In certain embodiments, n is 3. In certain embodiments, z is 2 or 4.

[0152] In some embodiments, the BA antibody is not an anti-PSMA antibody or an anti-CD70 antibody.

[0153] Non-limiting examples of BA antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR), such as a CDR3 peptide) or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single-domain antibodies, camelid antibodies (V HH fragments), domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs) and shark variable IgNAR domains are also included in the expression "antigen-binding fragment" used in the present invention.

[0154] The antigen-binding fragment of an antibody generally comprises at least one variable domain. The variable domain may be of any size or amino acid composition and generally comprises at least one CDR adjacent to or in frame with one or more framework sequences. L Domain-related V H In the antigen-binding fragment of the structural domain, the V H and V L The domains can be positioned relative to each other in any suitable arrangement. For example, the variable region can be dimeric and contain V H -V H 、V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may comprise a monomer V H or V L domain.

[0155] In certain embodiments, the antigen-binding fragment of an antibody may comprise at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found within the antigen-binding fragments of the antibodies disclosed herein include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ;(viii)V L -C H 1; (ix) V L -C H2;(x)V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C L . In any configuration of variable domains and constant domains, including any of the exemplary configurations listed above, the variable domains and constant domains may be directly connected to each other or may be connected by a complete or partial hinge or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that result in a flexible or semi-flexible connection between adjacent variable domains and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragments of the antibodies disclosed herein may comprise homodimers or heterodimers (or other multimers) of any of the variable domains and constant domains listed above, which are non-covalently bound to each other and / or to antibodies having one or more monomeric V H or V L The domains are non-covalently associated (e.g., via disulfide bonds).

[0156] As with complete antibody molecules, antigen-binding fragments can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies typically comprise at least two different variable domains, each of which is capable of specifically binding to a separate antigen or binding to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be used using conventional techniques available in the art and is suitable for use in the context of the antigen-binding fragments of the antibodies disclosed herein.

[0157] The antibodies of the present invention can act by complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). "Complement-dependent cytotoxicity" (CDC) refers to the cracking of cells expressing antigens by the antibodies of the present invention in the presence of complement. "Antibody-dependent cell-mediated cytotoxicity" (ADCC) refers to a cell-mediated reaction in which non-specific cytotoxic cells (e.g., natural killer (NK) cells, neutrophils and macrophages) expressing Fc receptors (FcRs) recognize the binding antibodies on target cells, thereby causing target cell lysis. CDC and ADCC can be measured using assays well known in the art and available. (See, e.g., U.S. Patent Nos. 5,500,362 and 5,821,337, and Clynes et al. (1998) Proc. Natl. Acad. Sci. (USA) 95: 652-656). The constant region of an antibody is important in the ability of an antibody to fix complement and mediate cell-dependent cytotoxicity. Thus, the isotype of an antibody can be selected based on whether the antibody is desired to mediate cytotoxicity.

[0158] The antibodies that can be used for the compounds of the present invention include human antibodies. The term "human antibody" used in the present invention is intended to include antibodies with variable regions and constant regions derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo), such as in CDR, particularly in CDR3. However, the term "human antibody" used in the present invention is not intended to include antibodies in which the CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been transplanted onto human framework sequences. The term "human antibody" is not intended to include naturally occurring molecules that exist in naturally occurring, unmodified organisms, usually without modification or human intervention / operation.

[0159] In some embodiments, the antibody may be a recombinant human antibody. The term "recombinant human antibody" as used herein is intended to include all human antibodies prepared, expressed, generated or isolated by recombinant means, such as antibodies expressed using recombinant expression vectors transfected into host cells (described further below); antibodies isolated from recombinant, combinatorial human antibody libraries (described further below); antibodies isolated from animals (e.g., mice) that are transgenic animals for human immunoglobulin genes (see, e.g., Taylor et al. (1992) Nucl. Acids Res. 20: 6287-6295); or antibodies prepared, expressed, generated or isolated by any other method involving splicing human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when animals with transgenic human Ig sequences are used, in vivo somatic mutagenesis), and thus the V H and V L The amino acid sequence of the region is derived from human germline V H and V L Sequences and sequences related thereto that may not naturally occur in the human antibody germline repertoire in vivo.

[0160] Human antibodies can exist in two forms related to hinge heterogeneity. In one form, the immunoglobulin molecule comprises a stable four-chain construct of approximately 150-160 kDa, in which the dimers are linked together by interchain heavy chain disulfide bonds. In the second form, the dimers are not linked by interchain disulfide bonds and form a molecule of approximately 75-80 kDa, which consists of covalently coupled light and heavy chains (half antibodies). These forms are extremely difficult to separate, even after affinity purification.

[0161] The frequency of the second form in various intact IgG isotypes is due to, but not limited to, structural differences associated with the hinge region of the antibody isotype. A single amino acid substitution in the hinge region of the human IgG4 hinge can significantly alter the second form (Angal et al. (1993) Molecular Immunology 30:105) is reduced to the level typically observed using human IgG1 hinge. The present disclosure includes hinge, C H 2 or C H Antibodies having one or more mutations in the 3 regions, which mutations may be desirable, for example, during production to increase production of a desired antibody form.

[0162] The antibodies useful in the compounds of the present invention may be isolated antibodies. As used herein, an "isolated antibody" refers to an antibody that has been identified and separated and / or recovered from at least one component of its natural environment. For example, for the purposes of the present invention, an antibody that has been separated or removed from at least one component of an organism or from a tissue or cell in which the antibody naturally occurs or is naturally produced is an "isolated antibody." Isolated antibodies also include antibodies in situ within recombinant cells. An isolated antibody is an antibody that has been subjected to at least one purification or separation step. According to certain embodiments, the isolated antibody may be substantially free of other cellular material and / or chemicals.

[0163] Compared to the corresponding germline sequence of the derived antibody, the antibodies that can be used for the compounds of the present invention may include one or more amino acid substitutions, insertions and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains. Such mutations can be easily determined by comparing the amino acid sequences disclosed in the present invention with germline sequences that can be obtained from, for example, public antibody sequence databases. The present invention includes antibodies and antigen-binding fragments thereof, which are derived from any amino acid sequence of the present invention, wherein one or more amino acid mutations in one or more framework and / or CDR regions are mutated to the corresponding residues of the germline sequence of the derived antibody, or mutated to the corresponding residues of another human germline sequence, or mutated to the conservative amino acid substitutions of the corresponding germline residues (such sequence changes are collectively referred to as "germline mutations" in the present invention). Those of ordinary skill in the art can easily generate many antibodies and antigen-binding fragments starting from the heavy and light chain variable region sequences disclosed in the present invention, and the antibodies and antigen-binding fragments include one or more individual germline mutations or combinations thereof. In certain embodiments, V H and / or V L In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention.In another embodiment, the present invention provides the antibody of the present invention. Once obtained, antibodies and antigen-binding fragments containing one or more germline mutations can be readily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as appropriate), reduced immunogenicity, etc.

[0164] In some embodiments, the antibody is a monoclonal antibody, a polyclonal antibody, an antibody fragment (Fab, Fab', and F(ab)2, miniantibodies, diabodies, triabodies, etc.) or a bispecific antibody. The antibodies described herein can be humanized using the methods described in U.S. Patent No. 6,596,541 and U.S. Publication No. 2012 / 0096572, each of which is incorporated herein by reference in its entirety.

[0165] When the binding agent is an antibody, it binds to an antigen binding partner that is a polypeptide, which may be a transmembrane molecule (eg, a receptor) or may be a growth factor that may be glycosylated or phosphorylated.

[0166] Suitable targets to which the binding agent binds include any target for which selective delivery of a steroid is desired. In some embodiments, the binding agent is an antibody, a modified antibody, or an antigen-binding fragment thereof that binds to a target selected from the group consisting of AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2 BTNL3, BTNL8, BTNL9, C10orf54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD248, CD25, CD27, CD2 74, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD46, CD47, CD48, CD5 , CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2. CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1 / 2, CXCR4, CXCR5, DDR1, DDR2, DEC–205, DLL4, DR6, FAP, FCamR, FCMR, FcR's, Fire, GITR, HHLA2, HLA Class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, IL22R1, IL22RA, IL23 R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, IL5R, IL7R, IL9R, Integrins, LAG3, LIFR, MAG / Siglec–4, MMR, MSR1, NCR3LG1, NKG2D, NKp30, N Kp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1 (sialic acid-binding immunoglobulin-like lectin-1), Siglec-10, Siglec-5, Siglec-6, Siglec-7, Siglec-8, Siglec-9, SIRPA, SLAMF7, TACI, TCR-list component / assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4 and VTCN1. In some embodiments, the binding agent is adalimumab or infliximab. In some embodiments, the binding agent is alemtuzumab, muromonab, rituximab, tosituzumab, or an agonistic antibody (where immune stimulation may be part of the intended mechanism of action).

[0167] The expression prolactin receptor "PRLR" used in the present invention refers to a human prolactin receptor comprising an amino acid sequence as shown in SEQ ID NO: 404 of WO2015026907 (which is incorporated herein by reference in its entirety). The expression "PRLR" includes monomeric PRLR molecules and multimeric PRLR molecules. The expression "monomeric human PRLR" used in the present invention refers to a PRLR protein or a portion thereof that does not comprise or has any multimeric domain and exists under normal conditions as a single PRLR molecule without being directly physically connected to another PRLR molecule. An exemplary monomeric PRLR molecule is a molecule referred to as "hPRLR.mmh" in the present invention, which comprises an amino acid sequence of SEQ ID NO: 401 of WO2015026907 (see, e.g., Example 3 of WO2015026907). The expression "dimeric human PRLR" used in the present invention refers to a construct comprising two PRLR molecules, which are connected to each other by a linker, a covalent bond, a non-covalent bond, or by a multimeric domain, such as an antibody Fc domain. An exemplary dimeric PRLR molecule is the molecule referred to herein as "hPRLR.mFc," which comprises the amino acid sequence of SEQ ID NO: 402 of WO2015026907 (see, e.g., Example 3 of WO2015026907).

[0168] Exemplary anti-PRLR antibodies are listed in Table 1 of WO2015026907, showing amino acid sequence identifiers - or substantially similar sequences thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity - heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementary determining region (HCDR1, HCDR2 and HCDR3), and light chain complementary determining region (LCDR1, LCDR2 and LCDR3) of exemplary anti-PRLR antibodies. Table 2 of WO2015026907 lists nucleic acid sequence identifiers - or substantially similar sequences thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity - HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 of exemplary anti-PRLR antibodies.

[0169] In some embodiments, the antibody or antigen-binding fragment thereof coupled to the linker-payload or payload can be an antibody targeting human prolactin receptor (PRLR). Exemplary anti-PRLR antibodies can be learned in, for example, WO 2015 / 026907. In some embodiments, the anti-PRLR antibody comprises: a heavy chain complementary determining region (HCDR) -1 comprising SEQ ID NO: 17; HCDR2 comprising SEQ ID NO: 19; HCDR3 comprising SEQ ID NO: 20; a light chain complementary determining region (LCDR) -1 comprising SEQ ID NO: 22; LCDR2 comprising SEQ ID NO: 23; and LCDR3 comprising SEQ ID NO: 24. In some embodiments, the anti-PRLR antibody comprises: a heavy chain variable region (HCVR) comprising SEQ ID NO: 17 and a light chain variable region (LCVR) comprising SEQ ID NO: 21. In any of the foregoing embodiments, the anti-PRLR antibody can be prepared by site-directed mutagenesis to insert a glutamine residue at the site without causing loss of antibody function or binding ability. For example, in any of the aforementioned embodiments, the anti-PRLR antibody can include Asn297Gln (N297Q) mutation. Such antibodies with N297Q mutation can also include one or more other naturally occurring glutamine residues in their variable region, and transglutaminase can approach these residues, and therefore can be coupled with payload or linker-payload (Table B). Table B. Sequences of exemplary antibodies H1H6958N (anti-PRLR)

[0170] In any compound or conjugate embodiment provided, BA is an antibody or its antigen binding fragment in conjunction with PRLR. In any compound or conjugate embodiment provided, BA is an antibody or its antigen binding fragment, and is coupled by at least one Q295 residue. In any compound or conjugate embodiment provided, BA is an antibody or its antigen binding fragment, and is coupled by two Q295 residues. In any compound or conjugate embodiment provided, BA is an N297Q antibody or its antigen binding fragment. In any compound or conjugate embodiment provided, BA is an N297Q antibody or its antigen binding fragment, and is coupled by at least one Q295 residue and at least one Q297 residue. In any compound or conjugate embodiment provided, BA is an N297Q antibody or its antigen binding fragment, and is coupled by two Q295 residues and two Q297 residues. In specific embodiments, numbering is carried out according to the EU numbering system.

[0171] In any of the above embodiments, the BA is an anti-MSR1 antibody. In certain embodiments, the BA is the anti-MSR1 antibody H1H21234N. In certain embodiments, the BA is the anti-MSR1 antibody H1H21234NN297Q. In certain embodiments, the BA is an anti-MSR1 antibody comprising a HCVR according to SEQ ID NO: 2 and a LCVR according to SEQ ID NO: 10. In certain embodiments, the BA is an anti-MSR1 antibody comprising one, two, three, four, five, or six of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 14, and SEQ ID NO: 16, respectively. In certain embodiments, the HCVR is encoded by SEQ ID NO: 1. In certain embodiments, the LCVR is encoded by SEQ ID NO: 9. In certain embodiments, one, two, three, four, five, or six of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are encoded by the polynucleotide sequences of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 15, respectively. N297Q indicates that one or more residues 297 are mutated from asparagine (N) to glutamine (Q). Preferably, each residue 297 is mutated to Q. In preferred embodiments, numbering is according to the EU numbering system. In certain embodiments of this paragraph, z is 1 to 4. In certain embodiments, z is 1, 2, 3, or 4. In certain embodiments, z is 2. In certain embodiments, z is 4.

[0172] The binding agent (e.g., an antibody or antigen-binding molecule) can be linked to the binding agent by attachment at a specific amino acid within the antibody or antigen-binding molecule. Exemplary amino acid attachments that can be used in the context of this aspect of the invention include, for example, lysine (see, e.g., US 5,208,020; US 2010 / 0129314; Hollander et al., Bioconjugate Chem., 2008, 19:358–361; WO 2008 / 0200704; et al., Bioconjugate Chem., 2008, 19:358–361). 2005 / 089808; US 5,714,586; US2013 / 0101546; and US2012 / 0585592), cysteine ​​(see, e.g., US 2007 / 0258987;WO 2013 / 055993;WO 2013 / 055990;WO 2013 / 053873;WO 2013 / 053872;WO 2011 / 130598; US2013 / 0101546; and US 7,750,116), selenocysteine ​​(see, e.g., WO 2008 / 122039; and Hofer et al., Proc. Natl. Acad. Sci., USA, 2008, 105:12451–12456), formylglycine (see, e.g., Carrico et al., Nat. Chem. Biol., 2007, 3:321–322; Agarwal et al., Proc. Natl. Acad. Sci., USA, 2013, 110:46–51, and Rabuka et al., Nat. Protocols, 2012, 10:1052–1067), unnatural amino acids (see, e.g., WO 2013 / 068874, and WO 2012 / 166559), and acidic amino acids (see, for example, WO 2012 / 05982). The linker can be coupled via glutamine via transglutaminase-based chemo-enzymatic coupling (see, for example, Dennler et al., Bioconjugate Chem. 2014, 25, 569–578). The linker can also be coupled to the antigen binding protein via attachment to a carbohydrate (see, for example, US 2008 / 0305497, WO 2014 / 065661, and Ryan et al., Food & Agriculture Immunol., 2001, 13: 127-130), and coupled to antigen binding proteins by attachment to a disulfide linker (see, e.g., WO 2013 / 085925, WO 2010 / 010324, WO 2011 / 018611, WO 2014 / 197854, and Shaunak et al., Nat. Chem. Biol., 2006, 2: 312-313). In some embodiments, the binding agent is an antibody, and the antibody is linked to the linker via a lysine residue. In some embodiments, the antibody is linked to the linker via a cysteine ​​residue.

[0173] In any of the above embodiments, BA is an anti-PRLR antibody. In certain embodiments, BA is an anti-PRLR antibody H1H6958N. In certain embodiments, BA is an anti-PRLR antibody H1H6958NN297Q. In certain embodiments, BA is an anti-PRLR antibody comprising an HCVR according to SEQ ID NO: 17 and an LCVR according to SEQ ID NO: 21. In certain embodiments, BA is an anti-PRLR antibody comprising 1, 2, 3, 4, 5, or 6 of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24, respectively. N297Q represents that one or more residues 297 are mutated to glutamine (Q) from asparagine (N). Preferably, each residue 297 is mutated to Q. In a preferred embodiment, numbering is carried out according to the EU numbering system. In certain embodiments of this paragraph, k is 1 to 4. In certain embodiments, k is 1, 2, 3, or 4. In certain embodiments, k is 4. D. Methods of Preparing Compounds

[0174] The conjugates of the present invention can be synthesized by coupling the linker-payload of the present invention to a binding agent, such as an antibody, under standard coupling conditions (see, for example, Drug Deliv. 2016 Jun; 23(5): 1662-6; AAPS Journal, Vol. 17, No. 2, March 2015; and Int. J. Mol. Sci. 2016, 17, 561, all of which are incorporated herein by reference in their entirety). The linker-payload is a synthetic intermediate comprising a target payload and a linker moiety, which is ultimately used as a group moiety (or portion thereof) for connecting the binding agent to the payload. The linker-payload comprises an active group that reacts with the binding agent to form the conjugate of the present invention. When the binding agent is an antibody, the antibody can be coupled to the linker-payload through one or more cysteine ​​residues, lysine residues or other residues of the antibody. The linker-payload can be, for example, by subjecting the antibody to a reducing agent (e.g., dithiothreitol) to cut the disulfide bonds of the antibody, for example, by purifying the reduced antibody through gel filtration, and then reacting the antibody with a linker-payload containing a suitable active group moiety (e.g., a maleimido group) to couple with the cysteine ​​residues. Suitable solvents include, but are not limited to, water, DMA, DMF, and DMSO. The linker-payload containing an active group such as an activated ester or acyl halide group can be coupled to the lysine residues of the antibody. Suitable solvents include, but are not limited to, water, DMA, DMF, and DMSO. The conjugate can be purified using known protein techniques, including, for example, size exclusion chromatography, dialysis, and ultrafiltration / diafiltration. Linker-steroid intermediate

[0175] The present invention provides a linker-steroid represented by formula (2000), RG-L 2 -(L 3 ) 0-1 -SP-D or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, which can be used to prepare an antibody-drug conjugate, in, D is selected from a) The two R in formula (a) x Both H; R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X1 -, where X 1 Compared with (L 3 ) 0-1 connect, -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (2000) 3 ) 0-1 Connection, -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (2000) 3 ) 0-1 connect, The attachment point on the right hand side (i.e., N) is the same as (L 3 ) 0-1 Connect, -CH2-NH-, wherein N and (L in formula (2000) 3 ) 0-1 connect, Wherein N and (L 3 ) 0-1 and wherein Ar is an optionally substituted arylene group (in some embodiments ) or optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Compared with (L 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Compared with (L 3 ) 0-1 Connect and each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Compared with (L 3 ) 0-1 Connect, or where X 4 Compared with (L 3 ) 0-1 connect; or The two R in formula (a) x All are F; R 4 is alkyl, aryl, arylalkyl, or N-containing heterocycloalkyl; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b Compared with (L 3 ) 0-1 connect, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Compared with (L 3 ) 0-1 connect, The attachment point on the right hand side (i.e., N) is the same as (L 3 ) 0-1 Connect, -CH2-NH-, wherein N and (L in formula (2000) 3 ) 0-1 connect, Wherein N and (L 3 ) 0-1 and wherein Ar is an optionally substituted arylene group (in some embodiments ) or optionally substituted heteroarylene, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Compared with (L 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Compared with (L 3 ) 0-1 Connect and each C1-C 10-alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Compared with (L 3 ) 0-1 Connect, or where X 4 Compared with (L 3 ) 0-1 Connect; and b) Compounds in Table A above, wherein the compounds in Table A are hydroxylated via a -C(O)CH2OH group (i.e., via -C(O)CH2-O-SP-(L 3 ) 0-1 -), or through the hydroxyl group of Mapracorat (i.e., through -O-SP-(L 3 ) 0-1 -) is connected to RG of the compound represented by formula (2000); X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; RG is the active group; L 2 is a connecting linker, and L 3 When present, it is a self-immolative linker.

[0176] The present invention provides a linker-steroid represented by formula (II), It can be used to prepare antibody-drug conjugates; wherein RG, L 2 , L 3 , SP, R 4 and R x All have the definitions described in the present invention.

[0177] In some or any embodiments, the compound of formula (II-P) is as follows: or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (II) 3 connect, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (II) 3 Connect, or where X 4 and L in formula (II) 3 connect; X 1 Yes-N(C 1-3 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; RG is the active group; L 2 is a connecting linker, and L 3 When present, it is a self-immolative linker.

[0178] In some or any embodiments, the compound of formula (II-P-1) is as follows: or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (II) 3 connect, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (II) 3 Connect, or where X 4and L in formula (II) 3 connect; X 1 Yes-N(C 1-3 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is -O-; R 5 is H, -OH, -OCH3, or alkyl; R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g Separately independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; RG is the active group; L 2 is a connecting linker, and L 3 When present, it is a self-immolative linker.

[0179] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are both H. In some or any embodiments, two R x All are F.

[0180] In some embodiments, the present invention provides compounds of formula (II), (II-P) and (II-P-1), wherein R 4 In some embodiments, R 4 is not cycloalkyl. In some of these embodiments, R 4 is a straight chain or branched chain alkyl group. In some of these embodiments, R 4 In some of these embodiments, R 4 is arylalkyl. In some of these embodiments, R 4 is an N-containing heterocycloalkyl. In some embodiments, R4 is an alkyl group, such as, but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, or nonyl. 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is octyl or nonyl. In some embodiments, R 4 is an aryl group, such as, but not limited to, phenyl, phenol, or naphthyl. In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is a heteroaryl group, such as but not limited to a thienyl group. 4 is an arylalkyl group, such as but not limited to benzyl. In some embodiments, R 4 is a heterocyclic alkyl group containing N, such as but not limited to piperidinyl. In some embodiments, the present invention provides a compound of formula (II), wherein the two R x are both H. In some or any embodiments, two R x In some embodiments, R 4 In some embodiments, R 4 In some embodiments, R 4 is a mixture of R and S configurations. 4 It is a mixture of R and S configurations, wherein the R:S mixture is about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or about 10:1.

[0181] In some embodiments, the present invention provides a compound represented by formula (II), wherein Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C10 -alkylene-X 1 -, where X 1 Connected to L in formula (II), -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (II), -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (II), -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -Alkylene (base)-NR 50a -, of which NR 50a Connected to L in formula (II), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -Alkylene (base)-NR 50a -, of which NR 50a Connected to L in formula (II) and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Connected to L in formula (II), or where X 4 Connected to L in formula (II); or Two R's x are F; and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b Connected to L in formula (II), -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Connected to L in formula (II), The right-hand side attachment point (ie, N) is connected to L in formula (II), -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -,in NR50a Connected to L in formula (II), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III) and each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups, or -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 Connected to L in formula (II).

[0182] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are H, and SP is -C(O)-C1-C 10 -alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-C2-C5-alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-CH2CH2-C(O)-.

[0183] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are all F, and SP is -C(O)-C1-C 10 -alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-C2-C5-alkylene-C(O)-. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-CH2CH2-C(O)-.

[0100] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are H, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1 -, where X1 and L in formula (II), (II-P), or (II-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (II), (II-P), or (II-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein X 1 Yes-N(C 1-3 In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(C 1-3 alkyl)-C2-C5-alkylene-X 1 In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(C 1-3 alkyl)-CH2CH2-X 1 -. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(CH3)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-.

[0184] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are F, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (II) 3 Connection, or -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-C1-C 10 -alkylene-X 1b-, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-C1-C6-alkylene-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-C1-C3-alkylene-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound represented by formula (II), wherein SP is -C(O)-N(H)-CH2CH2-X 1b -. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-C2-C5-alkylene-N(CH2CH3)-. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-CH2CH2-N(CH3)-.

[0185] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are F, and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -alkylene-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-C1-C6-alkylene-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-C1-C3-alkylene-X 1b -, where X 1b and L in formula (II) 3 In some embodiments, the present invention provides a compound represented by formula (II), wherein X 1b Yes-N(C 1-3In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-C2-C5-alkylene-X 1b In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-CH2CH2-X 1b -. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(CH3)-C2-C5-alkylene-N(CH3)-. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(CH2CH3)-C2-C5-alkylene-N(CH2CH3)-. In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-.

[0186] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are F, and SP is The right-hand attachment point (ie, N) is connected to L in formula (II).

[0187] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are H, and SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 connection, or -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound represented by formula (II), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (II). 3 connection, or -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3In some embodiments, the present invention provides a compound represented by formula (II), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (II). 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S and L in formula (II) 3 connect.

[0188] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are all F, and SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 connection, or -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound represented by formula (II), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (II). 3 connection, or -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3 In some embodiments, the present invention provides a compound represented by formula (II), wherein SP is -C(O)-N(H)-(C1-C6-alkylene)-S-, wherein S is connected to L in formula (II). 3 In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-6 alkyl)-(C1-C 10 -alkylene)-S-, wherein S and L in formula (II) 3In some embodiments, the present invention provides a compound of formula (II), wherein SP is -C(O)-N(C 1-3 alkyl)-(C1-C6-alkylene)-S-, wherein S and L in formula (II) 3 connect.

[0189] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are H, and SP is -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (II) 3 In some or any embodiments, the present invention provides a compound of formula (I), wherein SP is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(C1-C3-alkylene)-NR 50 C(O)-(C1-C3-alkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(linear C1-C3-alkylene)-NR 50 C(O)-(straight-chain C1-C3-alkylene)-NR 50a -.

[0190] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are all F, and SP is -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (II) 3 In some or any embodiments of Formula (I), SP is -(C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(C1-C3-alkylene)-NR 50 C(O)-(C1-C3-alkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(linear C1-C3-alkylene)-NR 50C(O)-(straight-chain C1-C3-alkylene)-NR 50a -.

[0191] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are H, and SP is -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a - and L in formula (II) 3 Connect and each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (II), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a -.

[0192] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x are F, and SP is -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a - and L in formula (II) 3 Connect and each C1-C 10 -alkylene is independently optionally substituted with one or more hydroxyl groups. In some or any embodiments of formula (II), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-hydroxyalkylene)-NR 50a In some or any embodiments of Formula (II), SP is -(branched C1-C6-alkylene)-NR 50 C(O)-(C1-C6-alkylene)-NR 50a -.

[0100] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are H, and SP is -C(O)-N(R 5)-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (II), (II-P), or (II-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(R 5 )-C1-C5-alkylene-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(R 5 )-CH2-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R 5 In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R 5 It is H or CH3.

[0193] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are F, and SP is -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -, where X 2 and L in formula (II) 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(R 5 )-C1-C5-alkylene-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(R 5 )-CH2-C(O)NH-NH-. In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R 5 In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R 5 It is H or CH3.

[0194] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two Rx are H, and SP is where X 4 and L in formula (II), (II-P), or (II-P-1) 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein the two R x are F, and SP is where X 4 and L in formula (II), (II-P), or (II-P-1) 3 In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is and X 3 In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is and X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein SP is and X 3 In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R d 、R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein R d and R e are independently -H or -OH. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein m is 0. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein m is 1. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein m is 1, and R f It is -H or –OH.

[0195] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are H, and SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (II), (II-P), or (II-P-1) 3 connection; SP is where X 3 is -CH2-, m is 1, and R d 、R e and R f All are -H; or SP is where X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 connected, m is 1, and R d 、R e and R f In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-, In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein the two R x are F, and SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, where X 1 and L in formula (II), (II-P), or (II-P-1) 3 connection; SP is where X 3 is -CH2-, m is 1, and R d 、R e and R f All are -H; or SP is where X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 connected, m is 1, and R d 、R e and R fIn some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein SP is -C(O)-N(CH3)-CH2CH2-N(CH3)-,

[0196] In some embodiments, the present invention provides a compound represented by formula (II), wherein the two R x All F or two R x Both H or R x As specified in this paragraph; SP is (Two of the R x All are F), (Two of the R x All are F),

[0197] In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein RG is selected from In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein RG is In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein RG is In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein RG is In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein RG is

[0198] In some embodiments, -L in formula (II), (II-P), or (II-P-1) 2 -(L 3 ) 0-1 -, refers to any divalent group or moiety that allows the active group (e.g., RG in Formula (II), (II-P), or (II-P-1)) to be linked, attached, or bound to the payload compound (e.g., steroid) described herein. Typically, suitable -L 2 -(L 3 ) 0-1 - are those that are stable enough to take advantage of the circulating half-life of the antibody and at the same time are able to release their payload upon antigen-mediated internalization of the conjugate. 2 -(L3 ) 0-1 - can be cleavable or non-cleavable. Cleavable linkers are linkers that are cleaved by intracellular metabolism after internalization, such as by hydrolysis, reduction, or enzymatic reactions. Non-cleavable linkers are linkers that release the attached payload by lysosomal degradation of the antibody after internalization. Suitable linkers include, but are not limited to, acid-labile linkers, hydrolytically unstable linkers, enzymatically cleavable linkers, reduction-labile linkers, self-immolative linkers, and non-cleavable linkers. Suitable linkers also include, but are not limited to, linkers that are or contain glucuronides, succinimide-thioethers, polyethylene glycol (PEG) units, carbamates, hydrazones, maleimide-caproyl units, disulfide units (e.g., –S–S–, –SSC(R 1 )(R 2 )–, where R 1 and R 2 are independently hydrogen or hydrocarbon), p-aminobenzyl (PAB) units, phosphate units, such as mono-, di- or tri-phosphate units, and peptides, such as peptide units containing 2, 3, 4, 5, 6, 7, 8, or more amino acid units, including but not limited to valine-citrulline units, valine-alanine units, valine-arginine units, valine-lysine units, -lysine-valine-citrulline units and -lysine-valine-alanine units. In some embodiments, -L 2 -(L 3 ) 0-1 - is trivalent and includes -L 2 -(L 3 ) 0-1 - is a cyclodextrin moiety connected to a trivalent group (e.g., a lysine residue) in the 3 In some embodiments, L 3 Does not exist.

[0199] In some embodiments, the present invention provides a compound represented by formula (II), (II-P), or (II-P-1), wherein L 2 Include -C(O)CH2CH2C(O)NH-, or cyclodextrin residue (CD); or a combination thereof. In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein L2 Include In some embodiments, the present invention provides a compound of formula (II), (II-P), or (II-P-1), wherein L 2 Containing a CD, wherein the CD is selected from the group consisting of:

[0200] In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein -L 2 -(L 3 ) 0-1 -Include

[0201] In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein when SP is -C(O)-C1-C 10 -alkylene-C(O)-, L 3 yes wherein the NH group and L 2 connection; or when SP is -C(O)-N(C 1-3 Alkyl)-C1-C 10 -alkylene-X 1 -, or -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -When, L 3 yes wherein the NH group and L 2 connection; or when SP is When L 3 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein when SP is -C(O)-C1-C 10 -alkylene-C(O)-, L 3 yes wherein the NH group and L 2 In some embodiments, the present invention provides compounds represented by formula (II), (II-P), or (II-P-1), wherein when SP is -C(O)-N(C 1-3Alkyl)-C1-C 10 -alkylene-X 1 -, or -C(O)-N(R 5 )-C1-C 10 -alkylene-C(O)NH-X 2 -When, L 3 yes wherein the NH group and L 2 In some embodiments, the present invention provides compounds of formula (II), (II-P), or (II-P-1), wherein when SP is When L 3 Does not exist.

[0202] The present invention also provides a compound having the following structure: Table 2. Budesonide-Spacer-Linker-Active Group

[0203] Binding agents (e.g., antibodies) can also be coupled via click chemistry reactions. In some embodiments of the click chemistry reaction, the linker-payload comprises an active group (e.g., an alkyne) capable of undergoing a 1,3-cycloaddition reaction with an azide. Such suitable active groups include, but are not limited to, strained alkynes, such as those suitable for strain-promoted alkyne-azide cycloaddition (SPAAC), cycloalkynes such as cyclooctynes, benzoannulated alkynes, and alkynes capable of undergoing a 1,3-cycloaddition reaction with an azide in the absence of a copper catalyst. Suitable alkynes also include, but are not limited to, DIBAC, DIBO, BARAC, DIFO, substituted alkynes such as fluorinated alkynes, aza-cycloalkynes, BCN, and derivatives thereof. Linkers-payloads comprising such active groups can be used to couple antibodies that have been functionalized with an azide group. Such functionalized antibodies include antibodies functionalized with an azide-polyethylene glycol group. In certain embodiments, such functionalized antibodies are obtained by reacting an antibody comprising at least one glutamine residue (e.g., Q295 of the heavy chain) with a compound of the formula H2N–LL–N3 (wherein LL is a divalent polyethylene glycol group) in the presence of the enzyme transglutaminase. For convenience, in certain formulas of the present invention, the antibody Ab is a modified antibody bearing one or more covalently attached –LL–N3 groups or residues thereof. Preferably, each –LL–N3 is covalently attached to the amino acid side chain of a glutamine residue of the antibody. Further preferably, –LL–N3 is a reactive group RG or can react with a reactive group RG to form a covalent bond to the linker-payload. Also for convenience, in certain formulas of the present invention, the –LL–N3 group is explicitly shown.

[0204] The present invention provides a method for synthesizing the conjugate of the present invention, the method comprising contacting a binding agent, such as an antibody, with a linker-payload of the present invention. In certain embodiments, the linker-payload comprises a cyclodextrin moiety.

[0205] Compounds represented by formula (II), (II-P), or (II-P-1) are linker-payloads that can be used as synthetic intermediates in the synthesis of the conjugates of the present invention. These linker-payloads contain reactive groups that can react with antibodies to form the conjugates of the present invention.

[0206] In some embodiments of Formula (II), (II-P), or (II-P-1), R 4 In some embodiments of Formula (II), (II-P) or (II-P-1), R 4is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, a pentyl moiety, a hexyl moiety, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments of formula (II), (II-P) or (II-P-1), R 4 In some embodiments of Formula (II), (II-P) or (II-P-1), R 4 is a methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, isobutyl, a pentyl moiety, or a hexyl moiety. In some embodiments of formula (II), (II-P), or (II-P-1), R 4 It's n-propyl.

[0207] In certain embodiments, RG-L 2 -(L 3 ) 0-1 -yes is an aryl or heteroaryl group; RG is an active group, as defined below; SP 1 and SP 2 In each case, each independently is absent, or each independently is a spacer residue, and wherein SP 1 Contains trivalent linker; AA 1 Is a trivalent linker containing amino acid residues; AA 2 is a peptide residue; PEG is a polyethylene glycol residue; wherein represents the atom through which the indicated chemical group is attached to the adjacent group in the formula, CD, in each case, is independently absent or is independently a cyclodextrin residue, wherein at least one CD is present, and subscript q is an integer selected from 0 to 5 (inclusive). In these embodiments, subscript q is 0, 1, 2, 3, 4, or 5. In some embodiments, subscript q is 0. In some embodiments, subscript q is 1. In some embodiments, subscript q is 2. In some embodiments, subscript q is 3. In some embodiments, subscript q is 4. In some embodiments, subscript q is 5. In some embodiments, AA 1 or AA 2 In some embodiments, any of the amino acids AA, AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA 1is an amino acid selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine or citrulline, a derivative thereof, or a combination thereof. In certain embodiments, AA 1 is lysine or a derivative of lysine. In certain embodiments, AA 1 In certain embodiments, AA 1 In certain embodiments, AA 1 In certain embodiments, the AA 2 is a dipeptide residue, a tripeptide residue, a tetrapeptide residue, or a pentapeptide residue. In certain embodiments, the AA 2 is a dipeptide residue. In certain embodiments, the AA 2 In certain embodiments, the AA 2 In certain embodiments, the AA 2 In certain embodiments, the AA 2 In certain embodiments, the AA 2 In certain embodiments, the AA 2 In certain embodiments, the AA 2 is a tripeptide residue. In certain embodiments, the AA 2 In some embodiments, the AA 2 In some embodiments, the AA 2 In some embodiments, the AA 2 In some embodiments, the AA 2 In some embodiments, the AA 2 is a tetrapeptide residue. In some embodiments, the AA 2 In some embodiments, the AA 2 is a pentapeptide residue. In some embodiments, the AA 2 is Gly-Gly-Gly-Gly-Gly. In some embodiments, SP 1 In each case, independently selected from the group consisting of: C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e、-NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, wherein subscript e is selected from an integer from 0 to 4 (inclusive), subscript u is selected from an integer from 1 to 8 (inclusive), and subscript v is selected from an integer from 1 to 8 (inclusive). In some embodiments, SP 2 In each case, independently selected from the group consisting of: C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e 、-NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, wherein subscript e is selected from integers from 0 to 4 (inclusive), subscript u is selected from integers from 1 to 8 (inclusive), and subscript v is selected from integers from 1 to 8 (inclusive).

[0208] In certain embodiments, the present invention provides a compound having a structure shown in formula (IIIc-R): RG is the active group; CD is cyclodextrin; SP 1 is a spacer group; AA 4 is an amino acid residue; AA 5 is a dipeptide residue; PEG is polyethylene glycol; q is an integer selected from 0 to 5 (inclusive); x is an integer selected from 0 to 30 (inclusive); R 4 Having the definition described in the present invention; SP 1 and SP 2 In each case, each independently is absent, or each independently is a spacer residue, and wherein SP 1 Contains trivalent linker; AA 4 Is a trivalent linker containing amino acid residues; AA 5 is a dipeptide residue; PEG is a polyethylene glycol residue; wherein represents the atom through which the indicated chemical group is attached to the adjacent group in the formula, CD, in each case, is independently absent or is independently a cyclodextrin residue, wherein at least one CD is present, and subscript q is an integer selected from 0 to 5 (inclusive). In these embodiments, subscript q is 0, 1, 2, 3, 4, or 5. In some embodiments, subscript q is 0. In some embodiments, subscript q is 1. In some embodiments, subscript q is 2. In some embodiments, subscript q is 3. In some embodiments, subscript q is 4. In some embodiments, subscript q is 5. In some embodiments, AA 4 or AA 5 In some embodiments, any of the amino acids AA, AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA , AA 4 is an amino acid selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine or citrulline, a derivative thereof, or a combination thereof. In certain embodiments, AA 4 In certain embodiments, AA 4 is lysine or a derivative of lysine. In certain embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 In some embodiments, the AA 5 is Glutamic acid-Valine-Citrulline. In some embodiments, SP 1 In each case, independently selected from the group consisting of: C1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e 、-NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v -, and combinations thereof, wherein subscript e is selected from an integer from 0 to 4 (inclusive), subscript u is selected from an integer from 1 to 8 (inclusive), and subscript v is selected from an integer from 1 to 8 (inclusive). In some embodiments, SP 2 In each case, independently selected from the group consisting of: C 1-6 Alkylene, -NH-, -C(O)-, (-CH2-CH2-O) e 、-NH-CH2-CH2-(-O-CH2-CH2) e -C(O)-, -C(O)-(CH2) u -C(O)-, -C(O)-NH-(CH2) v-, and combinations thereof, wherein subscript e is selected from an integer of 0 to 4 (including 0 and 4), subscript u is selected from an integer of 1 to 8 (including 1 and 8), and subscript v is selected from an integer of 1 to 8 (including 1 and 8). The reactive group (RG) is a functional group or group portion that reacts with the active (reactive) portion of an antibody, a modified antibody, or an antigen-binding fragment thereof. In certain embodiments, the "active group" is a functional group or group portion (e.g., maleimide or NHS ester) that reacts with a cysteine ​​or lysine residue of an antibody or an antigen-binding fragment thereof. In certain embodiments, the "active group" is a functional group or group portion that can undergo click chemistry reactions. In some embodiments of the click chemistry reaction, the reactive group is an alkyne that can undergo a 1,3-cycloaddition reaction with an azide. Such suitable reactive groups include, but are not limited to, strained alkynes, such as those suitable for strain-promoted alkyne-azide cycloaddition (SPAAC), cycloalkynes such as cyclooctynes, benzoannulated alkynes, and alkynes capable of undergoing 1,3-cycloaddition reactions with azides in the absence of a copper catalyst. Suitable alkynes also include, but are not limited to, DIBAC, DIBO, BARAC, substituted alkynes such as fluorinated alkynes, aza-cycloalkynes, BCN, and derivatives thereof. Linkers comprising such reactive groups can be used to couple antibodies that have been functionalized with azide groups. Such functionalized antibodies include antibodies functionalized with azide-polyethylene glycol groups. In certain embodiments, such functionalized antibodies are obtained by reacting an antibody comprising at least one glutamine residue (e.g., heavy chain Q295) with a compound of formula H2N-LL-N3 in the presence of the enzyme transglutaminase, wherein LL is, for example, a divalent polyethylene glycol group, or wherein LL is a trivalent group comprising polyethylene glycol and a cyclodextrin moiety. In some embodiments, the reactive group is an alkyne, for example It can be synthesized by click chemistry with azides (e.g. ) reaction to form click chemistry products, such as In some embodiments, the reactive group is an alkyne, for example It can be synthesized by click chemistry with azides (e.g. ) reaction to form click chemistry products, such as In some embodiments, the reactive group is an alkyne, e.g. It can be synthesized by click chemistry with azides (e.g. ) reaction to form click chemistry products, such as its regioisomers, or mixtures thereof. In some embodiments, the reactive group is a functional group, such as It reacts with cysteine ​​residues on antibodies or antigen-binding fragments thereof to form bonds therewith, e.g. Wherein Ab refers to an antibody or an antigen-binding fragment thereof, S refers to the S atom on a cysteine ​​residue, and the functional group is bound to Ab via the S atom on the cysteine ​​residue. In some embodiments, the active group is a functional group, for example It reacts with lysine residues on antibodies or antigen-binding fragments thereof to form bonds therewith, e.g. Wherein Ab refers to an antibody or an antigen-binding fragment thereof, -NH- refers to the terminal end of a lysine residue through which the functional group is bound to Ab. In some embodiments, the functional group is represented by the letter N above the bond through the N atom on the lysine residue, for example

[0209] In some embodiments, RG-L 2 -(L 3 ) 0-1 - is the formula (L A ) shown as a monovalent group portion; RG–(SP 1 ) q –(A) z –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w – (L A ); Among them, RG is the active group; A is an amino acid or peptide; R a is H or alkyl; B is aryl, heteroaryl, or heterocycloalkyl, wherein the aryl, heteroaryl, or heterocycloalkyl is optionally substituted by alkyl, -OH, or -NR a R b replace; SP 1 and SP 2 and q, z, s, t, u, v, and w are each independently 0 or 1.

[0210] In some embodiments, RG-L 2 -(L 3 ) 0-1 - is RG–(SP 1 ) q –(A) z In some embodiments, RG-L 2 -(L 3 )0-1 - is RG–(SP 1 ) q –(A)2–. In some embodiments, RG-L 2 -(L 3 ) 0-1 - is the formula (L A1 ) shown in the group part: where R AA1 and R AA2 Each is independently an amino acid side chain. A1 In some embodiments, SP 1 is a divalent polyethylene glycol group, and RG is a group containing an alkyne capable of undergoing a 1,3-cycloaddition reaction with an azide.

[0211] In some embodiments, RG-L 2 -(L 3 ) 0-1 - has the following structure: RG–(SP 1 )q–Z 1 –Z 2 –Z 3 0–1 – in: RG, SP 1 and q have the definitions described in the present invention; Z 1 is a polyethylene glycol group or a hexanoyl group; Z 2 is a dipeptide; and Z 3 It is a PAB group.

[0212] In some other embodiments, -L 1 -L 2 -(L 3 ) 0-1 - is the formula (L B ) shown as a trivalent group portion; –L 1 –(SP 1 ) q –(A) z –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w – (L B ); Among them L 1 Having the definition described in the present invention; A is a tripeptide or tetrapeptide, wherein at least one amino acid of the tripeptide or tetrapeptide is directly or indirectly linked to a cyclodextrin moiety; R a is H or alkyl; B is aryl, heteroaryl, or heterocycloalkyl, wherein the aryl, heteroaryl, or heterocycloalkyl is optionally substituted by alkyl, -OH, or -NR a R b Replacement; SP 1 and SP 2 are independently spacer groups; and in formula L B In each case, q, z, s, t, u, v and w are independently 0 or 1.

[0213] In some embodiments, the cyclodextrin (CD) is directly connected to an amino acid residue, such as a lysine amino acid residue. This means that the CD is one key position away from the lysine amino acid covalent linker. In some of these embodiments, the covalent linker is also directly connected to a payload group portion. This means that the covalent linker is one key position away from a payload (such as, but not limited to, a steroid payload of the present invention). In some of these embodiments, the covalent linker is also directly connected to a CD group portion. This means that the covalent linker is one key position away from a CD (such as, for example, a CD of the present invention). In some of these embodiments, the covalent linker is a lysine amino acid or a derivative thereof.

[0214] In some embodiments, the CD is indirectly linked to a linker group (e.g., L, -L 2 -(L 3 ) 0-1 - and –L 1 -L 2 -(L 3 ) 0-1). This means that the CD is more than one bond position away from the covalent linker. This also means that the CD is connected to the covalent linker through another group portion. For example, the CD can be connected to a maleimide group, which is connected to a polyethylene glycol group, which is connected to the covalent linker. In some of these embodiments, the covalent linker is also indirectly connected to a payload group portion. This means that the covalent linker is more than one bond position away from a payload (such as, but not limited to, a steroid payload of the present invention). This also means that the covalent linker is connected to the payload through another group portion. For example, the covalent linker can be connected to a dipeptide, such as, but not limited to, Val-Ala or Val-Cit, which can be connected to a p-aminobenzoyl group, which can be connected to the payload. In some of these embodiments, the covalent linker is also indirectly connected to a cyclodextrin group portion. This means that the covalent linker is more than one bond position away from the cyclodextrin (e.g., the cyclodextrin of the present invention). This also means that the covalent linker is attached to the cyclodextrin through another moiety. For example, the covalent linker can be attached to a polyethylene glycol group, which can be attached to a reactive group, which can be attached to the cyclodextrin. In some of these embodiments, the covalent linker is a lysine amino acid or a derivative thereof.

[0215] In some embodiments, -L 1 -L 2 -(L 3 ) 0-1 -Yes–L 1 –(SP 1 ) q –(A) z In some embodiments, -L 1 -L 2 -(L 3 ) 0-1 -yes- L 1 –(SP 1 ) q –(A)2–. In some embodiments, -L 1 -L 2 -(L 3 ) 0-1 - is the formula (L B1 ) shown in the group part: where R AA1 and R AA2 Each is independently an amino acid side chain. AA3is an amino acid side chain directly or indirectly linked to a cyclodextrin moiety. B1 In some embodiments, SP 1 is a divalent polyethylene glycol group, and L 1 It is the product of a 1,3-cycloaddition reaction between an alkyne and an azide.

[0216] In some embodiments, A is In some of these embodiments, R AA1 is the amino acid side chain, R AA2 is the amino acid side chain, and R AA3 It is an amino acid side chain that is directly or indirectly linked to a cyclodextrin moiety.

[0217] In some embodiments, A is in represents a bond directly or indirectly attached to a cyclodextrin moiety.

[0218] In some embodiments, including any of the preceding embodiments, CD, at each occurrence, is independently selected from In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is In some embodiments, the CD is

[0219] In some embodiments, A is

[0220] In some embodiments, the RG of the present invention is selected from click chemistry active groups.

[0221] In some other embodiments, the RG of the present invention is selected from a group that reacts with a cysteine ​​residue or a lysine residue on an antibody or antigen-binding fragment thereof.

[0222] In some embodiments, RG is (wherein the -OCH2C(O)- is contained in –L 2 -middle), In some embodiments, RG is In other embodiments, RG is In some other embodiments, RG is In some embodiments, RG is In other embodiments, RG is In other embodiments, RG is Wherein the -OCH2C(O)- is contained in -L 2 -middle.

[0223] In some embodiments, SP 1 Included in -L 2 -In some embodiments, SP 1 You can choose from: In some embodiments, SP 1 yes In some other embodiments, SP 1 yes In other embodiments, SP 1 yes In other embodiments, SP 1 yes In some other embodiments, SP 1 yes

[0224] In any of the above embodiments, the subscripts a, b, and c are each independently an integer selected from 1 to 20, inclusive.

[0225] In some embodiments, SP 1 Included in -L 2 -In any of the compounds, SP 1 yes:

[0226] In some embodiments, SP 1 Included in -L 2 -In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes

[0227] In some embodiments, SP 1 Included in -L 2 -In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes In some embodiments, SP 1 yes

[0228] In some embodiments, RG-SP 1 (where SP 1 Included in -L 2 - in) can be selected from the group consisting of: wherein b, c, and d, at each occurrence, are each independently an integer selected from 1 to 20, inclusive. In some of these embodiments, the subscripts b, c, and d, at each occurrence, are each independently an integer selected from 1 to 6, inclusive.

[0229] In some embodiments, RG-SP 1 -yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes In some embodiments, RG-SP 1 yes

[0230] In any of the compounds, RG–SP 1 yes:

[0231] In some embodiments, A is a peptide selected from valine-citrulline, citrulline-valine, lysine-phenylalanine, phenylalanine-lysine, valine-asparagine, asparagine-valine, threonine-asparagine, asparagine-threonine, serine-asparagine, asparagine-serine, phenylalanine-asparagine, asparagine-phenylalanine, leucine-asparagine, asparagine-leucine, isoleucine-asparagine, asparagine-isoleucine, glycine-asparagine, asparagine-glycine, glutamic acid-asparagine, asparagine-glutamic acid, citrulline-asparagine, asparagine-citrulline, alanine-asparagine, or asparagine-alanine.

[0232] In some embodiments, A is valine-citrulline, or citrulline-valine.

[0233] In some embodiments, A is valine-alanine, or alanine-valine.

[0234] In some embodiments, A is glutamate-valine-citrulline, or citrulline-valine-glutamate.

[0235] In some embodiments, A is valine.

[0236] In some embodiments, A is alanine.

[0237] In some embodiments, A is citrulline.

[0238] In some embodiments, A is In some of these embodiments, R AA1 is an amino acid side chain, and R AA2 It is the amino acid side chain.

[0239] In some embodiments, A is

[0240] In some embodiments, A is

[0241] In some embodiments, R a It’s H.

[0242] In some embodiments, R a It is an alkyl group.

[0243] In some embodiments, Ra is methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, or pentyl.

[0244] In some embodiments, B is aryl.

[0245] In some embodiments, B is phenyl.

[0246] In some embodiments, B is phenyl or pyridinyl.

[0247] In some embodiments of the invention, B is:

[0248] In these embodiments, R 10 is alkyl, alkenyl, alkynyl, alkoxy, aryl, alkylaryl, arylalkyl, halogen, haloalkyl, haloalkoxy, heteroaryl, heterocycloalkyl, hydroxy, cyano, nitro, NR a R b , or azido. In these embodiments, the subscripts p and m are each independently an integer selected from 0 to 4 (including 0 and 4). In some embodiments of the present invention, B is:

[0249] In these embodiments, p is 0, 1, 2, 3, or 4. In some of these embodiments, R 1 Each occurrence is independently alkyl, alkoxy, haloalkyl, or halogen. In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 In some embodiments, R 1 It's a halogen.

[0250] In the formula (L A ) in some embodiments, the –(NR a ) s –(B) t –(CH2) u –(O) v –(SP 2 ) w yes:

[0251] The present invention also provides a linker-payload for budesonide, a budesonide prodrug, a budesonide analog or derivative (including a fluorinated analog and derivative), or a prodrug of a budesonide analog or derivative (including a fluorinated analog and derivative). In some embodiments, the present invention provides a linker-payload having the following structure: Among them, RG, R 4 、L 2 、L 3 and SP have the definitions given in the present invention. E. Pharmaceutical Compositions and Methods of Treatment

[0252] The present invention includes treating disease, condition or illness (such as inflammatory disease and autoimmune disease), or controlling its symptom method, including administering one or more compounds disclosed in the present invention of effective dose.Including any disease, disease or the patient's condition related to glucocorticoid receptor, glucocorticoid binding and / or glucocorticoid receptor signaling.Such method includes administering steroid payload or its protein conjugate of the present invention to the patient.Therefore, included in the present invention is the method for treating the disease, disease or the patient's condition related to glucocorticoid receptor, including administering formula (I), formula IP, formula IP-1, formula (III-P), formula III-P-1, formula (3000) or formula (III) compound to the patient suffering from the disease, disease or the patient's condition.

[0253] The present invention includes methods for preventing certain diseases or conditions, comprising administering a therapeutically effective amount of one or more compounds disclosed herein (i.e., preventive use). Examples include, but are not limited to, preventing CD3 bispecific cytokine release syndrome, and adoptive cell therapies such as CAR T cells, systemic IL-2 administration, graft-versus-host disease, and postoperative nausea and vomiting. Examples also include, but are not limited to, therapeutic antibodies such as alemtuzumab, muromonab, rituximab, tosituzumab, or agonist Ab classes (wherein immune stimulation may be part of the intended mechanism of action).

[0254] In some embodiments, the disease, disorder or condition is an allergic state, including but not limited to asthma, atopic dermatitis, contact dermatitis, drug allergic reaction, allergic rhinitis, perennial or seasonal allergic rhinitis, and serum sickness; skin diseases, including but not limited to pruritus, seborrheic dermatitis, neurodermatitis, eczema, bullous dermatitis herpeticum, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome); endocrine disorders, including but not limited to Primary or secondary adrenal insufficiency, congenital adrenal hyperplasia, cancer-related hypercalcemia, and non-suppurative thyroiditis; gastrointestinal disorders; hematologic disorders, including but not limited to acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), adult idiopathic thrombocytopenic purpura, pure red cell aplasia, and secondary thrombocytopenia; trichinosis; tuberculous meningitis with or impending subarachnoid blockade block; neoplastic diseases, including but not limited to leukemia and lymphoma; neurologic diseases, including but not limited to acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumors, craniotomy, or head injury; ophthalmologic diseases, including but not limited to sympathetic ophthalmia, temporal arteritis, uveitis, dry eye, and ocular inflammation unresponsive to topical corticosteroids; renal diseases, including but not limited to induced idiopathic nephrotic syndrome or lupus erythematosus with diuresis or proteinuria resolution; respiratory diseases, including but not limited to beryllium poisoning, fulminant or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy, idiopathic eosinophilic pneumonia, symptomatic sarcoidosis; and rheumatic diseases, including but not limited to short-term adjunctive treatment (to tide patients over acute attacks or exacerbations) for acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, and for the treatment of dermatomyositis, polymyositis, stomatitis and systemic lupus erythematosus.

[0255] In some embodiments, the present invention provides a method for treating a disease, disorder or condition selected from the group consisting of autoimmune diseases, allergies (allergies), arthritis, asthma, respiratory disorders, blood disorders, cancer, collagen diseases, connective tissue diseases, skin diseases, eye diseases, endocrine problems, immune diseases, inflammatory diseases, intestinal diseases, gastrointestinal diseases, neurological diseases, organ transplant disorders, rheumatoid diseases, skin diseases, swelling disorders, wound healing disorders, and combinations thereof, comprising administering a steroid payload or conjugate thereof as described herein.

[0256] In some embodiments, the autoimmune disease is selected from multiple sclerosis, autoimmune hepatitis, herpes zoster, systemic lupus erythematosus (i.e., lupus), myasthenia gravis, Duchenne muscular dystrophy, and sarcoidosis. In some embodiments, the respiratory disorder is selected from asthma, chronic respiratory disease, chronic obstructive pulmonary disease, bronchitis, and acute bronchitis. In some embodiments, the cancer is selected from leukemia, lymphocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), and multiple myeloma. In some embodiments, the collagen disease is systemic lupus erythematosus. In some embodiments, the eye disease is keratitis. In some embodiments, the endocrine problem is selected from Addison's Disease, adrenal insufficiency, adrenocortical insufficiency, adrenal cortex and congenital adrenal hyperplasia. In some embodiments, the inflammatory disease is selected from postoperative inflammation of cataract surgery, joint inflammation, immune inflammation, tendon inflammation, bursitis, epicondylitis, Crohn's disease, inflammatory bowel disease, fatty pneumonia thyroiditis, urticaria, pericarditis, nephrotic syndrome, and uveitis. In some embodiments, the intestinal disease is selected from collagenous colitis, ulcerative colitis, Crohn's disease and inflammatory bowel disease. In some embodiments, the rheumatoid disease is selected from rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus. In some embodiments, the skin disease is selected from psoriasis, eczema, and poison ivy. In some embodiments, the neurological disease is chronic inflammatory demyelinating polyradiculoneuropathy.

[0257] In some embodiments, the compounds described herein are administered to a patient to treat acute inflammatory events, including but not limited to shock, cerebral edema, and graft-versus-host disease. In some embodiments, the compounds described herein are administered to treat lympholysis, including but not limited to those associated with hematological malignancies, such as leukemias, lymphomas, and myelomas.

[0258] In some embodiments, the present invention provides a method for reducing inflammation in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof according to the present invention. In some embodiments, the present invention provides a method for modulating the immune system of a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof according to the present invention. In some embodiments, the present invention provides a method for modulating the cortisol level of a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof according to the present invention. In some embodiments, the present invention provides a method for reducing lymphocyte migration in a subject in need thereof, comprising administering to a subject in need thereof a therapeutically effective amount of a steroid or conjugate thereof according to the present invention. In some embodiments, the present invention provides a method for treating hypercalcemia caused by cancer, Meniere's disease, migraine, cluster headache, severe aphthous ulcers, laryngitis, severe tuberculosis, Herxheimer reaction to syphilis, decompensated heart failure, allergic rhinitis or nasal polyps, comprising administering to a subject in need thereof a steroid payload or a conjugate thereof according to the present invention. In some embodiments, the compounds disclosed herein can be used to treat inflammatory bowel disease, Crohn's disease or ulcerative colitis. In some embodiments, the disease, disorder or condition is a chronic inflammatory disease, including but not limited to asthma, skin infections and eye infections. In some embodiments, the compounds described herein are used for immunosuppression in patients undergoing organ transplantation.

[0259] In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat neurological disorders associated with GR signaling, including but not limited to psychiatric disorders such as schizophrenia, drug addiction, post-traumatic stress disorder (PTSD), mood disorders, substance abuse, stress, and anxiety.

[0260] In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat diseases of the visual system, including but not limited to ocular inflammation (e.g., conjunctivitis, keratitis, uveitis), macular edema, and macular degeneration. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat cardiovascular disease. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat glucose and / or liver metabolic disorders. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat diseases of the musculoskeletal system. In some embodiments, the steroid payloads and conjugates thereof described herein are administered to patients to treat inflammatory conditions of the skin, such as eczema and psoriasis.

[0261] The protein conjugates of the present invention provide a method for targeted delivery of their steroid payload to specific cells or organ systems, thereby reducing or preventing side effects caused by administration of free, unconjugated steroid payload. Examples of such potential side effects to be reduced or prevented include the use of dexamethasone in approved Those side effects listed in the drug label, which are incorporated herein by reference in their entirety. In some embodiments, the side effects to be reduced or prevented are selected from the group consisting of increased blood pressure; sodium retention; water / fluid retention (edema, angioedema, pulmonary edema); increased potassium excretion; reversible hypothalamic-pituitary adrenal (HPA) axis suppression; potential corticosteroid insufficiency after discontinuation of the drug; increased susceptibility to infection; worsening of systemic fungal infections; worsening of the severity of varicella in pediatric and adult patients; worsening of the severity of measles in pediatric and adult patients; posterior subcapsular cataracts; glaucoma that may damage the optic nerve; increased establishment of secondary eye infections due to bacteria, fungi, or viruses; increased new episodes of optic neuritis; Kaposi's sarcoma; drug-induced secondary adrenal insufficiency; and the presence of active or latent Increased risk of perforation in patients with chronic peptic ulcer disease, diverticulitis, fresh intestinal anastomosis, and nonspecific ulcerative colitis; peritoneal irritation following gastrointestinal perforation; decreased bone formation; increased bone resorption; inhibition of osteoblast function; inhibition of bone growth in pediatric patients; development of osteoporosis at any age; acute myopathy (which may affect the eyes and respiratory muscles and may lead to quadriplegia); elevated creatinine kinase; confusion, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations; worsening of existing emotional lability or psychotic tendencies; increased intraocular pressure; bradycardia; cardiac arrest; irregular heartbeat; cardiomegaly; circulatory collapse; congestive heart failure; fat embolism; hypertension; hypertrophy of prematurity cardiomyopathy; myocardial rupture after a recent myocardial infarction; syncope; tachycardia; thromboembolism; thrombophlebitis; vasculitis; acne; atopic dermatitis; xerosis cutis scaly; ecchymoses and petechiae; erythema; impaired wound healing; increased sweating; rash; striae; suppressed response to skin testing; fragile skin; thinning scalp hair; urticaria; impaired carbohydrate and glucose tolerance; development of Cushing's state; hyperglycemia; glycosuria; hirsutism; excessive hair growth; increased requirement for insulin or oral hypoglycemic agents in patients with diabetes (insulin resistance); potential manifestations of diabetes; menstrual irregularities; secondary adrenocortical and pituitary unresponsiveness (particularly during periods of stress, such as trauma, surgery, or illness); growth suppression in pediatric patients; and in susceptible patients. Congestive heart failure; fluid retention; hypokalemic alkalosis; potassium wasting; sodium retention; abdominal distension; elevated serum liver enzyme levels (usually reversible after discontinuation of the drug); hepatomegaly; increased appetite; nausea; pancreatitis; peptic ulcer with possible perforation and bleeding; perforation of the small and large intestine (particularly in patients with inflammatory bowel disease); ulcerative esophagitis; negative nitrogen balance due to protein catabolism; aseptic necrosis of the femoral and humeral heads; decreased muscle mass; muscle weakness; osteoporosis; pathological fractures of long bones; steroid myopathy; tendon rupture; vertebral compression fractures; seizures; depression; mood lability; euphoria; headache; increased intracranial pressure with papilledema (pseudotumor cerebri) usually after discontinuation of the drug; insomnia; mood swings; neuritis; neuropathy;Paresthesia; personality changes; mental disorders; vertigo; proptosis; glaucoma; increased intraocular pressure; posterior subcapsular cataracts; abnormal fat deposits; decreased resistance to infection; hiccups; increased or decreased sperm motility and count; malaise; moon face; and weight gain; as well as those side effects associated with drug-drug interactions. In some embodiments, the side effects to be reduced or prevented are side effects associated with drug-drug interactions. In some embodiments, the side effects to be reduced or prevented are those associated with drug-drug interactions with the use of corticosteroids with aminoglutethimide, including reducing the side effects of drug-drug interactions with the following drugs and adrenal suppression: corticosteroids; amphotericin B injection and potassium-depleting drugs, including hypokalemia, heart enlargement, and development of congestive heart failure; antibiotics, including a significant decrease in corticosteroid clearance; anticholinesterases, including producing severe weakness in patients with myasthenia gravis; oral anticoagulants, including inhibiting the response to warfarin; antidiabetic drugs, including increasing blood glucose concentrations; anti-tuberculosis drugs, including decreasing serum levels of isoniazid. concentration; cholestyramine, including increased clearance of corticosteroids; cyclosporine, including increased activity of cyclosporine and corticosteroids, and the incidence of convulsions; interference with the dexamethasone suppression test (DST), including false-negative results in patients treated with indomethacin; digitalis glycosides, including increased risk of arrhythmias due to hypokalemia; ephedrine, including enhanced metabolic clearance of corticosteroids, leading to decreased blood levels and decreased physiological activity; estrogens, including oral contraceptives, including decreased hepatic metabolism of some corticosteroids and associated increases in their effects; hepatic enzyme inducers, inhibitors, and substrates (drugs that induce cytochrome P450 3A4 (CYP 3A4) enzyme activity, such as barbiturates, phenytoin, carbamazepine, rifampicin), including enhanced metabolism of corticosteroids; drugs that inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin), including possible increases in plasma concentrations of corticosteroids; Drugs metabolized by 3A4 (e.g., indinavir, erythromycin), including increased clearance leading to decreased plasma concentrations; ketoconazole, including decreased metabolism of certain corticosteroids by up to 60%, resulting in an increased risk of corticosteroid side effects, and inhibition of adrenal corticosteroid synthesis, which may lead to adrenal insufficiency during corticosteroid withdrawal; nonsteroidal anti-inflammatory drugs (NSAIDS), including increased risk of gastrointestinal side effects and increased clearance of salicylates; phenytoin, including increased or decreased phenytoin levels, altered seizure control; skin test agents, including suppressed responses to skin tests; thalidomide, including toxic epidermal necrolysis; and vaccines, including decreased responses to toxoids and live or inactivated vaccines, due to suppression of the antibody response contained in live attenuated vaccines or enhanced replication of certain organisms.

[0262] Thus, the present invention provides a method for treating a disease, disorder or condition associated with a glucocorticoid receptor, comprising administering a conjugate of formula (III) to a patient suffering from the disease, disorder or condition, wherein the side effects associated with the administration of the free steroid payload of the conjugate are reduced. In addition, the present invention provides a method for delivering a compound of formula (III-P), formula III-P-1, formula (3000) or formula (III) to a cell, comprising contacting the cell with a protein conjugate of a compound of formula (III-P), formula III-P-1, formula (3000) or formula (III), wherein the protein conjugate comprises an antibody or antigen-binding fragment thereof that binds to the cell surface antigen.

[0263] The compounds described herein can be administered alone or in combination with one or more additional therapeutic agents. The one or more additional therapeutic agents can be administered prior to, concurrently with, or shortly after administration of the compounds described herein. The present invention also includes pharmaceutical compositions comprising any of the compounds described herein in combination with one or more additional therapeutic agents, as well as methods of treatment comprising administering such combinations to a patient in need thereof.

[0264] Suitable additional therapeutic agents include, but are not limited to, a second glucocorticoid, an autoimmune therapeutic agent, a hormone, a biologic, or a monoclonal antibody. Suitable therapeutic agents also include, but are not limited to, any pharmaceutically acceptable salts, acids, or derivatives of the compounds of the present invention.

[0265] The compounds of the present invention may also be combined / co-administered and / or co-formulated with antivirals, antibiotics, analgesics, corticosteroids, steroids, molecular oxygen, antioxidants, COX inhibitors, cardioprotectants, metal chelators, IFN-γ, and / or NSAIDs.

[0266] In some embodiments of the methods described herein, multiple doses of a compound of the invention (or a pharmaceutical composition comprising a combination of a compound of the invention and any additional therapeutic agent mentioned herein) may be administered to a subject over a prescribed time period. The methods of this aspect of the invention comprise sequentially administering multiple doses of a compound of the invention to a subject. As used herein, "sequential administration / administration" means that each dose of the compound is administered to the subject at different time points, for example, on different days separated by predetermined intervals (e.g., hours, days, weeks, or months). The present invention includes methods comprising sequentially administering to a patient a single initial dose of a compound of the invention, followed by one or more secondary doses of the compound, and optionally, subsequent administration of one or more tertiary doses of the compound.

[0267] The terms "initial dose", "secondary dose", and "tertiary dose" refer to the chronological order of administration of the compounds described herein. Thus, an "initial dose" is a dose administered at the start of a treatment regimen (also referred to as a "baseline dose"); a "secondary dose" is a dose administered after the administration of the initial dose; and a "tertiary dose" is a dose administered after the administration of the secondary dose. The initial, secondary, and tertiary doses may all contain the same amount of a compound of the invention, but may generally differ from one another in terms of frequency of administration. In certain embodiments, the amounts of the compounds contained in the initial, secondary, and / or tertiary doses vary from one another (e.g., adjusted up or down, as appropriate) during the course of treatment. In certain embodiments, at the start of a treatment regimen, two or more (e.g., 2, 3, 4, or 5) doses are administered as "loading doses," followed by less frequent subsequent doses (e.g., "maintenance doses").

[0268] In some exemplary embodiments described herein, each second and / or third dose is administered 1 to 26 weeks (e.g., 1, 1 1 / 2, 2, 2 1 / 2, 3, 3 1 / 2, 4, 4 1 / 2, 5, 5 1 / 2, 6, 6 1 / 2, 7, 7 1 / 2, 8, 8 1 / 2, 9, 9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 / 2, 15, 15 1 / 2, 16, 16 1 / 2, 17, 17 1 / 2, 18, 18 1 / 2, 19, 19 1 / 2, 20, 20 1 / 2, 21, 21 1 / 2, 22, 22 1 / 2, 23, 23 1 / 2, 24, 24 1 / 2, 25, 25 1 / 2, 26, 26 1 / 2, or more). As used herein, the phrase "immediately following the preceding dose" means that in a sequence of multiple administrations, a dose of a compound of the invention is administered to a patient prior to the administration of the immediately next dose, without an intervening dose in the administration sequence.

[0269] The methods of this aspect of the invention may comprise administering to the patient any number of secondary and / or tertiary doses of a compound of the invention. For example, in certain embodiments, only a single secondary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) secondary doses are administered to the patient. Similarly, in certain embodiments, only a single tertiary dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8 or more) tertiary doses are administered to the patient. The dosing regimen may be continued indefinitely over the lifespan of a particular subject, or until such treatment is no longer necessary or beneficial.

[0270] In embodiments involving multiple secondary doses, each secondary dose can be administered / dosed at the same frequency as the other secondary doses. For example, each secondary dose can be administered to the patient 1 to 2 weeks or 1 to 2 months after the previous dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose can be administered / dosed at the same frequency as the other tertiary doses. For example, each tertiary dose can be administered to the patient 2 to 12 weeks after the previous dose. In certain embodiments of the present invention, the frequency of administering secondary and / or tertiary doses to the patient can vary over the course of the treatment regimen. The frequency of administration can also be adjusted by the physician during treatment based on the needs of the individual patient after clinical examination.

[0271] The present invention includes dosing regimens in which a loading dose is administered to a patient 2 to 6 times at a first frequency (e.g., weekly, biweekly, three-weekly, monthly, every two months, etc.), followed by two or more maintenance doses administered to the patient less frequently. For example, according to this aspect of the invention, if a loading dose is administered monthly, a maintenance dose may be administered every 6 weeks, every two months, every three months, etc.

[0272] The present invention includes pharmaceutical compositions of the compounds and / or conjugates of the present invention, such as compounds represented by Formula (I), Formula IP, Formula IP-1, Formula (III-P), Formula III-P-1, Formula (3000), and Formula (III), for example, compositions comprising the compounds of the present invention, their salts, stereoisomers, polymorphs, and pharmaceutically acceptable carriers, diluents, and / or excipients. Examples of suitable carriers, diluents, and excipients include, but are not limited to, buffers for maintaining an appropriate pH value for the composition (e.g., citrate buffer, succinate buffer, acetate buffer, phosphate buffer, lactate buffer, oxalate buffer, etc.), carrier proteins (e.g., human serum albumin), nanoparticles, saline, polyols (e.g., trehalose, sucrose, xylitol, sorbitol, etc.), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene esters (polyoxolates), etc.), antimicrobial agents, and antioxidants.

[0273] In some embodiments, the present invention provides a method for treating a disease, disorder or condition, comprising administering to a patient suffering from the disorder a therapeutically effective amount of a compound of Formula (I), Formula IP, Formula IP-1, Formula (III-P), Formula III-P-1, Formula (3000), or Formula (III) or a pharmaceutical composition thereof.

[0274] In some embodiments, the present invention provides a method of treating a disease, disorder, or condition comprising administering to a patient suffering from the disorder a therapeutically effective amount of a compound of the present invention or a pharmaceutical composition thereof.

[0275] In some embodiments, the present invention provides a method of treating a disease, disorder or condition selected from the group consisting of an immune disease, an autoimmune disease, inflammation, asthma, or inflammatory bowel disease, Crohn's disease, ulcerative colitis.

[0276] In some embodiments, the present invention provides a method for treating a disease, disorder or condition by targeting an antigen (e.g., an antigen expressed on the surface of a cell) wherein steroid administration can achieve therapeutic benefit, comprising administering a conjugate of the present invention. In some embodiments, the antigen is AXL, BAFFR, BCMA, BCR-list components, BDCA2, BDCA4, BTLA, BTNL2BTNL3, BTNL8, BTNL9, C10orf54, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR9, CCR10, CD11c, CD137, CD138, CD14, CD168, CD177, CD19, CD20, CD209, CD209L, CD22, CD226, CD 248, CD25, CD27, CD274, CD276, CD28, CD30, CD300A, CD33, CD37, CD38, CD4, CD40, CD44, CD45, CD47, CD46 , CD48, CD5, CD52, CD55, CD56, CD59, CD62E, CD68, CD69, CD70, CD74, CD79a, CD79b, CD8, CD80, CD86, CD90.2. CD96, CLEC12A, CLEC12B, CLEC7A, CLEC9A, CR1, CR3, CRTAM, CSF1R, CTLA4, CXCR1 / 2, CXCR4, CXCR5, DDR1, DDR2, DEC–205, DLL4, DR6, FAP, FCamR, FCMR, FcR's, Fire, GITR, HHLA2, HLA Class II, HVEM, ICOSLG, IFNLR1, IL10R1, IL10R2, IL12R, IL13RA1, IL13RA2, IL15R, IL17RA, IL17RB, IL17RC, IL17RE, IL20R1, IL20R2, IL21R, I L22R1, IL22RA, IL23R, IL27R, IL29R, IL2Rg, IL31R, IL36R, IL3RA, IL4R, IL6R, IL5R, IL7R, IL9R, Integrins, LAG3, LIFR, MAG / Siglec -4 (sialic acid-binding immunoglobulin-like lectin-4), MMR, MSR1, NCR3LG1, NKG2D, NKp30, NKp46, PDCD1, PROKR1, PVR, PVRIG, PVRL2, PVRL3, RELT, SIGIRR, Siglec-1 (sialic acid-binding immunoglobulin-like lectin-1), Siglec–10, Siglec–5, Siglec–6, Siglec–7, Siglec–8, Siglec–9, SIRPA, SLAMF7, TACI, TCR-list components / assoc, PTCRA, TCRb, CD3z, CD3, TEK, TGFBR1, TGFBR2, TGFBR3, TIGIT, TLR2, TLR4, TROY, TSLPR, TYRO, VLDLR, VSIG4, or VTCN1. In some embodiments, the antigen is IL2R-γ.

[0277] In some embodiments, the present invention provides methods for treating a disease, disorder, or condition selected from an immune disease, an autoimmune disease, an inflammatory disease, a skin disease, or a gastrointestinal disease.

[0278] In some embodiments, the disease is Crohn's disease, ulcerative colitis, Cushing's syndrome, adrenal insufficiency, or congenital adrenal hyperplasia.

[0279] In some embodiments, the disease is inflammation, asthma, or inflammatory bowel disease.

[0280] In some embodiments, the disease is an autoimmune disease selected from multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, psoriasis, or eczema.

[0281] In some embodiments, the present invention provides a method for reducing or ameliorating the side effects of chemotherapy, wherein the method comprises administering a therapeutically effective amount of a compound or composition of the present invention to a patient suffering from the disorder.

[0282] In some embodiments, the present invention provides a method for reducing or ameliorating the side effects of immunosuppressive therapy, wherein the method comprises administering to a patient suffering from the disorder a therapeutically effective amount of a compound or composition of the present invention.

[0283] In some embodiments, the present invention provides a method for treating cancer, wherein the method comprises administering a therapeutically effective amount of a compound or composition of the present invention to a patient suffering from the condition. In some embodiments, the cancer is selected from acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), or multiple myeloma, among others.

[0284] F. Examples

[0285] Certain embodiments are illustrated by the following non-limiting examples.

[0286] Unless otherwise specifically stated, reagents and solvents were obtained from commercial sources such as Sinopharm Chemical Reagent Co. (SCRC), Sigma-Aldrich, Alfa, or other suppliers.

[0287] Recording on BrukerAVIII 400 or BrukerAVIII 500 1 HNMR and other NMR spectra were processed using Nuts software or MestReNova software, and the proton shifts in parts per million (ppm) downfield from the internal standard tetramethylsilane were measured.

[0288] HPLC-MS measurements were performed on an Agilent 1200HPLC / 6100SQ system using the following conditions:

[0289] Method A for HPLC-MS determination includes as mobile phase: A: water (0.01% trifluoroacetic acid TFA) and B: acetonitrile (0.01% TFA). The gradient phase is 5% B, which increases to 95% B at a flow rate of 1.0 mL / min over a period of 15 minutes (min). The chromatographic column used is a SunFire C18, 4.6x50 mm, 3.5 μm. The column temperature is 50° C. The detector includes an analog-to-digital converter ELSD (evaporative light scattering detector, hereinafter referred to as "ADC ELSD"), a DAD (diode array detector, 214 nm and 254 nm) and electrospray ionization-atmospheric pressure ionization (ES-API).

[0290] Method B for HPLC-MS analysis included the following mobile phases: A: water (10 mM NH4HCO3) and B: acetonitrile. The gradient was 5% B, increasing to 95% B over a 15-minute period at a flow rate of 1.0 mL / min. The column used was an XBridge C18, 4.6 x 50 mm, 3.5 μm. The column temperature was 50°C. Detectors included an ADC ELSD, a DAD (214 nm and 254 nm), and a mass detector (MSD ES-API).

[0291] LC-MS assays were run on an Agilent 1200HPLC / 6100SQ system using the following conditions:

[0292] Method A for LC-MS determination was performed on a WATERS2767 instrument. The chromatographic column was a Shimadzu Shim-Pack, PRC-ODS, 20x250 mm, 15 μm, two of which were connected in series. The mobile phase was A: water (0.01% TFA) and B: acetonitrile (0.01% TFA). The gradient phase was 5% B, which increased to 95% B at a flow rate of 1.8-2.3 mL / min over a period of 3 minutes. The chromatographic column used was a SunFire C18, 4.6x50 mm, 3.5 μm. The column temperature was 50°C. The detectors included an analog-to-digital converter ELSD (evaporative light scattering detector), a DAD (diode array detector) (214 nm and 254 nm), and an ES-API.

[0293] Method B, used for LC-MS analysis, was performed on a Gilson GX-281 instrument. The column was an Xbridge Prep C18 10 μm OBD, 19 x 250 mm. The mobile phases were A: water (10 mM NH₄HCO₃) and B: acetonitrile. The gradient was 5% B increasing to 95% B over a 3-minute period at a flow rate of 1.8-2.3 mL / min. The column used was an XBridge C18, 4.6 x 50 mm, 3.5 μm. The column temperature was 50°C. Detectors included an ADC ELSD, a DAD (214 nm and 254 nm), and a mass selective detector (MSD) (ES-API).

[0294] Preparative high pressure liquid chromatography (preparative HPLC) was performed on a Gilson GX-281 instrument. Two solvent systems were used, one acidic and one basic. The acidic solvent system included a Waters SunFire 10 μm C18 column ( 250 x 19 mm). Solvent A for preparative HPLC was 0.05% TFA in water, and solvent B was acetonitrile. The elution condition was a linear gradient from 5% solvent B to 100% solvent B over a period of 20 minutes at a flow rate of 30 mL / min. The basic solvent system consisted of a Waters Xbridge 10 μm C18 column ( 250 x 19 mm). Solvent A for preparative HPLC was a 10 mM aqueous solution of ammonium bicarbonate (NH4HCO3), and solvent B was acetonitrile. The elution condition was a linear gradient increasing from 5% solvent B to 100% solvent B over a period of 20 minutes at a flow rate of 30 mL / min.

[0295] Flash chromatography was performed on a Biotage instrument using an Agela Flash Column silica-CS. Unless otherwise specifically stated, reversed-phase flash chromatography was performed on a Biotage instrument using a Boston ODS or an Agela C18.

[0296] The following abbreviations are used in the examples and throughout the specification: Preparation method Example 1

[0297] Figure 3Scheme 1 in Figure 1 shows the synthesis of budesonide-spacers containing active groups, suc-acids (compound 1c), carbamate analogs (1d, 1e), THP-analogs (1g and 1h), glucose analogs (1i and 1j), phosphate analogs (1k and 1l), and a commercially available phosphate analog (1m). Intermediate 3a 1-[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy}carbonyl)oxy]pyrrolidine-2,5-dione (3a)

[0298] To a solution of budesonide 1a (0.10 g, 0.26 mmol) in DCM (1 mL) was added bis(2,5-dioxopyrrolidin-1-yl) carbonate (71 mg, 0.30 mmol), triethylamine (47 mg, 0.52 mmol) and DMAP (3.0 mg, catalytic amount). The reaction mixture was stirred at 15-25 ° C for 12 hours until budesonide was exhausted and monitored by LCMS. The reaction mixture was then diluted with DCM and washed with water. The organic solution was dried over sodium sulfate. After filtration, the solution was concentrated in vacuo, and the residue (crude 3a) was used directly in the next step without purification (93 mg, yield 71%). ESI m / z: 572.2 (M + H) + . Example 1c 4-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy}-4-oxobutanoic acid (1c)

[0299] See WO2015005459; WO2013074988; Research in Pharmaceutical Science, 2011, 6(2), 107-116; and International Journal of Pharmaceutics, 2009, 365(1-2), 69-76.

[0300] To a solution of budesonide (1a, 0.10 g, 0.26 mmol) in DCM (1 mL) were added succinic anhydride (30 mg, 0.30 mmol), triethylamine (47 mg, 0.52 mmol) and DMAP (3 mg, catalytic amount, 0.02 mmol). The mixture was stirred at room temperature for 12 hours until budesonide was consumed and monitored by TLC and LCMS. The reaction mixture was then diluted with DCM and washed with water. The organic solution was dried over sodium sulfate. After filtration, the solution was concentrated in vacuo and the resulting residue was purified by preparative HPLC to give the title compound 1c (22 mg, 18% yield) as a white solid. ESI m / z: 531.3 (M+H) + . 1 H NMR (500MHz, CDCl3) δ7.48 (d, J = 10Hz, 1H), 6.28-6.26 (m, 1H), 6.04-6.02 (m, 1H), 5.23-5.11 (m, 1H), 5.06-4.99 (m, 1H), 4.83-4.68 (m, 1H), 4.45- 4.43(m,1H),2.76-2.63(m,5H),2.41-2.39(m,1H),2.26-2.12(m,2H),1 .99-1.66(m,6H),1.57-1.38(m,6H),1.32(s,1H),1.16-0.94(m,8H)ppm. Example 1d 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-methyl-N-[2-(methylamino)ethyl]carbamate (1d)

[0301] To a solution of crude intermediate 3a (63 mg, 0.11 mmol) in DCM (5 mL) was added N,N'-dimethylethane-1,2-diamine (28 mg, 0.32 mmol) and triethylamine (38 mg, 0.38 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 hours until most of 3a was consumed, as monitored by LCMS. The volatiles were removed in vacuo and the resulting residue was purified by preparative HPLC (Method B) to afford 1d (4 mg, 4.5% yield) as a white solid. ESI m / z: 545.3 (M+H) + . 1 H NMR (500MHz, CDCl3) δ7.32-7.30(m,1H),6.28-6.25(m,1H),6.02-6.01(m,1H),4.42(br s,1H),3.50-3.23(m,3H),3.10-3.02(m,3H),2.82-2.71(m,3H),2.57-2.55(m,1H),2.35-2.33(m,1H),2.15-2.06(m, 2H),1.96-1.79(m,12H),1.60-1.56(m,3H),1.46(m,3H),1.37-1.33(m,2H),1.23-1.04(m,4H),0.92-0.86(m,3H)ppm. Example 1e 2-[(1S,2S,4R,8S,9S,11S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-[(hydrazinecarbonyl)methyl]carbamate (1e)

[0302] To a mixture of 3a crude product (0.16 g, 0.28 mmol) in DMF (3 mL) was added Boc-2-(2-aminoacetyl)hydrazine (80 mg, 0.42 mmol) and triethylamine (85 mg, 0.84 mmol). The reaction mixture was stirred at 25 ° C for 16 hours, and the intermediate 3a was exhausted and monitored by LCMS. The mixture was then quenched with water and extracted with ethyl acetate. The combined organic solution was dried over anhydrous sodium sulfate. After filtration, the solution was concentrated in vacuo. The resulting residue was purified by silica gel column chromatography (30-50% ethyl acetate in petroleum ether) to give Boc-1e (70 mg) as a white solid (ESI m / z: 646 (M + H) +) was dissolved in DCM (2 mL). TFA (1 mL) was added dropwise to this solution at 0°C. The mixture was stirred at 25°C for 2 hours until Boc-1e was consumed, as monitored by LCMS. The volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC to afford the title compound 1e (7 mg, 12% yield) as a white solid. ESI m / z: 546 (M+H) + . Example 1g (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-{[6-(hydroxymethyl)tetrahydropyran-2-yl]oxy}acetyl)-9,13-dimethyl-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]Eicosan-14,17-dien-16-one (1g)

[0303] To a solution of budesonide (1a, 50 mg, 0.12 mmol) in anhydrous DCM (4 mL) was added (3,4-dihydro-2H-pyran-2-yl)methanol (0.11 g, 0.93 mmol) and p-toluenesulfonic acid (31 mg, 0.18 mmol) at 0°C. The reaction mixture was stirred at room temperature for 4 days and monitored by LCMS. The volatiles were removed by vacuum concentration, and the residue was dissolved in DMF and separated by preparative HPLC (method B) to give the title compound 1g (13 mg, 20% yield) as a white solid. ESI m / z: 545 (M+H) + . Example 1h 2-[(6-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}tetrahydropyran-2-yl)methoxy]acetic acid methyl ester (1h)

[0304] Under nitrogen protection at 0°C, sodium hydride (60% mineral oil, 0.88 g, 22 mmol) was added in portions to a solution of (3,4-dihydro-2H-pyran-2-yl)methanol (2.0 g, 18 mmol) in THF (30 mL). The suspension was stirred at 0°C until hydrogen evolution was complete. A solution of 2-bromoethyl acetate (4.0 g, 26 mmol) in THF (18 mL) was then added to the resulting mixture. The mixture was stirred at room temperature overnight until most of the starting material was consumed according to LCMS monitoring. After cooling to 0°C, the reaction was quenched with water under nitrogen protection and extracted with ethyl acetate. The combined organic solution was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The resulting residue was purified by flash chromatography (0-8% ethyl acetate in petroleum ether) to give ethyl 2-((3,4-dihydro-2H-pyran-2-yl)methoxy)acetic acid (0.70 g, 21% yield) as a colorless oil. ( 1 H NMR (500 MHz, DMSO d6 )δ6.36(d,J=6.0Hz,1H),4.67(m,1H),4.16(s,2H),3.92(m,1H),3.65(s,3H),3.57(d ,J=5.5Hz,2H),2.50-1.99(m,1H),1.93-1.82(m,1H),1.80(m,1H),1.60(m,1H)ppm.)

[0305] To a solution of budesonide (1a, 0.11 g, 0.25 mmol) in anhydrous DCM (8 mL) was added ethyl 2-((3,4-dihydro-2H-pyran-2-yl)methoxy)acetate (0.35 g, 1.9 mmol) and p-toluenesulfonic acid (66 mg, 0.35 mmol) obtained above at 0°C. The reaction mixture was stirred at room temperature for 4 hours and monitored by LCMS. The volatiles were removed by vacuum concentration, and the residue was dissolved in DMF and separated by preparative HPLC (Method A) to give the title compound 1h (46 mg, 29% yield) as a white solid. ESI m / z: 617 (M+H) + . Example 1i (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-6-propyl-8-(2-{[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy}acetyl)-5,7-dioxopentacyclo[10.8.0.0 2,9 .0 4,8 .0 13,18 ]Eicosan-14,17-dien-16-one (1i, including diastereomers)

[0306] To a mixture of budesonide (1a, 0.22 g, 0.50 mmol) and acetyl bromide-α-D-glucose (0.33 g, 0.80 mmol) in DCM (15 mL) was added Molecular sieves (1.0 g), the resulting mixture was stirred at room temperature for half an hour, and then silver trifluoromethanesulfonate (0.19 g, 0.75 mmol) was added at 0°C. The suspension was stirred at room temperature under nitrogen protection for one weekend (72 hours) in a dark environment. The mixture was filtered through celite and the filtrate was concentrated in vacuo. The resulting residue was purified by preparative HPLC (method B) to give Ac-1i (25 mg, yield 9.2%) as a white solid. ESI m / z: 761 (M+H) + . 1 HNMR (DMSO d6 , 400 MHz) (including diastereomers) δ7.34-7.30 (m, 1H), 6.19-6.14 (m, 1H), 5.91 (s, 1H), 5.29 (t, J = 9.2 Hz, 1H), 5.17-5.15 (m, 0.5H), 5.03-5.01 (m, 0.5H), 4.96-4.90 (m, 1H), 4.85-4.74 (m, 3H), 4.70-4.67 (m, 1H), 4.64-4.63 (m, 0.5H), 4.59-4.5 6(m,0.5H),4.39-4.28(m,2H),4.20-4.16(m,1H),4.05-3.99(m,2H),2.56-2.40(m,1H),2.32-2.26(m,1H),2.13- 1.89(m,14H),1.83-1.63(m,3H),1.59-1.48(m,3H),1.44-1.21(m,6H),1.15-0.91(m,2H),0.86-0.81(m,6H)ppm.

[0307] To a solution of compound Ac-1i (30 mg, 39 μmol) obtained above in water (1 mL) and methanol (3 mL) was added lithium hydroxide monohydrate (17 mg, 0.40 mmol) at 0°C. After the mixture was stirred at 0°C for 1 hour, the mixture was directly purified by preparative HPLC (Method B) to give 1i (24 mg, 98% yield) as a white solid. ESI m / z: 593 (M+H) + . 1 H NMR (MeOD d4, 400 MHz) (including diastereomers) δ7.46 (t, J = 10.4 Hz, 1H), 6.26 (dt, J = 10.0 and 2.0 Hz, 1H), 6.02 (s, 1H), 5.21 and 4.64 (t, J = 4.8 Hz, 1H), 5.16 (t, J = 7.2 Hz, 0.5H), 4.94-4.80 (m, 2.5H), 4.57-4.47 (m, 1H), 4.44-4.41 (m, 1H), 4.34- 4.31(m,1H),3.90-3.87(m,1H),3.70-3.64(m,1H),3.39-3.24(m,4H),2.70-2.62(m,1H),2.41-2.36(m, 1H),2.27-2.08(m,2H),2.00-1.93(m,1H),1.88-1.81(m,1H),1.74-1.32(m,9H),1.22-0.90(m,8H)ppm. Example 1j (2S,3S,4S,5R,6R)-3,4,5-trihydroxy-6-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy}tetrahydropyran-2-carboxylic acid (1j, including diastereomers)

[0308] Following a similar procedure as 1i, except that acetyl bromide-α-D-glucuronic acid methyl ester was used instead of acetyl bromide-α-D-glucose, compound 1j (24 mg, 9.2% yield over 2 steps) was obtained as a white solid. ESI m / z: 607 (M+H) + . 1 HNMR (MeOD d4,400MHz)δ7.48(t,J=10.0Hz,1H),6.28-6.24(m,1H),6.02(s,1H),5.22-5.15(m,1H),4.98-4. 81(m,2.5H),4.65-4.56(m,1.5H),4.45-4.39(m,2H),3.62-3.59(m,1H),3.52-3.46(m,1H),3. 41(t,J=8.8Hz,1H),3.30-3.28(m,1H),2.70-2.62(m,1H),2.40-2.36(m,1H),2.27-2.10(m,2H ),1.95-1.92(m,2H),1.75-1.54(m,3H),1.50(s,3H),1.51-1.32(m,3H),1.12-0.90(m,8H)ppm. Example 1k (2,2113-ethoxy)({21H)S,2S,4R,8S,9S,11S,12S,13R)13-oxy)({21H),3.30-3.28(m,1H),2.70-2.62(m,1H),2.40-2.36(m,1H) 2,9 .0 4,8 .0 13,18 ]eicosane)({21H,3.30-3.28oxyethoxy})phosphinic acid (1k)

[0309] To a solution of triethylamine (0.67 g, 6.6 mmol) in chloroform (4 mL) was added phosphorus oxychloride (0.51 mg, 3.3 mmol) at 0 ° C., followed by a solution of budesonide (1a, 1.3 g, 3.0 mmol) in chloroform (4 mL). After the mixture was stirred at 20 ° C. for 2 hours, the mixture was cooled to 0 ° C., and a solution of Boc-ethanolamine (0.41 mg, 2.6 mmol) in chloroform (4 mL) and pyridine (3 mL) was added. The mixture was stirred at 20 ° C. for 1 hour until the reaction was completed according to LCMS monitoring, and the reaction mixture was quenched by adding water (2 mL) at 0 ° C. The mixture was stirred at 20 ° C. overnight. The volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC (method B) to give crude Boc-1k (330 mg, 17%) as a yellow film. ESI m / z: 676 (M + Na) + .

[0310] To a solution of Boc-1k (0.18 g, 0.28 mmol) in DCM (5 mL) was added trifluoroacetic acid (0.5 mL) at 0°C. The resulting mixture was stirred at 23°C for 2 hours until Boc was completely removed according to LCMS monitoring. The volatiles were removed in vacuo. The resulting residue was purified by preparative HPLC (Method B) to afford 1k as a white solid (90 mg, 59% yield). ESI m / z: 554 (M+H) + . 1 H NMR (500 MHz, MeOD d4 ) δ 7.49 (d, J = 10.1 Hz, 1H), 6.28 (d, J = 10.1 Hz, 1H), 6.03 (s, 1H), 5.24-5.15 (m, 1H), 4.87-4.62 (m, 3H), 4.45 (d, J = 6.1 Hz, 1H), 4.18-4.15 (m, 2H), 3.22-3.20 (m, 2H), 2.71-2.64 (m, 1H), 2.40 (d, J = 13.4 Hz, 1H), 2.29-1.71 (m, 6H), 1.65-1.32 (m, 9H), 1.22-0.91 (m, 7H) ppm. Analytical HPLC: >99.9%, retention time: 3.90 min (Method B). Example 11 (2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}ethoxy)phosphonic acid

[0311] See J. Am. Chem. Soc., 2016, 138(4), 1430-1445; WO2015153401; and Phosphorus, Sulfur and Silicon and the Related Elements, 2000, 165, 83-90.

[0312] To a mixture of Fmoc-ethanolamine (1.1 g, 3.9 mmol) in THF (16 mL) was added pyrophosphoryl chloride (2.2 g, 8.8 mmol) via a syringe at -40 ° C. The mixture was stirred at -40 ° C for 1 hour until the starting material was completely consumed by LCMS monitoring. The reaction mixture was quenched with water (1 mL) at -40 ° C., treated with saturated aqueous sodium bicarbonate solution (200 mL), and then kept at 10-20 ° C overnight. The resulting mixture was acidified to pH 2 with concentrated hydrochloric acid and then extracted with ethyl acetate. The combined organic solution was dried over sodium sulfate and concentrated to give the crude title compound (1.6 g, crude product) as a white solid, which was used in the next step without purification. ESI m / z: 364 (M + H) +. (2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}ethoxy)({[hydroxy({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4, 8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy})phosphoryl]oxy})phosphinic acid (Fmoc-11)

[0313] According to the above method, except that budesonide (1a, 0.86 g, 20 mmol) was used instead of Fmoc-ethanolamine, the budesonide phosphonate intermediate 1a-PO3H2 (1.1 g, crude product) was obtained as a white solid (ESI m / z: 551 (M+H) + ).

[0314] To a solution of crude (2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}ethoxy)phosphonic acid (0.29 g, 0.80 mmol) in DMF (5 mL) was added triethylamine (81 mg, 0.80 mmol) and 1,1'-carbonyldiimidazole (CDI, 0.32 g, 2.0 mmol) at 10 ° C. The mixture was stirred at 10-20 ° C for 30 minutes, and then the budesonide phosphonate intermediate 1a-PO3H2 (0.41 g, 0.80 mmol) and zinc chloride (0.87 g, 6.4 mmol) obtained above were added to the reaction mixture. The resulting mixture was stirred at 10-20 ° C overnight and the starting material was completely consumed according to LCMS monitoring. The reaction was then quenched with a dilute aqueous HCl solution (1N, 50 mL) and extracted with ethyl acetate. The combined organic solution was concentrated and the resulting residue was purified by preparative HPLC (Method B) to afford Fmoc-11 (0.32 g, 47% yield) as a white solid. ESI m / z: 856 (M+H) + . (2-aminoethoxy)({[hydroxy({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy})phosphoryl]oxy})phosphinic acid (11)

[0315] See WO2015153401.

[0316] To a solution of Fmoc-11 (0.10 g, 0.12 mmol) in DCM (2 mL) was added piperidine (67 mg, 0.79 mmol) at 10°C. The reaction mixture was stirred at 10-20°C for 16 hours. According to LCMS monitoring, compound Fmoc-11 was completely consumed. The volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC (Method B) to afford 11 (50 mg, 68% yield) as a white solid. ESI m / z: 634 (M+H) + . 1 H NMR (500 MHz, MeOD d4 ) δ 7.50 (d, J = 10.0 Hz, 1H), 6.28 (d, J = 9.9 Hz, 1H), 6.03 (s, 1H), 5.23-5.16 (m, 1H), 5.02-4.97 (m, 1H), 4.88-4.67 (m, 1H), 4.45 (d, J = 3.4 Hz, 1H), 4.23 (s, 2H), 3.24 (s, 2H), 2.67 (dd, J = 13.5, 8.3 Hz, 1H), 2.40 (d, J = 11.3 Hz, 1H), 2.28-1.32 (m, 15H), 1.23-0.92 (m, 8H) ppm. Analytical HPLC: >99.9%, retention time: 2.74 min (Method B).

[0317] Table 1a below shows the steroid compounds prepared using the method of the present invention. Table 1a - Structural formula and chemical and physical properties of compounds Scheme 2. Synthesis of VC-PAB spacer-budesonide General Method A for the Synthesis of MC-Spacer-Budesonide (2a & 2c)

[0318] To a DMF solution (approximately 1 mL / 10 mg amine) of vcPAB-budesonide (4a A=CO, 1.0 equiv) or amine 9 (1.0 equiv) in Scheme 2 was added activated NHS ester 5 (1.5-3.0 equiv) and DIPEA (2.0 equiv) from the table below at room temperature. The reaction mixture was stirred overnight at room temperature until the NHS ester and most of the amine were consumed as monitored by LCMS spectroscopy. After filtration, the reaction solution was directly purified by preparative HPLC or reverse-phase flash chromatography to give the desired amide 2 (approximately 17% yield) as a white solid. c. TFA salt General Method B for the Synthesis of Amide Precursors 2b, 2l, and 2m from Acids

[0319] To a solution of acid 5 (1.0-1.5 equiv) in DMF, DCM, or THF (1 mL / 5 mg of 5) at room temperature was added DIPEA (2.0-5.0 equiv) and HATU (1.4-2.2 equiv). The resulting mixture was stirred at this temperature for 0.5-1 hour, after which vcPAB-budesonide (4, 1.0 equiv) was added. The reaction mixture was stirred at room temperature for 3-16 hours until the amine was completely consumed, as monitored by LCMS. The reaction mixture was filtered through a membrane, and the filtrate was then separated by preparative HPLC or reverse-phase flash chromatography to afford amide 2 (21-54% yield) as a white solid. Additional details are provided in the table below. General Method C for the Synthesis of Intermediates 7 and 10

[0320] To a solution of intermediate 6 (1.2-1.4 equivalents) in DMF was added HATU (1.5-1.7 equivalents) at room temperature. The resulting solution was stirred at room temperature for 1 hour. To this suspension was added a solution of vcPAB-budesonide (4a, 1.0 equivalent) in DMF (0.10 mL / mg of 4a), followed by NMM (2.3-3.0 equivalents). The reaction mixture was stirred at room temperature for 16 hours, becoming clear. The reaction was monitored by LCMS until compound 4a was completely consumed. Diethylamine (excess) was then added to the reaction mixture, and the resulting mixture was stirred at room temperature for 1-3 hours until Fmoc removal was observed according to LCMS. Volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC (Method A) to yield compound 7 (18% yield from compound 4a), or by preparative HPLC (Method B) to yield compound 10 (5% yield) as a white solid. The following table provides additional details. General Method D for the Synthesis of Carbamates 2j, 2k, 2r, and 2s

[0321] The mixture was stirred at room temperature for 3-24 hours until the PNP activated ester was completely consumed, monitored by LCMS. The reaction mixture was filtered through a membrane, and the filtrate was directly separated by preparative HPLC to obtain compound 2 (with or without diastereomers, yield 11-63%) as a white solid. The following table provides additional details. Synthesis of 2a-d

[0322] According to Scheme 2, budesonide-linkers 2a-d can be prepared by three methods. The first method is to directly perform an amide coupling reaction on vcPAB-budesonide (4a), which is obtained from the activated ester of budesonide 3a and linker 5. The second method is to generate budesonide-linker 7 by an initial amide coupling reaction of vcPAB-budesonide (4a) with intermediate 6a, followed by a 3+2 cyclization with galactose-azide (8a) to generate intermediate 9, and finally by a secondary amide coupling reaction with 5. The third method is to first perform an amide coupling reaction on 4 with intermediate 6b, then form an amide with 5b, and then sequentially deprotect the acetone to obtain 2d. Intermediate 4a

[0323] To a solution of 3a (1.4 mmol) in dry DMF (10 mL) was added Boc-vc-PAB (12a) [WO2008 / 34124A2] (0.59 g, 1.2 mmol), DMAP (0.30 g, 2.4 mmol) and pyridine (0.29 g, 3.7 mmol). The mixture was stirred at room temperature for 16 hours until 3a was completely consumed according to LCMS monitoring. The reaction mixture was directly purified by reverse phase flash chromatography (50-80% acetonitrile in water) to give intermediate Boc-4a (0.74 g, 38% yield, ESI m / z: 936 (M+H) + ) was obtained as a white solid, which was dissolved in DCM (40 mL). TFA (0.5 mL) was added dropwise to 5 mL of DCM solution (containing 94 mg of Boc-4a) at 0°C. The mixture was stirred at room temperature for 1.5 hours until Boc-4a was exhausted and monitored by LCMS. The resulting mixture was concentrated in vacuo to give the crude title product 4a (83 mg, 34% yield from budesonide) of its TFA salt as a colorless oil, which was used for the next step of synthesis without purification. 20 mg of crude 4a was purified by preparative HPLC (method B) to give pure 4a (8 mg) as a free base for plasma stability testing. ESI m / z: 836 (M+H) + . 1 HNMR (400 MHz, DMSO d6 )δ10.17(s,1H),8.12(br s,1H),7.62(d,J=8.5Hz,2H),7.31(d,J=10.2Hz,3H),6.17(d,J=10.1Hz,1H),5.97(t,J=5.7Hz,1H),5. 92(s,1H),5.40(s,2H),5.22-5.01(m,4H),4.89-4.62(m,3H),4.53-4.40(m,1H),4.30(s,1H),3.09-2. 87(m,3H),2.36-2.22(m,1H),2.14-1.87(m,4H),1.81(d,J=5.6Hz,2H),1.75(s,2H),1.62-1.52(m,4H) ,1.51-1.41(m,2H),1.40-1.19(m,8H),1.18-0.92(m,2H),0.92-0.82(m,9H),0.78(d,J=6.8Hz,3H)ppm. Example 2a N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide (2a)

[0324] The title compound 2a (10 mg, 17% yield) was obtained as a white solid according to General Method A. ESI m / z: 1029 (M+H) + Analytical HPLC: 92.5%, retention time: 7.66 min (Method A). Example 2b 1-(4-{2-azatricyclic[10.4.0.0 4,9 ] Hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-)-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-dioxopentacyclo[10.8.0.0]] 2 ,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-3,6,9,12-tetraoxapentadecan-15-amide (2b)

[0325] The title compound 2b (3.0 mg, 21% yield) was obtained as a white solid according to General Method B. ESI m / z: 686 (M / 2+H) + . 1 HNMR (400 MHz, DMSO d6)δ10.05(s,1H),8.15(d,J=7.5Hz,1H),7.88(d,J=8.8Hz,1H),7.77(t,J=5.7Hz,1H),7.71-7.66(m,1H),7.66-7.59(m,3H),7.52-7.27( m,9H),6.17(d,J=10.0Hz,1H),6.03-5.95(m,1H),5.92(s,1H),5.79-5.74(m,1H),5.43(s,2H),5.22-4.99(m,6H),4.88-4.84(m,1H),4. 84-4.60 (m, 2H), 4.42-4.34 (m, 1H), 4.33-4.26 (m, 1H), 4.26-4.20 (m, 1H), 3.65-3.55 (m, 3H), 3.48-3.44 (m, 12H), 3.32-3.26 (m, 2H), 3.12-2.91 (m, 4H), 2.63-2.54 (m, 1H), 2.41-2.19 (m, 3H), 2.03-1.94 (m, 4H), 1.84-1.78 (m, 2H), 1.63-1.22 (m, 14H), 1.03-0.82 (m, 15H) ppm. Analytical HPLC: 96.9%, retention time: 8.10 min (Method B). Example 2c (2R)-2-amino-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-6-[2-(cyclooct-2-yn-1-yloxy)acetamido]hexanamide (7)

[0326] ESI m / z:565(M / 2+H) + . 1 H NMR (500 MHz, DMSO d6)δ10.17-10.00(m,1H),8.47-7.73(m,2H),7.69-7.57(m,3H),7.38-7.26(m,3H),6.17(d,J=10.0Hz,1H),5.99( s,1H),5.92(s,1H),5.76(s,1H),5.42(s,2H),5.23-5.01(m,4H),4.88-4.61(m,3.4H),4.43-4.16(m,4.6H),3.8 5(d,J=14.7Hz,1H),3.73(d,J=14.5Hz,1H),3.23-3.18(m,1H),3.09-2.90(m,4H),2.33-2.18(m,3H),2.18-2.0 4(m,3H),2.03-1.66(m,10H),1.64-1.50(m,7H),1.49-1.22(m,13H),1.17-0.90(m,4H),0.90-0.79(m,12H)ppm. (2R)-2-amino-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-6-[2-({1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-1H,4H,5H,6H,7H,8H,9H-cycloocta[d][1,2,3]triazol-4-yl}oxy)acetamido]hexanamide (9)

[0327] After filtration, the resulting solution of 9 was used directly in the next step. ESI m / z: 667 (M / 2+H) + . N-[(1R)-1-{[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 ,9 .04,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]carbamoyl}-5-[2-({1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-4H,5H,6H,7H,8H,9H-cycloocta[d][1,2,3]triazol-4-yl}oxy)acetamido]pentyl]-1-(2,5-dioxopyrrol-1-yl)-3,6,9,12-tetraoxapentadecan-15-amide (Mc-PEG4-N(Sugar-COT)Lys-vc-PAB-Budesonide) (2c)

[0328] ESI m / z:831(M / 2+H) + . 1 H NMR (400 MHz, DMSO d6 )δ9.73(s,1H),8.21-8.07(m,3H),7.94-7.82(m,1H),7.71-7.59(m,3H),7.39-7.26(m,4H),7. 02(s,1H),6.17(d,J=10.0Hz,1H),6.09-5.98(m,1H),5.92(s,1H),5.56-5.28(m,4H),5.25-5.0 1 (m, 4H), 4.90-4.62 (m, 5H), 4.39-4.13 (m, 5H), 3.84-3.69 (m, 4H), 3.59-3.40 (m, 16H), 3.17-2.79 (m, 9H), 2.43-1.71 (m, 13H), 1.71-1.42 (m, 15H), 1.40-1.19 (m, 11H), 1.04-0.77 (m, 15H) ppm. Analytical HPLC: 97.6%, retention time: 7.63 min (Method A). Example 2d (2R)-2-amino-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-N'-[(2S)-2-[(4R,5R)-5-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-1,3-dioxolan-4-yl]-2-hydroxyethyl]glutaramide (10)

[0329] According to the general method C, compound 10 (13 mg, 5% yield) was obtained as a white solid. ESI m / z: 605 (M / 2+H) + . 1 HNMR (500 MHz, DMSO d6 )δ10.08(s,1H),8.34-8.17(m,1H),7.98(s,1H),7.93-7.81(m,1H),7.62(d,J=8.4Hz,2H),7.42-7.26(m,3H),6.17 (d,J=10.1Hz,1H),5.99(s,1H),5.92(s,1H),5.76(s,1H),5.42(s,2H),5.23-5.01(m,4H),4.91-4.61(m,4H),4.43 -4.20(m,3H),4.10-3.72(m,6H),3.60-3.54(m,1H),3.24-3.09(m,2H),3.07-2.91(m,2H),2.32-2.25(m,1H),2.22 -2.10(m,2H),2.04-1.93(m,2H),1.88-1.67(m,5H),1.64-1.22(m,27H),1.17-0.93(m,3H),0.91-0.81(m,12H)ppm. (2R)-2-amino-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 [(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]glutaramide (10A)]

[0330] To a mixture of compound 10 (13 mg, 11 μmol) in DCM (1 mL) was added TFA (1 mL) dropwise. The mixture was stirred at room temperature for 1 hour and monitored by LCMS. The volatiles were removed in vacuo to give the crude deprotected product 10A (13 mg) as a light yellow oil, which was used in the next step without further purification. ESI m / z: 565 (M / 2+H) + . (2R)-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4 ,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]-2-[1-(2,5-dioxopyrrol-1-yl)-3,6,9,12-tetraoxapentadecan-15-amido]-N'-[(2S3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]glutaramide (2d)

[0331] The title compound 2d (3.5 mg, 1% overall yield from 4a) was obtained as a white solid according to General Method A. ESI m / z: 829.7 (M / 2+H) + . 1 H NMR (400 MHz, DMSO d6)δ10.10(s,0.25H),9.79(s,0.75H),8.22(d,J=7.1Hz,1H),8.12(d,J=7.5Hz,1H),8.07(d,J=7.8Hz,1H),7.79-7.71(m,1 H),7.69-7.60(m,2H),7.38-7.27(m,4H),7.02(d,J=1.4Hz,2H),6.17(dt,J=7.6,1.6Hz,1H),6.03-5.97(m,1H),5.92(s, HPLC: >99%, retention time: 6.40 min (Method A). Synthesis of Scheme 3.2e Example 2e 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-[(4-aminophenyl)methyl]carbamate (13)

[0332] To a solution of 4-aminobenzylamine (9.7 mg, 79 μmol) and DIPEA (12 mg, 93 μmol) in THF (10 mL) was added a solution of 3a (24 mg, 44 μmol) in THF (5.0 mL) at room temperature. The mixture was stirred at room temperature for 3 hours until 3a was completely consumed, which was monitored by LCMS. The volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC (Method B) to give compound 13 (5.6 mg, 22% yield) as a white solid. ESI m / z: 579.2 (M+H) + . 1 H NMR (400 MHz, MeOD d4)δ7.48-7.45(m,3H),7.31-7.28(m,2H),6.27-6.24(m,1H),6.02(s,1H) ,5.22(m,1H),5.12-5.11(m,1H),4.96(m,1H),4.86-4.81(m,2H),4.66( m,1H),4.44-4.35(m,3H),2.66-2.65(m,1H),2.40-2.36(m,1H),2.15-2 .10(m,2H),1.97-1.60(m,6H),1.53-1.36(m,6H),1.09-0.92(m,7H)ppm. 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-({4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanamido]phenyl}methyl)carbamate (2e)

[0333] To a mixture of MC-VC-OH 5f (WO2014 / 191578A1) (5.7 mg, 12 μmol) in dry DMF (1.5 mL) was added HATU (4.6 mg, 12 μmol) and NMM (4.0 mg, 40 μmol) at room temperature. The mixture was stirred at room temperature for 10 minutes, and then compound 13 (4.7 mg, 8.1 μmol) was added to the reaction mixture. The resulting mixture was stirred at room temperature overnight. According to LCMS monitoring, compound 13 was completely consumed and the desired product was detected as the major product. The mixture was directly purified by preparative HPLC to give the title compound 2e (2.9 mg, yield 35%) as a white solid. ES m / z: 1029.1 (M+H) + ,514.7(M / 2+H) + Analytical HPLC: >99%, retention time: 7.54 min (Method A). Scheme 4. Synthesis of Linker-Spacer-Budesonide 2f & 2g (via Ester) Compound No. R 2f MC 2g <![CDATA[DIBAC-suc-PEG4]]> Example 2f 1-{4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanamido]phenyl}methyl 4-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl}succinate (2f)

[0334] To a solution of 1c (20 mg, 38 μmol) in DMF (2 mL) was added MC-VCPAB (12b, 0.11 g, 0.19 mmol), TBTU (63 mg, 0.19 mmol), HOBt (26 mg, 0.19 mmol) and DIPEA (41 mg, 0.19 mmol) at room temperature. The resulting mixture was stirred at 70 ° C for 12 hours. No further product 2f was formed as monitored by LCMS. The reaction mixture was directly purified by preparative HPLC (Method A) to give the title compound 2f (2.6 mg, yield 6%) as a white solid. ESI m / z: 1085.3 (M+H) + . 1 HNMR (400MHz, CDCl3) δ7.55-7.52(m,1H),7.34-7.30(m,1H),6.67(br s,1H),6.30-6.27(m,1H),6.03(br s,1H),5.16-5.11(m,2H),5.09-4.87(m,2H),4.80-4.61(m,1H),4.60-4.30(m,2H),3.47-3.44(m,1H),3.21-3.10(m,1H) ,3.03-2.96(m,2H),2.79-2.55(m,4H),2.35-1.73(m,28H),1.71-1.32(m,15H),1.29-1.07(m,4H),0.99-0.85(m,9H)ppm. Example 2g 1-{4-[(2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4,9]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentanamido]phenyl}methyl 4-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxopentacyclo[10.8.0.0 2,9 .04,8.0 13 ,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl}succinate (2g)

[0335] The method of Example 2f was followed, except that DIBAC-suc-PEG4-vc-PAB (12c) was used instead of 12b to obtain the title compound 2g (15 mg, 19% yield) as a white solid. ESI m / z: 714 (M / 2+H) + . 1 H NMR (500 MHz, MeOD d4 )δ 7.67-7.60(m,4H),7.48-7.46(m,4H),7.38-7.32(m,4H),7.26(d,J=6.8Hz,1H),6.27(d,J=10.0Hz,1H),6.03( s,1H),5.24-5.10(m,4H),5.02-4.97(m,1H),4.85-4.66(m,2H),4.61(s,1H),4.53(dd,J=9.1,4.9Hz,1H),4.45 -4.43 (m, 1H), 4.22 (dd, J = 6.7, 4.7 Hz, 1H), 3.78-3.69 (m, 3H), 3.60-3.55 (m, 11H), 3.47-3.40 (m, 2H), 3.26-3.10 (m, 4H), 2.78-2.54 (m, 8H), 2.41-2.35 (m, 2H), 2.25-2.11 (m, 4H), 2.02-1.31 (m, 17H), 1.21-0.92 (m, 14H) ppm. Analytical HPLC: 99.5%, retention time: 7.86 min (Method B). Scheme 5. Synthesis of Linker-Spacer-Budesonide 2j-2n (via Amide or Carbamate)

[0336] In Scheme 5, Bud refers to budesonide.

[0337] Most budesonide-linkers (2) with VC-PAB moieties were synthesized via amide or carbamate reactions using three methods (Scheme 5). Compounds 1d and 1e were coupled to the linker via amide coupling to yield amide or carbamate reactions (Scheme 5). The following table provides additional details. Intermediate 4c 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (4c)

[0338] To a solution of compound 1d (40 mg, 73 μmol) in DMF (3 mL) was added Fmoc-vcPAB-PNP (11d, 60 mg, 78 μmol), DMAP (9.0 mg, 74 μmol) and DIPEA (20 mg, 0.16 mmol) at room temperature. The mixture was stirred at room temperature for 3 hours until most of the starting material was consumed, as monitored by LCMS. Piperidine (1 mL) was then added to the reaction mixture. After stirring at room temperature for 1 hour until the removal of Fmoc reaction was complete (monitored by LCMS), the reaction mixture was directly purified by preparative HPLC (Method B) to give compound 4c (9.0 mg, 13% yield, second peak in LC) as a white solid. ESI m / z: 951 (M+H) + ,973(M+Na) + . Example 2j 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18]eicosane-14,17-dien-8-yl]-2-oxoethyl N-({N'-[({4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanamido]phenyl}methoxy)carbonyl]hydrazinecarbonyl}methyl)carbamate (2j)

[0339] ESI m / z:1144.3(M+H) + . 1 HNMR (400MHz, CDCl3) δ10.02(s,1H),9.77(s,1H),9.18(s,1H),8.12(d,J=7.2Hz,1H),7.83(d,J=8.4Hz,1H),7.73-7.70(m,1H),7.61-7. 59(m,2H),7.32-7.29(m,3H),7.01(s,2H),6.19-6.16(m,1H),6.00-5.92(m,2H),5.05-5.00(m,2H),4.95-4.85(m,2H),4.71-4.62(m,2H) ,4.40-4.17(m,3H),3.71-3.58(m,2H),3.45-3.39(m,2H),3.06-2.89(m,3H),2.33-2.28(m,2H),2.20-2.07(m,3H),2.02-1.91(m,3H),1. 81-1.75(m,2H),1.75-1.62(m,2H),1.60-1.44(m,11H),1.42-1.20(m,6H),1.19-1.12(m,4H),1.00-0.92(m,2H),0.88-0.81(m,10H)ppm. Example 2k 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (2k-A and 2k-B)

[0340] According to General Method D, the title compounds 2k-A (3.3 mg, 10% yield, second peak in LC) and 2k-B (4.1 mg, 12% yield, first peak in LC) were obtained as diastereomers as white solids. 2k-A: ESI m / z: 1143.4 (M+H) + , retention time: 1.70 min (method A). 2k-B: ESI m / z: 1143.4 (M+H) + , retention time: 1.65 min (Method A). Example 21 Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-(14-{[(1S)-1-{[(1S)-4-(carbamoylamino)-1-[(4-{[({2-[({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}carbonyl)(methyl)amino]ethyl}(methyl)carbamoyl)oxy]methyl}phenyl)carbamoyl]butyl]carbamoyl}-2-methylpropyl]carbamoyl}-3,6,9,12-tetraoxatetradec-1-yl)carbamate (2l)

[0341] ESI m / z:687.5 (M / 2+H) + ,1396.8(M+Na) + (50%). 1 H NMR (500 MHz, MeOD d4)δ7.66(d,J=7.5Hz,2H),7.50(d,J=10.0Hz,1H),7.36(d,J=7.0Hz,2H),6.28(d,J=10.0Hz,1H),6.04(s,1H),5.15-5.05(m,2H),4.87-4.62 (m,4H),4.53(s,1H),4.46(s,1H),4.21(d,J=6.5Hz,1H),4.16(d,J=8.0Hz,2H),3.83-3.72(m,2H),3.66-3.60(m,12H),3.56-3.52(m,3H), 3.49-3.42(m,1H),3.30(s,3H),3.25-3.09(m,3H),3.02-2.96(m,4H),2.87(dd,J=16.6,4.8Hz,2H),2.72-2.64(m,1H),2.58(t,J=6.0Hz,2 H),2.40(d,J=13.1Hz,1H),2.31-2.10(m,9H),2.01-1.91(m,3H),1.81-1.70(m,2H),1.63(s,7H),1.51(s,3H),1.48-1.30(m,4H),1.11(s, 1H), 1.02-0.91 (m, 15H) ppm. Analytical HPLC: >99.9%, retention time: 9.40 min (Method A). Example 2m 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-[(2R)-6-(4-{2-azatricyclo[10.4.0.0 4,9 ]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]hexanoyl]-3-methylbutyramido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (2m-precursor)

[0342] According to General Method B, crude compound 2m-precursor (precursor of 2m) (5 mg) was obtained as a light yellow oil, which was used directly in the next step. ESI m / z: 780 (M / 2+H) + . 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-5-(carbamoylamino)-2-[(2S)-2-[(2R)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-6-[4-(3-{[31,32,33,34,35,36,37,38,39,40,41,42-dodecahydroxy-10,15,20,25,30-penta(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29-dodecaoxaline] 3,6 .2 8 ,11 .2 13,16 .2 18,21 .2 23,26 ]tetradecane-5-yl]methyl}-3,4,5,13-tetraazatetracyclo[13.4.0.0 2,6 .0 7,12 ]nonadecan-1(15),2(6),4,7(12),8,10,16,18-octaen-13-yl)-4-oxobutanamido]hexanamido]-3-methylbutanamido]pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (2m)

[0343] To a solution of crude 2m (5 mg) in DMF (1 mL) was added CD-N3 (8b, 63 mg, 63 μmol). The resulting mixture was stirred at room temperature for 72 hours and monitored by LCMS. The resulting mixture was directly purified by preparative HPLC (Method A) to afford compound 2m (2 mg, 4% yield from 4c) as a white solid. ESI m / z: 1278.8 (M / 2+H) + Analytical HPLC: 97.9%, retention time: 6.49 min (Method A). Example 2n 2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-[(4R)-4-amino-4-[(2-azidoethyl)carbamoyl]butanamido]-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (2n)

[0344] The reaction mixture was stirred at room temperature overnight. According to LCMS monitoring, compound 4c was completely consumed. The mixture was separated by preparative HPLC (method A) and lyophilized to obtain Fmoc-2n (20 mg), which was dissolved in DMF (2 mL). Diethylamine (4 drops, about 0.08 mL) was added to the DMF solution. The reaction mixture was stirred at room temperature for 2 hours until the de-Fmoc reaction was completed and monitored by LCMS. The mixture was filtered through a filter membrane, and the solution was purified by preparative HPLC (method A) to obtain the title compound 2n (10 mg, yield 8.4%) as a white solid. ESI m / z: 1147 (M+H) + Analytical HPLC: 99.6%, retention time: 5.67 min (method A); 7.72 min (method B). Scheme 6. Synthesis of Linker-Budesonide 2q (THP Analog) Example 2q (2S)-(3,4-Dihydro-2H-pyran-2-yl)methyl 2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-5-ureidopentanate (15)

[0345] To a mixture of Fmoc-Cit-OH (14, 0.29 g, 0.73 mmol) in DMF (5 mL) was added DHP (0.10 mg, 0.88 mmol), TBTU (0.70 g, 2.2 mmol) and triethylamine (0.37 g, 3.7 mmol). The resulting mixture was stirred at room temperature for 24 hours. 15% of the desired mass was detected by LCMS. The reaction was quenched with water (30 mL) and extracted with ethyl acetate (10 mL×3). The combined organic solution was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The crude product was purified by reverse phase flash chromatography (0-100% acetonitrile in water) to give the title compound 15 (110 mg, 30% yield) as a colorless oil. ESI m / z: 494 (M+H) + . (6-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}tetrahydropyran-2-yl)methyl (2S)-2-amino-5-(carbamoylamino)pentanoate (16)

[0346] At room temperature under the protection of an argon balloon, a solution of budesonide (1a, 70 mg, 0.16 mmol) and p-toluenesulfonic acid (42 mg, 0.24 mmol) in anhydrous DCM (2 mL) was added to a solution of compound 15 (80 mg, 0.16 mmol) in anhydrous DCM (3 mL) by syringe. The reaction mixture was stirred in an argon balloon at 30 ° C for 12 hours. According to LCMS monitoring, most of compound 15 was exhausted. The reaction mixture was cooled to room temperature, and diethylamine (1 mL) was added to the reaction mixture. The reaction mixture was stirred at room temperature for 1 hour until the de-Fmoc reaction was completed and monitored by LCMS. The volatiles were removed in vacuo, and the resulting residue was purified by preparative HPLC (method B) to give the title compound 16 (17 mg, yield 31%) as a white solid. ESI m / z: 702 (M+H) + . (S)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-methylbutanoic acid (5i)

[0347] To a solution of L-valine (0.12 g, 1.0 mmol) in anhydrous DMF (2 mL) was added compound 5a (0.31 g, 1.0 mmol) and triethylamine (0.51 g, 5.0 mmol) at room temperature. The reaction mixture was stirred at room temperature for 8 hours until compound 5a was completely consumed, as monitored by LCMS. The reaction mixture was filtered through a membrane filter, and the filtrate was directly purified by preparative HPLC (method A) to give the title compound 5i (0.14 g, 46% yield) as a colorless oil. ESI m / z: 311 (M+H) + . 6-{2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxoethoxy}tetrahydropyran-2-yl)methyl (2S)-5-(carbamoylamino)-2-[(2S)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido]-3-methylbutanamido]pentanoate (2q)

[0348] To a solution of compound 5i (5.8 mg, 19 μmol) in DMF (1 mL) was added HATU (10 mg, 26 μmol) and DIPEA (6.6 mg, 51 μmol) at room temperature. The mixture was stirred at room temperature for 15 minutes, and then compound 16 (12 mg, 17 μmol) was added to the solution at RT. The resulting mixture was stirred at room temperature for 4 hours until compound 5i was completely consumed, which was monitored by LCMS. The reaction mixture was then filtered through a filter membrane, and the filtrate was directly purified twice by preparative HPLC (method A) to give the title compound 2q (2 mg, yield 12%) as a white solid. ESI m / z: 995.3 (M+H) + Analytical HPLC: 83.5%, retention time: 10.36 min (Method B) Scheme 7. Synthesis of linker-phosphate-budesonide 2r and 2s

[0349] Phosphate-budesonide was coupled with BCN-PNP (11c) to afford BCN-phosphate-budesonide (compounds 2r and 2s) (Scheme 7). Example 2r {2-[({Bicyclo[6.1.0]non-4-yn-9-ylmethoxy}carbonyl)amino]ethoxy}({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 ,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy})phosphinic acid (2r)

[0350] According to the general method D, compound 2r (40 mg, 61% yield) was obtained as a white solid. ESI m / z: 730 (M+H) + . 1 HNMR (500 MHz, MeOD d4 )δ7.49(d,J=10.1Hz,1H),6.29-6.26(m,1H),6.03(s,1H),5.23-5.16(m, 1H),4.88-4.64(m,3H),4.45(dd,J=8.0,3.1Hz,1H),4.23-4.13(m,2H),3. 97(dd,J=11.9,5.7Hz,2H),3.36(t,J=4.7Hz,2H),2.67(td,J=13.4,5.3H z, 1H), 2.40 (d, J = 9.6Hz, 1H), 2.30-1.34 (m, 23H), 1.21-0.92 (m, 10H) ppm. Analytical HPLC: >99.9%, retention time: 5.26 min (Method B). Example 2s {2-[({Bicyclo[6.1.0]non-4-yn-9-ylmethoxy}carbonyl)amino]ethoxy}({[hydroxy({2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy})phosphoryl]oxy})phosphinic acid (2s)

[0351] ESI m / z:810(M+H) + . 1 H NMR (500 MHz, MeOD d4)δ7.51(d,J=10.1Hz,1H),6.28(d,J=10.0Hz,1H),6.03(s,1H),5.22-5.16(m,1H),4.98-4.66(m,3H),4.46(s,1H),4.12(dt,J=45 .0,13.0Hz,4H),3.39(t,J=11.9Hz,2H),2.67(dd,J=13.3,8.0Hz,1H),2.40(d,J=11.2Hz,1H),2.30-1.32(m,23H),1.22-0.92(m, 10H) ppm. Analytical HPLC: >99.9%, retention time: 4.03 min (Method B). Experimental methods for intermediates Table 4. Key intermediates and starting materials Synthesis of Scheme 8.5e (2R)-6-(4-{2-azatricyclo[10.4.0.0 4,9 ]Hexadecan-1(12),4,6,8,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-2-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoamido]hexanoic acid (5e)

[0352] To a mixture of HD-Lys(Boc)-OH (17, 0.25 g, 1.0 mmol) in DMF (10 mL) was added 6-maleimidocaproic acid-NHS (5a, 0.31 g, 1.0 mmol) and diisopropylethylamine (DIPEA, 0.26 g, 2.0 mmol) at room temperature. After stirring the reaction at room temperature overnight, compound 5a was completely consumed. The mixture was directly separated by reverse phase flash chromatography (0-100% acetonitrile in water (0.05% TFA)) to give intermediate Boc-18 (ESI m / z: 440 (M+H) + ) was obtained as a colorless oil, which was dissolved in DCM (5 mL). TFA (0.5 mL) was added dropwise to the solution at 0°C, and the mixture was stirred at room temperature for 1 hour. The reaction was monitored by LCMS, and the intermediate Boc-18 was completely consumed. The volatiles were removed in vacuo to give crude product 18 (ESI m / z: 340 (M / 2+H) +), which was used in the next step without further purification. To a mixture of crude compound 18 (0.21 g, 0.62 mmol) in DMF (5 mL) was added activated ester 19 (0.20 g, 0.50 mmol) and DIPEA (50 mg, 0.39 mmol) at room temperature. After the reaction mixture was stirred at room temperature overnight, compound 19 was completely consumed, as monitored by LCMS. The reaction mixture was then directly separated by reverse phase flash chromatography (0-100% acetonitrile in water) to give the title compound 5e (0.10 g, 20% yield over three steps from 5a) as a white solid. ESI m / z: 627 (M+H) + . 1 H NMR (DMSO d6 ,400MHz): δ7.89(d,J=13.2Hz,1H),7.69-7.62(m,3H),7.48-7.47(m,3H) ,7.36-7.28(m,3H),6.99(s,2H),5.03(d,J=13.6Hz,1H),4.09-4.04(m,1 H),3.60(d,J=13.6Hz,1H),3.38-3.34(m,1H),2.90-2.87(m,2H),2.61-2 .55(m,1H),2.25-2.17(m,1H),2.08-1.51(m,5H),1.46-1.15(m,12H)ppm. Synthesis of Scheme 9.5g (2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4,9 ]Hexadecan-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentanoic acid (5 g)

[0353] To a solution of compound 5c (0.30 g, 0.54 mmol) in DMF (10 mL) was added HATU (0.31 g, 0.81 mmol) and DIPEA (0.14 g, 1.1 mmol) at room temperature. The mixture was stirred at room temperature for 15 minutes. Val-Cit-OH (20 (CAS#159858-33-0), 0.21 g, 0.76 mmol) was added to the reaction solution at room temperature, and the resulting mixture was stirred at room temperature for 3 hours until most of the material was consumed, monitored by LCMS. The reaction mixture was filtered through a filter membrane, and the filtrate was directly purified by reverse flash chromatography (0-100% acetonitrile in water (containing 10 mmol / L ammonium bicarbonate)) to give the title intermediate 5g (0.25 g, yield 57%) as a white solid. ESI m / z: 809.5 (M+H) + . Scheme 10. Synthesis of Intermediate 5h Tert-butyl (4R)-4-[(2-azidoethyl)carbamoyl]-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoate (22)

[0354] To a mixture of Fmoc-D-Glu(OTBU)-OH (21, (104091-08-9), 0.30 g, 0.71 mmol) and 2-azidoethylamine (87156-40-9, 73 mg, 0.85 mmol) in DCM (50 mL) was added HATU (0.41 g, 1.1 mmol) and triethylamine (0.3 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. Then, according to TLC and LCMS monitoring, most of compound 21 was consumed. After the reaction mixture was quenched with water (50 mL) at room temperature, the organic solution was washed with water and brine, dried over sodium sulfate, and concentrated in vacuo. The resulting residue was purified by preparative TLC (silica gel, eluted with petroleum ether / ethyl acetate (v / v=1)) to give the title compound 22 (0.30 g, yield 76%) as a yellow viscous oil. ESI m / z: 494 (M+H) + . 1 HNMR (400 MHz, DMSO d6 ): δ8.09(m,1H),7.84-7.90(m,4H),7.33-7.44(m,4H),6.28(s,2H),3.35(m ,6H),3.26(m,1H),2.50(m,2H),2.25(m,1H),1.80(m,1H),1.39(s,9H)ppm. (4R)-4-[(2-Azaethyl)carbamoyl]-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}butanoic acid (5h)

[0355] The resulting mixture was stirred at room temperature for 2 hours until compound 22 was completely consumed, as monitored by TLC and LCMS. The volatiles were removed in vacuo to afford crude compound 5h (17 mg, 96% yield) as a yellow oil, which was used in the next step without further purification. ESI m / z: 438 (M+H) + . Scheme 11. Synthesis of Intermediate 6a (2R)-6-[2-(Cyclooct-2-yn-1-yloxy)acetamido]-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}hexanoic acid (6a)

[0356] To a mixture of commercially available compound 23 (65 mg, 0.23 mmol, CAS: 1425803-45-7) in DMF (2 mL) was added Fmoc-D-Lys-OH (85 mg, 0.23 mmol) and triethylamine (52 mg, 0.51 mmol). The reaction mixture was stirred at room temperature for 30 minutes. The mixture was directly separated by reverse phase flash chromatography (0-100% acetonitrile in water (0.05% TFA)) to afford intermediate 6a (85 mg, 70% yield) as a white solid. ESI m / z: 533 (M+H) + . 1 H NMR (MeOD d4 ,500MHz): δ7.70(d,J=7.5Hz,2H),7.59(t,J=8.0Hz,2H),7.30(t,J=7.5Hz,2H), 7.22(t,J=7.4Hz,2H),4.35-4.22(m,2H),4.22-4.09(m,2H),4.09-3.99(m,1H), 3.94-3.81(m,1H),3.79-3.67(m,1H),3.15(t,J=6.9Hz,2H),2.17-1.96(m,3H), 1.96-1.86(m,1H),1.85-1.66(m,4H),1.66-1.41(m,5H),1.41-1.25(m,3H)ppm. Scheme 12. Synthesis of Intermediates 11b and 12c 1-(4-{2-azatricyclic[10.4.0.0 4,9 ]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-N-[(1S)-1-{[(1S)-4-(carbamoylamino)-1-{[4-(hydroxymethyl)phenyl]carbamoyl}butyl]carbamoyl}-2-methylpropyl]-3,6,9,12-tetraoxapentadecan-15-amide (12c)

[0357] The mixture was stirred at room temperature for 15 minutes. vc-PAB (24 (159857-79-1), 0.21 g, 0.54 mmol) was added to the reaction solution at room temperature, and the resulting mixture was stirred at room temperature for 3 hours until most of the material was consumed, monitored by LCMS. The reaction mixture was filtered through a filter membrane, and the filtrate was directly purified by reverse flash chromatography (0-100% acetonitrile in water (containing 10 mmol / L ammonium bicarbonate)) to obtain the title intermediate 12c (0.30 g, 60% yield) as a white solid. ESI m / z: 617 (M+H) + . {4-[(2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4,9 ]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentyramido]phenyl}methyl 4-nitrophenyl carbonate (11b)

[0358] To a solution of compound 12c (0.15 g, 0.16 mmol) in DMF (10 mL) at 0°C were added bis(4-nitrophenyl) carbonate (0.15 g, 0.49 mmol) and DIPEA (63 mg, 0.49 mmol). The mixture was then stirred at room temperature for 3 hours until 12c was mostly consumed, monitored by LCMS. The reaction mixture was filtered through a filter membrane, and the filtrate was directly purified by reverse flash chromatography (0-100% acetonitrile in water (containing 10 mmol / L ammonium bicarbonate)) to give the title intermediate 11b (50 mg, 28% yield) as a white solid. ESI m / z: 1079 (M+H) + .

[0359] Table 5 below shows the linker payloads prepared using the method of the present invention. Table 5. Examples of linker-payloads Table 6. Linker-Payload Characterization Data Synthesis of linker-payload LP1-4 Scheme 101. Synthesis of Payload 100, Its Spacer-Payloads 101a-d, and Linker-Payloads LP1-4 (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]Eicosan-14,17-dien-16-one (100)

[0360] To a mixture of fluocinonide (10 g, 22 mmol) and silica gel (100 g) in heptane (900 mL) was added butyraldehyde (3.0 mL, 33 mmol) at a temperature below 10°C, and the resulting suspension was stirred at 10-20°C for 30 minutes. Perchloric acid (70%, 7.6 mL, 91 mmol) was added dropwise to the mixture at 0°C. The reaction mixture was then stirred at room temperature overnight. According to TLC and LCMS monitoring, most of the fluocinonide was consumed. The reaction mixture was diluted with petroleum ether and quenched with saturated aqueous sodium carbonate. The suspension was filtered and the resulting solid was washed with DCM / methanol (v / v=1:1). The combined filtrate was concentrated in vacuo. The resulting residue was purified by flash chromatography (0-1.5% methanol in DCM) to give compound 100 (8.0 g, 78% yield) as a white solid. ESI m / z:467.1 (M+H) + . 1-[({2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxyethoxy}carbonyl)oxy]pyrrolidine-2,5-dione (101-1a)

[0361] To a solution of compound 100 (0.47 g, 1.0 mmol) in DCM (20 mL) was added bis(2,5-dioxopyrrolidin-1-yl) carbonate (0.28 g, 1.1 mmol), triethylamine (0.40 g, 4.0 mmol) and DMAP (3.0 mg, catalytic amount). The reaction mixture was stirred at RT for 4 hours until compound 100 was exhausted and monitored by LCMS. The reaction mixture was then diluted with DCM and washed with water. The organic solution was dried over sodium sulfate. After filtration, the solution was concentrated in vacuo, and the resulting residue (crude 101-1a) was used directly in the next step without purification. ESI m / z: 608.2 (M+H) + . (1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-8-{2-[(4-nitrophenoxycarbonyl)oxy]acetyl}-6-propyl-5,7-dioxolane[10.8.0.0 2,9 .0 4,8 .0 13,18 ]Eicosan-14,17-dien-16-one (101-1b)

[0362] A mixture of compound 100 (0.80 g, 1.7 mmol), bis(4-nitrophenyl) carbonate (1.6 g, 5.2 mmol) and DIPEA (1.1 g, 8.6 mmol) in THF (20 mL) was stirred at room temperature for 4 hours and monitored by LCMS. The mixture was concentrated in vacuo. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to afford compound 101-1b (0.75 g, 69% yield) as a colorless oil. ESI m / z: 632 (M+H) + . General Synthesis of Compound 101

[0363] To a solution of compound 101-1a or 101-1b (crude product, calculated as 1.0 mmol) in DCM (20 mL) was added diamine 101-2 (a, b, c or d) (1.1 mmol) and DMAP (0.1 mmol). The reaction mixture was stirred at room temperature for 4 hours, and then TFA (1 mL) was added. The mixture was stirred at room temperature for half an hour (for R 13 = Boc, the reaction was stirred until complete removal of Boc, monitored by LCMS). The resulting mixture was concentrated in vacuo and the residue was purified by reverse phase flash chromatography (50-80% acetonitrile in aqueous TFA (0.5%)) to afford compound 101 (a, b, c or d) as a colorless oil. 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-[2-(methylamino)ethyl]carbamate (101a)

[0364] According to the general method, compound 101-1a and Boc-diamine 101-2a were used to obtain compound 101a (0.38 g, 57% yield over 2 steps, TFA salt) as a colorless oil. ESI m / z: 567 (M+H) + . 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-methyl-N-[2-(methylamino)ethyl]carbamate (101b)

[0365] According to the general method, compound 101-1a and diamine 101-2b were used to obtain compound 101b (0.45 g, 66% yield over 2 steps, TFA salt) as a colorless oil. ESI m / z: 581 (M+H) + . 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-ethyl-N-[2-(ethylamino)ethyl]carbamate (101c)

[0366] According to the general method, compound 101-1b and diamine 101-2c were used to obtain compound 101c (24 mg, 18% yield over 2 steps, TFA salt) as a colorless oil. ESI m / z: 609 (M+H) + . 1 H NMR (500 MHz, DMSO d6 )δ8.38(s,2H),7.30(d,J=10.5Hz,1H),6.24(dd,J=10.5Hz,2.0Hz,1H),6.11(s,1H),5.70-5.54(m,2H ),5.10-4.91(m,1H),4.85-4.65(m,3H),4.25-4.16(m,1H),3.60-3.40(m,2H),3.33-3.20(m,4H),3.2 0-2.90(m,4H),2.67-2.53(m,1H),2.30-2.20(m,1H),2.10-2.00(m,2H),1.80-1.70(m,1H),1.64-1.5 1(m,4H),1.49(s,3H),1.40-1.30(m,2H),1.20-1.10(m,4H),1.10-1.00(m,1H),0.90-0.80(m,6H)ppm. 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .04 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethylpiperazine-1-carboxylate (101d)

[0367] Compound 101-1b and piperazine (101-2d) were used according to the general method, but without TFA treatment, and purified by silica gel column chromatography (0-10% methanol in DCM) to afford compound 101d (0.21 g, 49% yield over 2 steps, free base) as a colorless oil. ESI m / z: 579 (M+H) + . General Synthesis Method of Compound 101-3

[0368] To a solution of compound 101a, 101b or 101d (0.20 mmol) in DMF (3 mL) was added Fmoc-VC-PAB-PNP11d (0.17 g, 0.22 mmol), HOBT (41 mg, 0.30 mmol) and DIPEA (77 mg, 0.60 mmol). The mixture was stirred at room temperature for 3 hours and monitored by LCMS. Piperidine (0.3 mL) was then added to the mixture. The reaction mixture was stirred at room temperature for 1 hour until the Fmoc residue was completely removed according to LCMS monitoring. The resulting mixture was directly purified by reverse phase flash chromatography (50-80% acetonitrile in NH4HCO3 aqueous solution (10 mM)) to obtain compound 101-3a, 101-3b or 101-3d as a white solid. 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)carbamate (101-3a)

[0369] According to the general method, compound 101a was used to obtain compound 101-3a (0.11 g, 57% yield) as a white solid. ESI m / z: 972 (M+H) + . 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-methyl-N-[2-(methylamino)ethyl]carbamate (101-3b)

[0370] According to the general method, compound 101b was used to obtain compound 101-3b (0.13 g, 65% yield) as a white solid. ESI m / z: 986 (M+H) + . 1-{4-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-5-(carbamoylamino)pentanamido]phenyl}methyl 4-{2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl}piperazine-1,4-dicarboxylate (101-3d)

[0371] According to the general method, compound 101d (58 mg, 0.10 mmol) was used to obtain compound 101-3d (52 mg, 53% yield) as a white solid. ESI m / z: 984 (M+H) + . 1 H NMR (500 MHz, DMSO d6)δ10.0(s,1H),8.14(d,J=7.5Hz,1H),7.60(d,J=8.5Hz,2H),7.31(d,J=8.5Hz,2H),7.26 (d,J=8.5Hz,1H),6.30(dd,J=1.5Hz,10.5Hz,1H),6.11(s,1H),6.02-5.88(m,1H),5.70-5 .50(m,2H),5.42(s,2H),5.20-4.92(m,3H),4.80-4.62(m,3H),4.50-4.45(m,1H),4.25- 4.15(m,1H),3.50-3.35(m,8H),3.05-2.90(m,3H),2.70-2.54(m,2H),2.32-2.20(m,1H), 2.10-1.50(m,10H),1.46(s,3H),1.45-1.30(m,5H),0.95(d,J=7.5Hz,1H),0.90-0.80(m,9H),0.77(d,J=7.0Hz,3H)ppm. General Synthesis of Compounds LP1, LP2, and LP4

[0372] To a solution of compound 5c (34 mg, 60 μmol) in DMF (1 mL) were added HATU (27 mg, 71 μmol) and DIPEA (20 mg, 0.15 mmol). The mixture was stirred at room temperature for 5 minutes, and then compound 101-3a, 101-3b, or 101-3d (50 μmol) was added to the mixture. The mixture was stirred at room temperature for 2 hours and monitored by LCMS. The resulting mixture was directly purified by preparative HPLC (Method B) to obtain compound LP1, LP2, or LP4 as a white solid. 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4 , 9]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)carbamate (LP1)

[0373] According to the general method, compound 101-3a was used to obtain the linker-payload LP1 (20 mg, 26% yield) as a white solid. ESI m / z: 754 (M / 2+H) + . 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxolane[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl N-(2-{[({4-[(2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4 , 9 ]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentanamido]phenyl}methoxy)carbonyl](methyl)amino}ethyl)-N-methylcarbamate (LP2)

[0374] According to the general method, compound 101-3b was used to obtain the linker-payload LP2 (20 mg, 26% yield) as a white solid. ESI m / z: 761 (M / 2+H) + . 1 HNMR (500 MHz, DMSO d6)δ9.98(s,1H),8.12(d,J=7.4Hz,1H),7.87(d,J=8.6Hz,1H),7.76(t,J=5.4Hz ,1H),7.69-7.66(m,1H),7.64-7.57(m,3H),7.51-7.44(m,3H),7.40-7.33(m,2 H),7.32-7.25(m,4H),6.33-6.27(m,1H),6.11(s,1H),5.98(t,J=5.5Hz,1H),5 .70-5.55(m,2H),5.41(s,2H),5.08-4.91(m,4H),4.79-4.66(m,2H),4.41-4.3 5m,1H),4.25-4.17(m,2H),3.64-3.56(m,3H),3.49-3.41(m,15H),3.30-3.27 (m,2H),3.13-3.00(m,3H),2.98-2.75(m,8H),2.65-2.54(m,2H),2.48-2.43(m ,1H),2.41-2.34(m,1H),2.28-2.19(m,2H),2.07-1.94(m,4H),1.81-1.67(m,3 H),1.63-1.53(m,5H),1.48(s,3H),1.45-1.31(m,5H),0.88-0.82(m,13H)ppm. 1-{4-[(2S)-2-[(2S)-2-[1-(4-{2-azatricyclo[10.4.0.0 4 , 9 ]hexadec-1(12),4(9),5,7,13,15-hexaen-10-yn-2-yl}-4-oxobutyramido)-3,6,9,12-tetraoxapentadecan-15-amido]-3-methylbutyramido]-5-(carbamoylamino)pentanamido]phenyl}methyl 4-{2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-9,13-dimethyl-16-oxo-6-propyl-5,7-dioxopentacyclo[10.8.0.0 2 , 9 .0 4 , 8 .0 13 , 18 ]eicosane-14,17-dien-8-yl]-2-oxoethyl}piperazine-1,4-dicarboxylate (LP4)

[0375] According to the general method, compound 101-3d was used to obtain linker-payload LP4 (35 mg, 44% yield) as a white solid. ESI m / z: 760 (M / 2+H) + . 1 HNMR (500 MHz, DMSO d6 )δ...

Claims

1. Compound represented by formula (III): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -, where X 1 Connected to L in formula (III), -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), -C(O)-N(C 1-6 Alkyl)-(C1-C 10 -alkylene)-S-, wherein S is connected to L in formula (III), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (III), -CH2-NH-, wherein N is connected to L in formula (III), Wherein N is connected to L in formula (III), -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III) and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -Alkylene-C(O)NH-X 2 -, where X 2 connected to L in formula (III), or Where X 4 Connected to L in formula (III); or Two R's x are all F; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -, where X 1b Connected to L in formula (III), -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b Connected to L in formula (III), wherein the right-hand attachment point (i.e., at N) is connected to L in formula (III), -CH2-NH-, wherein N is connected to L in formula (III), Wherein N is connected to L in formula (III), -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III), -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a Connected to L in formula (III) and each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups, -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -, where X 2 connected to L in formula (III), or Where X 4 connected to L in formula (III); and X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is-O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d , R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g are each independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; z is an integer selected from 1-30 (inclusive); L is a linker; and BA is a binding agent.

2. Compound represented by formula (II): or a pharmaceutically acceptable salt, solvate, stereoisomer, or derivative thereof, in: R 4 is an alkyl group, an aryl group, an arylalkyl group, or a N-containing heterocycloalkyl group; Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -, where X 1 With formula (II) in (L 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(C 1-6 Alkyl)-(C1-C 10 -alkylene)-S-, wherein S and (L in formula (II) 3 ) 0-1 connect, The right-hand side attachment point (i.e., N) is the same as (L 3 ) 0-1 Connect, -CH2-NH-, wherein N and (L in formula (II) 3 ) 0-1 connect, Wherein N and (L 3 ) 0-1 Connection, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With formula (II) in (L 3 ) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With formula (II) in (L 3 ) 0-1 Connect and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-C1-C 10 -Alkylene-C(O)NH-X 2 -, where X 2 With formula (II) in (L 3 ) 0-1 Connect, or Where X 4 With L in formula (II) 3 connect; or Two R's x are all F; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -, where X 1b With formula (II) in (L 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b With formula (II) in (L 3 ) 0-1 connect, The right-hand side attachment point (i.e., N) is the same as (L 3 ) 0-1 connect, -CH2-NH-, wherein N and (L in formula (II) 3 ) 0-1 connect, Wherein N and (L 3 ) 0-1 Connection, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With formula (II) in (L 3 ) 0-1 connect, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a With formula (II) in (L 3 ) 0-1 Connect and each C1-C 10 -alkylene is optionally substituted with one or more hydroxyl groups, -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -,in X 2 With formula (II) in (L 3 ) 0-1 Connect, or Where X 4 With formula (II) in (L 3 ) 0-1 Connect; and X 1 Yes-N(C 1-6 alkyl)-; X 1b is -S-, -NH-, or -N(C 1-6 alkyl)-; X 2 is -NH-; X 3 It is -CH2-, X 3 It is -CH2-O-(C1-C 10 -alkylene)-C(O)-, wherein the C(O) and X 4 Connect, or X 3 is -C(O)-; X 4 is-O-; R 5 is H, -OH, -OCH3, or C 1-6 alkyl; R 50 and R 50a are each independently H or C1-C6-alkyl; R d , R e and R f are independently -H, -OH, hydroxyalkyl, alkoxycarbonyl, -C(O)OH, or -CH2OR g , where each R g are each independently -CH2C(O)OH or -CH2C(O)O(alkyl); and m is 0 or 1; RG is the active group; L 2 is a connecting linker; and L 3 When present, it is a self-immolative linker.

3. The compound according to claim 1 or 2, wherein R 4 It is a straight chain or branched chain alkyl group.

4. The compound according to claim 1 or 2, wherein R 4 It is an aromatic group.

5. The compound according to claim 1 or 2, wherein R 4 It is an arylalkyl group.

6. The compound according to claim 1 or 2, wherein R 4 It is a N-containing heterocycloalkyl group.

7. The compound according to any one of claims 1 to 6, wherein R 4 It is R configuration.

8. The compound according to any one of claims 1 to 7, wherein Two R's x are H; and SP is -C(O)-C1-C 10 -alkylene-C(O)-, -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1 -, where X 1 and L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-S-, wherein S is the same as L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(C 1-6 Alkyl)-(C1-C 10 -alkylene)-S-, wherein S is the same as L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (III) or (L in formula (II) 3) 0-1 Connection, -C(O)-(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (III) or (L in formula (II) 3 ) 0-1 Connect and each C1-C 10 -alkylene groups are independently optionally substituted with one or more hydroxy groups, -C(O)-N(R 5 )-C1-C 10 -Alkylene-C(O)NH-X 2 -, where X 2 and L in formula (III) or (L in formula (II) 3 ) 0-1 Connect, or Where X 4 and L in formula (III) or (L in formula (II) 3 ) 0-1 connect; or Two R's x are all F; and SP is -C(O)-N(C 1-6 Alkyl)-C1-C 10 -Alkylene-X 1b -, where X 1b and L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -C(O)-N(H)-(C1-C 10 -alkylene)-X 1b -, where X 1b and L in formula (III) or (L in formula (II) 3 ) 0-1 connect, The right-hand side attachment point (i.e., N) is connected to L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -(C1-C 10 -alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (III) or (L in formula (II) 3 ) 0-1 Connection, -C(O)-(C1-C 10-alkylene)-NR 50 C(O)-(C1-C 10 -alkylene)-NR 50a -, of which NR 50a and L in formula (III) or (L in formula (II) 3 ) 0-1 Connect and each C1-C 10 -alkylene is optionally substituted independently with one or more hydroxyl groups, or -C(O)-N(R 5 )-(C1-C 10 -alkylene)-C(O)NH-X 2 -, where X 2 and L in formula (III) or (L in formula (II) 3 ) 0-1 connect.

9. The compound according to any one of claims 1 to 8, wherein SP is -C(O)-C1-C 10 -alkylene-C(O)-.

10. The compound according to any one of claims 1 to 9, wherein SP is -C(O)-C2-C5-alkylene-C(O)-.